<allTrials totalCount="92" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">45000842</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimisation of incision hernia surgery treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Open mesh repair hernia surgery is better than suture repair hernia surgery of incision hernia treatment
2. The recurrence rate using suture hernia repair technique is much higher than mesh repair technique
3. The recovering time to the normal physical activity after surgery is faster, quality of life is better using mesh repair with sublay technique than mesh repair with onlay technique or suture repair technique of the incision hernia treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Recurrence rate, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Quality of life, measured using the 36-item Short Form health survey version 2 (SF-36 v2)at 2 weeks, 1, 3, 6 and 12 months after surgery</primaryOutcome>
      <secondaryOutcome>1. Postoperative complications, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Change of the blood gas and intra-abdominal pressure, measured before and after surgery
3. Recovering time to the normal physical activity after surgery, measured at 2 weeks, 1, 3, 6 and 12 months after surgery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Kaunas Biomedical Research Ethics Committee on the 5th June 2007 (ref: BE-2-41).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45000842</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>73/2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lithuania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dab1e29b-4963-4afa-8cd1-4bd21622092f">
	  <name>Eiveniu str. 2</name>
	  <address/>
	  <city>Kaunas</city>
	  <state/>
	  <country>Lithuania</country>
	  <zip>LT50009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All 18 - 80 years old patients with incision hernia, who will be operated and agree to participate in this clinical trial.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50 patients in each group, 150 patients in all</totalTarget>
      <exclusion>1. Patients older than 80 years
2. Incarcerated incision hernia
3. Mental patients with incision hernia
4. Pregnant women with incision hernia
5. Patients with incision hernia do not agree to participate in this clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hernia</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Hernia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Three groups:
1. Keel technique
2. Onlay technique
3. Sublay technique

The follow up period is 2 weeks, 1, 3, 6 and 12 months after surgery. Surgery, blood gas analysis and intra-abdominal pressure investigation before and after operation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17283-0</funderId>
      <contactId>Contact55244_17283</contactId>
      <sponsorId>Sponsor53812</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55244_17283">
    <title>Dr</title>
    <forename>Linas</forename>
    <surname>Venclauskas</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53812">
    <organisation>Kaunas Medical University Hospital (Lithuania) - Department of Surgery </organisation>
    <website>http://www.kmu.lt/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.45083.3a</gridId>
    <rorId>https://ror.org/0069bkg23</rorId>
  </sponsor>
  <funder id="Funder17283-0">
    <name>Kaunas Medical University Hospital (Lithuania) - Department of Surgery</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">72781592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Short versus long buprenorphine-naloxone treatment in intravenous buprenorphine withdrawal: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>BUNXLOW</acronym>
      <studyHypothesis>1. To investigate the effectiveness of buprenorphine-naloxone compared with treatment as usual (lofexidine) in withdrawal of intravenous buprenorphine dependence
2. To determine whether a longer regime is more effective than a shorter one</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Completion of withdrawal
2. Retention in rehabilitation for one month
3. Abstinence at one month after withdrawal
4. Abstinence at six months after withdrawal</primaryOutcome>
      <secondaryOutcome>1. The extent of withdrawal symptoms experienced, recorded every day during withdrawal
2. The amount of additional medication needed, recorded every day during withdrawal
3. Whether the patient begins naltrexone medication, patients will be offered an opportunity to begin naltrexone three days before finishing withdrawal 
4. Patient satisfaction, measured at the last day of withdrawal, whether at the intended finishing date, or at premature termination of withdrawal. Satisfaction will be measured by a self-made questionnaire of seven questions concerning the satisfaction with the medication, the length of medication, the additional medication, the length of withdrawal, the staff, the opportunity of beginning naltrexone and the overall satisfaction with the withdrawal treatment. Answers will be recorded with a five-grade scale</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The Ethics Committee for Pediatrics, Adolescent Medicine and Psychiatry/Hospital District of Helsinki and Uusimaa on the 15th May 2007; amendment on the form of informed consent was approved 19th June 2007 (ref: 148/E7/2007)
2. The National Agency for Medicines approval on the 22nd August 2007 (ref: 96/2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72781592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HDL07-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, three-arm, parallel group, single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="587bfde4-7c31-404f-a050-a7361d54ff19">
	  <name>Munkkisaarenkatu 16</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>01500</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Opiate dependence (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition [DSM IV])
2. Current misuse of buprenorphine intravenously (mimimun 3 mg/day) (use confirmed by urinalysis)
3. Willingness to participate in withdrawal in the treatment centre and in rehabilitation afterwards
4. Aged between 18 and 50</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="50.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 patients</totalTarget>
      <exclusion>1. Other than buprenorphine as the primary drug of misuse
2. Misuse of other opiates then buprenorphine during the last week (confirmed by urinalysis)
3. Opiate maintenance therapy
4. Psychotic symptoms at recruitment
5. Psychiatric or somatic disease or symptoms that may require hospitalisation at near future
6. Salient increase in alanine aminotransferase (ALAT)
7. Pregnancy
8. Allergy to lofexidine, buprenorphine or naloxone
9. Former participation to the same study
10. Concurrent participation to other intervention studies
11. Native language other than Finnish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intravenous misuse of buprenorphine</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Opiate dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Short buprenorphine-naloxone (Bu-nx) arm: for 9 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 5: 8 mg
Days 6 - 7: 4 mg 
Days 8 - 9: 2 mg

2. Long buprenorphine-naloxone arm: for 25 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 9: 8 mg
Days 10 - 12: 6 mg 
Days 13 - 16: 4 mg 
Days 17 - 20: 2 mg 
Days 21 - 25: 1 mg

3. Lofexidine arm: lofexidine according to clinical assessment, maximum dose 2.4 mg/d divided into two to three doses, maximum duration 21 days

 In all arms, the intended withdrawal duration (in-patient treatment) is 28 +/- 7 days, and the follow-up period is up to six months after that.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Buprenorphine-naloxone, iofexidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16935-0</funderId>
      <funderId>Funder16935-1</funderId>
      <funderId>Funder16935-2</funderId>
      <contactId>Contact54896_16935</contactId>
      <sponsorId>Sponsor53461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54896_16935">
    <title>Dr</title>
    <forename>Outi</forename>
    <surname>Kuikanmäki</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53461">
    <organisation>Helsinki Deaconess Institute (Finland)</organisation>
    <website>http://www.hdl.fi</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Outi Kuikanmäki
Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487156.9</gridId>
    <rorId>https://ror.org/04zqw9t81</rorId>
  </sponsor>
  <funder id="Funder16935-0">
    <name>Academy of Finland (Finland)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002341</fundRef>
  </funder>
  <funder id="Funder16935-1">
    <name>National Public Health Institute (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16935-2">
    <name>Helsinki Deaconess Institute (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">84133969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fractional photothermolysis versus triple therapy for the treatment of melasma: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Fractional photothermolysis may be an effective and safe alternative for the treatment of melasma and the effect of the treatment with fractional photothermolysis may last longer than the effect of the triple therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Observer blinded clinical score (Melasma Area and Severity Index [MASI] score), measured before treatment and during 3, 12 and 24 weeks of follow-up
2. Objective colour measurement by reflectance spectroscopy, measured before treatment and during 3, 12 and 24 weeks of follow-up</primaryOutcome>
      <secondaryOutcome>1. Visual assessment of side effects and quality of life measurements (skindex):
1.1. Fraxel laser group: after laser treatment and during follow-up (3, 12, 24 weeks)
1.2. Triple group: during follow-up (3, 12, 24 weeks)
2. Registration of side effects noticed by the patient: 
2.1. Fraxel group: after laser treatment and during follow-up
2.2. Triple group: after three weeks of treatment by telephone</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Centrale Commissie Mensgebonden Onderzoek (CCMO) on the 19th September 2007 (ref: NL18605.018.07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84133969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>fraxel-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, observer blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fe24a693-9360-407e-8947-a0ba8e4e612a">
	  <name>Meibergdreef 35</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients with melasma
2. Skin photo type II - V
3. Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders
4. Aged at least 18 years
5. Subject is willing and able to give written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Bleaching cream during the past four weeks
2. Local corticosteroids during the past four weeks
3. Subjects with a history of keloids
4. Subjects with active eczema
5. Subjects with active acne in the face
6. Subjects with a history of facial eczema
7. Suspect allergy to lidocaine or the triple therapy
8. Use of roaccutane in the past six months
9. Subjects not competent to understand what is involved
10. Pregnancy
11. Lesion suspicious for malignancy
12. High exposure to sunlight (vacation in southern countries) or ultraviolet (UV) light (UVA or UVB)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melasma</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Disorders of pigmentation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will be randomly allocated to one of two groups who receive either triple therapy (bleaching cream [hydrochinon 5%, tretinoin 0.05% and triamcinolon acetonide 0.1% in cremor lanette II]) or fractional photothermilysis using the fraxel laser. 

Triple therapy: 
The triple therapy will be applied once a day in the evening on all hyperpigmented macules for eight weeks. Follow-up will take 3, 12 and 24 weeks post therapy. 

Fractional photothermolysis: 
Subject will receive a total of four laser treatments, with two week intervals. A topical anaesthetic ointment will be applied to the skin before treatment. The treated area will be less than 3% of the body surface. Follow-up will take place 3, 12 and 24 weeks post therapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triple therapy bleaching cream (hydrochinon, tretinoin, triamcinolon acetonide)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16718-0</funderId>
      <contactId>Contact54676_16718</contactId>
      <sponsorId>Sponsor53232</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54676_16718">
    <title>Dr</title>
    <forename>Albert</forename>
    <surname>Wolkerstorfer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53232">
    <organisation>Academic Medical Centre (AMC) (The Netherlands) </organisation>
    <website>http://www.amc.uva.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16718-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">14127815</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The SphynX trail: a randomised clinical trial comparing the outcome of endoluminal fundoplication with EsophyX™ to laparoscopic Nissen fundoplication for refractory gastro-esophageal reflux disease (GERD)</title>
      <scientificTitle/>
      <acronym>SphynX</acronym>
      <studyHypothesis>Endoluminal fundoplication with Esophyx™ will not be less effective than laparoscopic Nissen fundoplication, expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effectiveness will be expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery (Visick grading). Visick classification: grade I: No symptoms, resolved; grade II: Mild occasional symptoms easily controlled, improved; grade III: Mild symptoms not controlled, unchanged; grade IV: Not improved, worsened. Success will be defined as grade I or II and failure will be defined as grade III or IV.</primaryOutcome>
      <secondaryOutcome>1. Success expressed as the percentage of patients with normalisation of acid exposure on pH metry, minus the percentage of patients needing reintervention (dilatation or re-operation) for troublesome dysphagia at six months

Definition of objective normalisation of acid exposure: 
The combination of the following:
a. Upright acid exposure &lt;8.4%
b. Supine acid exposure &lt;3.4 % 
c. Total acid exposure &lt;5.8% on post-operative 24-h pH-monitoring
The presence of troublesome dysphagia will render the procedure unsuccessful. 

2. Percentage of patients free from PPIs at three and six months
3. Quality of Life (QoL) assessment: Visual analogue scale [VAS] score, the 36-item Short Form health survey (SF-36) and EuroQol (EQ-5D) at three and six months
4. Impact of reflux symptoms on QoL: The Gastro-Oesophageal Reflux Disease Health-Related Quality-of-Life scale  (GORD-HRQoL) at three and six months
5. Esophageal symptoms: OES18 score at three and six months
6. Prevalence of esophagitis on upper endoscopy at six months
7. Cost-effectiveness expressed as costs per successfully treated patients and incremental costs per Quality Adjusted Life Year gained at six months</secondaryOutcome>
      <trialWebsite>http://www.esophyx.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Independent central medical ethics committee of the University Medical Center Utrecht has approved the study protocol. Date of approval: 08/01/2008 (EC ref: 07-214; CCMO ref: 1795404107)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14127815</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>07-214</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised non-inferiority multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2009-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="944ca3ea-fb2a-4784-b3d4-d6b483d46e6a">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. GERD patients of eight Dutch hospitals with reflux symptoms persisting for over 6 months despite double dose of Proton Pump Inhibitor (PPI) (&gt;40 mg omeprazole/24 hours or comparable therapy) and/or patients who refuse or do not tolerate to take acid suppressing drugs for life.  
2. Documented temporal relation between pathological reflux and symptoms during 24-hr pH monitoring. 
Pathological reflux is defined as upright acid exposure &gt;8.4%, supine acid exposure &gt;3.4 % and/or total acid exposure &gt;5.8% on 24-hr pH monitoring. A documented relation between reflux and symptoms is reflected by a Symptom Association Probability (SAP) &gt;95%. 
3. Patients without a diaphragmatic hernia or a sliding hernia not exceeding 2 cm (endoscopically measured distance from Z-line and impression of the diaphragm). 
4. Age between 18 and 65 years. 
5. Informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Patients with a diaphragmatic hernia other than of the sliding type and/or larger than 2 cm.
2. Grade C and D esophagitis according to the Los Angeles classification.
3. Histologically proven long-segment Barrett's oesophagus.
4. Patients with severe esophageal or gastric motility disorders. 
5. Patients with a history of esophageal- or gastric surgery. 
6. American Society of Anaesthesiologists classification III and IV patients. 
7. Patients with a psychiatric disease or other conditions making them incapable of filling out the questionnaires or completing the objective esophageal function tests. 
8. Pregnancy.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2009-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastro-esophageal reflux disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastro-esophageal reflux disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endoluminal fundoplication with EsophyX™ versus laparoscopic Nissen fundoplication.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17532-0</funderId>
      <funderId>Funder17532-1</funderId>
      <funderId>Funder17532-2</funderId>
      <funderId>Funder17532-3</funderId>
      <funderId>Funder17532-4</funderId>
      <funderId>Funder17532-5</funderId>
      <funderId>Funder17532-6</funderId>
      <funderId>Funder17532-7</funderId>
      <funderId>Funder17532-8</funderId>
      <contactId>Contact55494_17532</contactId>
      <sponsorId>Sponsor54078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55494_17532">
    <title>Prof</title>
    <forename>H G</forename>
    <surname>Gooszen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht 
P.O. Box 85500 
H.P. G04.228 </address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54078">
    <organisation>University Medical Center Utrecht and seven participating hospitals (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500 
H.P. G04.228</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder17532-0">
    <name>The costs of this trial are internally covered by the eight participating hospitals in the Netherlands:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-1">
    <name>University Medical Center Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-2">
    <name>Meander Medical Center Amersfoort</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-3">
    <name>Lange Land Hospital Zoetermeer</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-4">
    <name>Catharina Hospital Eindhoven</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-5">
    <name>Medical Center Leeuwarden</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-6">
    <name>Antonius-Mesos Hospital Nieuwegein-Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-7">
    <name>Rivierenland Hospital Tiel</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-8">
    <name>Amphia Hospital Breda</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">09659857</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Outpatient chemotherapy protocol using 3 cosolidated drugs (cisplatin, 5 fluoururacil and leucovorin) in a different scheme for the treatment of head and neck and oesophageal cancer, designed for patients without surgical and radiation therapy options</title>
      <scientificTitle>Low cost, outpatient, cisplatinum, 5-fluoururacil and leucovorin chemotherapy regimen for advanced head and neck, and upper oesophageal carcinomas</scientificTitle>
      <acronym/>
      <studyHypothesis>Evaluate the combination of bolus CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL) in patients with advanced (residual, metastatic or recurrent) squamous cell carcinoma (SCC) of head (H)/neck (N) and oesophagus (E), aiming at a feasible and low cost chemotherapy (CHT) regimen to circumvent the need of infusion pumps and/or hospital admission.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Quality of life (QoL) evaluated using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire, previously used in Portuguese, at the beginning of study and before each cycle
2. Toxicities analysed according to National Cancer Institute (NCI) criteria before each cycle together with KPS, clinical reassessment and laboratory evaluation
3. Response, evaluated by computed tomography (CT) scans after 3rd and 6th cycles of chemotherapy and analysed by response evaluation criteria in solid tumours (RECIST)
4. Performance status by measured with Karnofsky Performance Status (KPS)</primaryOutcome>
      <secondaryOutcome>1. Overall survival - time between enrolment and death
2. Progression Free Survival - time between enrolment and disease progression</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ABC Medical School Ethics Committee in December 2004 (ref: 185/2004).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09659857</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II, single arm study conducted at a single Brazilian Institution</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5eb15996-b980-4766-868b-86b9b89146f3">
	  <name>Rua Mere Amedea 833</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>02125-001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Advanced or recurrent, histologically confirmed, head and neck and oesophagus squamous cell carcinoma
2. Patients have to be 18 years of age or older, either sex
3. Normal renal function
4. Measurable disease by the response evaluation criteria in solid tumours (RECIST)
5. Karnofsky performance status (KPS) equal or greater to 50%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15 patients</totalTarget>
      <exclusion>1. Not meeting the inclusion criteria
2. Concomitant radiation therapy
3. Not a candidate for chemotherapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and Neck and Upper oesophageal carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Squamous cell carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chemotherapy as follows:
Leucovorin 20 mg/m^2/day bolus infusion for four days (D1 - D4), followed by 5-fluoururacil  370 mg/m^2/day bolus infusion for four days (D1 - D4), and Cisplatinum 25 mg/m^2/day in 90 minutes infusion for three days (D1 - D3), every 21 to 28 days, depending upon hematological recovery.

Follow up is until patient death, expected to be less then 24 months for each patient.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17436-0</funderId>
      <funderId>Funder17436-1</funderId>
      <contactId>Contact55397_17436</contactId>
      <sponsorId>Sponsor53967</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55397_17436">
    <title>Dr</title>
    <forename>Vanessa</forename>
    <surname>Fabricio</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Mere Amedea 833</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>02125-001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vcf35@terra.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53967">
    <organisation>Hospital Mario Covas (Brazil) </organisation>
    <website>http://www.hospitalmariocovas.org.br</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Rua Henrique Calderazzo, 321
Bairro Paraíso </address>
      <city>Santo Andre</city>
      <country>Brazil</country>
      <zip>09190-615 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sau@hesa-fuabc.org.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487168.4</gridId>
    <rorId>https://ror.org/00s7ek396</rorId>
  </sponsor>
  <funder id="Funder17436-0">
    <name>ABC Foundation (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17436-1">
    <name>Hospital Mario Covas (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">76047793</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Adhesion prevention with icodextrin</title>
      <scientificTitle>The effect of 4% icodextrin solution vs lactated Ringer's solution on adhesiolysis during Hartmann's reversal: A multi-centre randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Laparotomy almost always causes peritoneal adhesions, which further causes morbidity and even mortality. A regimen to prevent peritoneal adhesions is urgently needed. Icodextrin has been shown to prevent adhesion formation, and our study investigated further the efficacy of icodextrin in colorectal operation. 

Study hypothesis: 
4% icodextrin solution decreases adhesion formation and time needed to divide them after hartmann's procedure compared to lactated Ringer's solution.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Time needed to separate postoperative adhesions, assessed approximately 3 months after hartmann's reversal procedure
2. Total operative time</primaryOutcome>
      <secondaryOutcome>1. Complications and recovery after Hartmann's reversal procedure. Duration of follow-up: 1 month 
2. Safety of icodextrin. Duration of follow-up: 1 month</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>National approval of the study received on 30 April 2003 from the Ethical Committee of Päijät-Häme Hospital District ETL-code Q36. Further approved by every local ethical committee of participating hospitals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76047793</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, multi-centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="df6e5043-6d70-403e-b683-1823b1916eaf">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Lahti</city>
	  <state/>
	  <country>Finland</country>
	  <zip>15850</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients having rectosigmoid colon obstruction, perforation or diverticulitis (with or without perforation) for which a Hartmann's operation was planned</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Refusal to consent
2. Pregnancy
3. Peritoneal carcinoma
4. Postoperative radiotherapy before restorative surgery
5. Reoperation violating study protocol
6. Severe concomitant disease or other reason that would probably interfere with the restorative surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Laparotomy/ peritoneal adhesions</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Laparotomy/ peritoneal adhesions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study group receives at the end of Hartmann's procedure 1000 ml of 4 % icodextrin instilled into the abdomen. The control group receives same amount of lactated Ringer's solution.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17400-0</funderId>
      <contactId>Contact55361_17400</contactId>
      <sponsorId>Sponsor53931</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55361_17400">
    <title>Dr</title>
    <forename>Jyrki</forename>
    <surname>Kössi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Päijät-Häme Central Hospital
Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53931">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder17400-0">
    <name>Internally funded by the Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">65305620</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is misoprostol a safe alternative to manual vacuum aspiration in women with incomplete abortions in developing countries?</title>
      <scientificTitle>Is misoprostol a safe alternative to manual vacuum aspiration in women with early pregnancy failure in a low resource setting?: a randomized controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Misoprostol is just as effective as Manual Vacuum Aspiration (MVA) in treatment of first trimester pregnancy failure, but is more acceptable to clients in a rural setting in low resource countries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Ultrasonographic endometrium thickness at day 8</primaryOutcome>
      <secondaryOutcome>The following will be assessed at day 8: 
1. Changes in hemoglobin (Hb) level
2. Side effects including pain 
3. Adverse events 
4. Patients satisfaction and acceptability 

If any problem is observed on day 8, the patient will be reviewed again on day 15 (No review at day 15 if no problem is observed).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The National Institute of Medical Research Dar es Salaam, approved on 18 October 2007 (ref: NIMR/HR/R.8a/Vol. IX/628)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65305620</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blinded, single-centre, randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-02-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e226d8a5-b2b9-4ac5-ba03-7f20cc8cad96">
	  <name>PO box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. History of passage of tissue and/or blood and &gt;30 mm endometrial thickness on TransVaginal Sonography (TVS) 
2. On TVS an anembryonic gestation or fetal death with an embryonic crown-rump length between 5 and 62 mm without cardiac activity (in case of a Crown-Rump Length [CRL] of 5-9 mm TVS will be repeated after one week to ensure absence of cardiac activity) or an anembryonic gestational sac of 16-45 mm (TVS will be repeated after one week to ensure growth of the gestational sac is &lt;3 mm and exclude a viable pregnancy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. On TVS present fetal heart activity, a crown-rump length &gt;62 mm, molar pregnancy or a endometrial thickness less than or equal to 30 mm
2. Fundal height of more than halfway the umbilicus and the symphysis indicating a gestational age &gt;12 weeks
3. Known allergy to prostaglandins
4. Heavy blood loss or a pulse rate of &gt;120/min
5. Axillary temperature of &gt; 38°C or signs of septic abortion such as pus draining from uterus
6. Ectopic pregnancy</exclusion>
      <patientInfoSheet>Patient information form in Kiswahili is available on request. Please use the contact details below to request.</patientInfoSheet>
      <recruitmentStart>2008-02-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-02-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>First trimester pregnancy failure</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>First trimester pregnancy failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Misoprostol 600 microgram 3 doses (one dose every 4 hours) sublingually versus MVA</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17482-0</funderId>
      <contactId>Contact55444_17482</contactId>
      <sponsorId>Sponsor54024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55444_17482">
    <title>Dr</title>
    <forename>Regine</forename>
    <surname>Unkels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54024">
    <organisation>Tanzanian German Program to Support Health  (TGPSH)  (Tanzania)</organisation>
    <website>http://www.tgpsh.or.tz</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Lindi Office
PO box 97</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17482-0">
    <name>Tanzanian German Program to Support Health (TGPSH) (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-15T00:00:00.000Z">82469428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</title>
      <scientificTitle>A randomised, double-blind, comparative, multi-centre study of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</scientificTitle>
      <acronym/>
      <studyHypothesis>Is 5 x 200 mg iron sucrose over 3 weeks more effective in the treatment of restless legs than placebo?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>International RLS Study Group Rating Scale at 11 weeks</primaryOutcome>
      <secondaryOutcome>1. Epworth Sleepiness Scale at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months
2. Incidences and severities of adverse events, assessed after 3 , 7 and 11 weeks, 5, 8 and 12 months
3. To assess the ability of the treatments to correct aberrant haematology and iron status at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University Hospital, Uppsala. Date of approval: 13 June 2003 (ref: 03-141)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82469428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPV-0105</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-22T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbc1ec18-e878-47d5-87a1-f050de824c58">
	  <name>Medical Department</name>
	  <address/>
	  <city>Avesta</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-774 82</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18-70 years
2. RLS defined by four cardinal criteria
3. Ten points or more on the International RLS (IRLS) Study Group Rating Scale 
4. S-ferritin below 45 µg/L, and with folic acid and vitamin B12 within reference values
5. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Treatment with any of the following: 
1.1. Psychopharmacological treatment with antidepressive and dopaminergic agents, sedatives, anticonvulsants and/or pain relievers, i.e. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or stronger, during the preceding 2 weeks. This was changed in study protocol clarification number 2 to "...i.e. with the exception of NSAIDs - during the last 2 weeks". 
1.2. Calcium antagonists, antihistaminic or antiemetic drugs during the preceding 2 weeks. 
1.3. Iron administration during the preceding 2 months 
1.4. Nutritional supplements or natural pharmaceuticals containing iron 
1.5. Antiepileptics 
1.6. Vitamin B12 or folic acid 
2. Presence of clinically significant disease/dysfunction, which in the opinion of the investigator should disqualify the patient from this study, such as asymptomatic intestinal bleeding 
3. Patients suffering from obstructive sleep apnoea syndrome 
4. S-creatinine &gt;130 µmol/L 
5. Positive result of pregnancy test 
6. Breast-feeding women 
7. Contraindications for iron sucrose</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2003-06-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-22T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Restless legs syndrome</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Restless legs syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg iron sucrose intravenously 5 times over 3 weeks versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>iron sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17503-0</funderId>
      <contactId>Contact55465_17503</contactId>
      <sponsorId>Sponsor54046</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55465_17503">
    <title>Prof</title>
    <forename>Jan</forename>
    <surname>Ulfberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Department
Avesta Hospital</address>
      <city>Avesta</city>
      <country>Sweden</country>
      <zip>SE-774 82 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54046">
    <organisation>Renapharma AB (Sweden)</organisation>
    <website>http://www.renapharma.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Box 938</address>
      <city>Uppsala</city>
      <country>Sweden</country>
      <zip>SE-751 09  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476652.4</gridId>
    <rorId>https://ror.org/03x49ea82</rorId>
  </sponsor>
  <funder id="Funder17503-0">
    <name>Renapharma AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-01T00:00:00.000Z">20442117</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of hemodynamic effects of cascade hemofiltration in septic shock</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of the hemodynamic improvement using cascade hemofiltration in patients treated for septic shock</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of days without catecholamines at the 28th day of randomization</primaryOutcome>
      <secondaryOutcome>1. Rate of decrease of catecholamines during the first 72h 
2. Number of days without mechanical ventilation at the 90th day 
3. Number of days without Renal Replacement Therapy (RRT) at the 90th day 
4. Number of days without ICU requirement at the 90th day 
5. Death or survivor status at the 90th day</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Committee for Protection of Research Subjects (Comité de Protection des Personnes [CPP]) Ile de France VI, approved on 16 July 2007 
2. France's Sanitary Safety in Health Products Agency (AFSSAPS), approved on 30 October 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20442117</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1450</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-center, pilot, prospective, parallel-group, randomised controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9dfb7251-5081-41cd-802c-fb80dbccd2fe">
	  <name>Gambro Industries</name>
	  <address/>
	  <city>Lyon</city>
	  <state/>
	  <country>France</country>
	  <zip>69357</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with a septic shock diagnosed by the medical staff team
2. Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (superior or equal to 1.0 mg/h of norepinephrine or epinephrine) for more than 120 minutes and &lt;24h
Note: Patients with renal failure (treated or not) can be included</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Age (years) &lt;18 or &gt;85 
2. Weight &gt;120 kg 
3. Thrombocytopenia 50&lt; G/l or Neutrophils &lt;0.5 Giga/l 
4. Contra indication to heparin anticoagulation 
5. Patient requiring catecholamines (epinephrine or norepinephrine superior or equal to 1 mg/h) for &gt;24h 
6. Patient admitted to the Intensive Care Unit (ICU) superior or equal to 7 days before the inclusion criteria 
7. Patient with intercurrent disease limiting his/her self-sufficiency (need of help before septic shock) 
8. Inclusion (&lt;28 days) in another study interfering with the goals of the current investigation 
9. Pregnancy and patient under guardianship 
10. Immune compromised patients (e.g., being treated for cancer, treated by immunosuppressors or steroids, AIDS)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Septic shock/ hemofiltration</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Septic shock/ hemofiltration</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Either standard hemofiltration or Cascade hemofiltration (2 types of membrane evaluated)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17411-0</funderId>
      <contactId>Contact55372_17411</contactId>
      <sponsorId>Sponsor53942</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55372_17411">
    <title>Mrs</title>
    <forename>Nathalie</forename>
    <surname>Loughraieb</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Gambro Industries
Clinical Affairs Department
61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53942">
    <organisation>Gambro Industries, Clinical Affairs Department (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder17411-0">
    <name>Gambro Industries (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-09T00:00:00.000Z">07427212</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of experimental hyperglycemia and AT1 receptor blockade on renal hemodynamics in impaired glucose tolerance</title>
      <scientificTitle/>
      <acronym>IGT-FRA-oo30-I</acronym>
      <studyHypothesis>The study aim is to investigate whether: 
1. Experimental hyperglycemia reduces renal hemodynamics (glomerula filtration rate, renal plasma flow) 
2. Angiotensin II Type 1 (AT1) receptor blocker treatment prevents hyperglycemia induced changes of renal hemodynamics</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at rest (U1 rest, U2 rest) and during hyperglycemic stress testing (U1 stress, U2 stress) with and without AT1 receptor blocker treatment:
1. Glomerular filtration rate (inulin clearance) 
2. Renal plasma flow (Para-AminoHippurate [PAH] clearance) 

U1: Without AT1 receptor blocker
U2: After a 4-week treatment with valsartan</primaryOutcome>
      <secondaryOutcome>The following were assessed at U1 and U2: 
1. High-sensitivity C-Reactive Protein (CRP) 
2. Adiponectin 
3. HbA1c (blood tests) 

U1: Without AT1 receptor blocker 
U2: After a 4-week treatment with valsartan</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Ethical Committee of the Technical University of Munich.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07427212</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, open, prospective, longitudinal, non-randmoised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="de9d23a8-a9e7-4440-ba4b-1b5baaf9d01a">
	  <name>Nephrology Department</name>
	  <address/>
	  <city>Munich</city>
	  <state/>
	  <country>Germany</country>
	  <zip>81675</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males 
2. 18-70 years old
3. Impaired Glucose Tolerance (for the intervention group [IGT-Group]) (tested by the oral glucose tolerance test according to the World Health Organisation) and normoglycemic patients (for control group [healthy subjects])</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Male</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Renal or liver insufficiency 
2. Micro-or macro-albuminuria 
3. Overt diabetes mellitus</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Impaired glucose tolerance/ renal changes in prediabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Impaired glucose tolerance/ renal changes in prediabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>12 participants were recruited in each of the two groups. Statistical calculation was carried out by the Institute of Statistics, Technical University of Munich. 

Participants of both groups (control and IGT-group) received the following two interventions: 
1. Experimental hyperglycemia (clamp technique) 
2. Valsartan (AT1 receptor blocker)(oral, taken once a day in the morning) treatment for 4 weeks. The initial dose was 80 mg/day, and the dosage was increased after 7 +/- 2 days of administration to 160 mg /day. 

A safety visit was made at 5 +/- 2 days after the beginning of the study for the measurement of serum creatintine, potassium and blood pressure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>AT1 receptor blocker</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17381-0</funderId>
      <contactId>Contact55342_17381</contactId>
      <sponsorId>Sponsor53912</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55342_17381">
    <title>Dr</title>
    <forename>Helga</forename>
    <surname>Frank</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nephrology Department
Klinikum rechts der Isar
Ismaninger Strasse 22</address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53912">
    <organisation>Technical University of Munich (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ismaninger Strasse 22 </address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 89 4140 2231</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Helga.Frank@lrz.tum.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6936.a</gridId>
    <rorId>https://ror.org/02kkvpp62</rorId>
  </sponsor>
  <funder id="Funder17381-0">
    <name>Novartis (International)</name>
    <fundRef>http://dx.doi.org/10.13039/100004336</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">76293435</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the effectiveness of endoscopic and microscopic removal of cerumen (wax) from the ear canal</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>What is the best preparation to use for otitis externa in the first instance?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76293435</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0212177259</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="563a1fcd-6767-4778-9b84-bb2997da2fe5">
	  <name>ENT</name>
	  <address/>
	  <city>Bath</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BA1 3NG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with otitis externa</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ear, Nose and Throat: Otitis externa</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Otitis externa</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Dewaxing using microscope
2. Dewaxing using endoscope</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17014445 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3d1cb828-f3d4-4b99-985d-35f98f8f341e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17014445"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17027-0</funderId>
      <contactId>Contact54988_17027</contactId>
      <sponsorId>Sponsor53553</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54988_17027">
    <title>Mr</title>
    <forename>David</forename>
    <surname>Pothier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>ENT
Royal United Hospital
B&amp;NES
</address>
      <city>Bath</city>
      <country>United Kingdom</country>
      <zip>BA1 3NG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">David.Pothier@ruh-bath.swest.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53553">
    <organisation>Record Provided by the NHSTCT Register - 2007 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17027-0">
    <name>Royal United Hospital Bath NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-04-25T00:00:00.000Z">27453314</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical evidence continuous medical education: randomised educational trial of an e-learning program for transferring evidence based information in primary and secondary care</title>
      <scientificTitle/>
      <acronym>ICEKUBE (Italian Clinical Evidence Knowledge Utilisation Behaviour Evaluation)</acronym>
      <studyHypothesis>This trial is designed to test the effectiveness of ECCE (the Italian acronym for Continuing Education Clinical Evidence) e-learning program for transferring evidence based information to medical doctors after three months of ECCE usage and the retention of the transferred information after six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is the basic knowledge of Clinical Evidence contents assessed through the scoring of clinical vignettes selected from ECCE. The test will consist of fixed and multiple choice questions of the selected valid and reliable vignettes and will be administered before (pre-test), immediately after (12 weeks post-test one), and six months after the intervention (post-test two).</primaryOutcome>
      <secondaryOutcome>Satisfaction with the information source and its perceived value for the medical education and clinical practice.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local research ethics committee (Research Ethics Board Azienda Sanitaria Locale &#147;Città di Milano&#148;, Milano) on the 15th December 2007 (ref: 43-06 SO).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27453314</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>43-06 SO</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A before and after pragmatic educational randomised controlled trial utilising a two by two incomplete block design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="595541a4-729a-4656-955e-731234e1778a">
	  <name>Italian Cochrane Centre</name>
	  <address/>
	  <city>Milano</city>
	  <state/>
	  <country>Italy</country>
	  <zip>20156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All Italian doctors naïve to ECCE who voluntarily adhere to participate. New users to ECCE who connect to ECCE are automatically invited to participate.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>A sample size of 54 practitioners per study arm</totalTarget>
      <exclusion>There are no exclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knowledge of the best available evidence for effective healthcare.</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Healthcare knowledge</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that as of 20/07/2007 the anticipated end date has been extended to 31/09/2007 due to a low recruitment rate. The previous end date of this trial was 31/07/2007. On 18/12/2007 the anticipated end date was extended again to 01/04/2008 due to a continued low recruitment rate. On the 05/03/2008 the anticipated end date was again amended to show the end date as the 29/02/2008 - this is the date this trial was closed to enrolment. 

Sample size/power calculation:
Based on a preliminary examination, we determined that the &#147;minimal&#148; important difference for this intervention to be considered useful was a 20% absolute improvement.

Based on a preliminary test of 300 doctors, we determined that the &#147;mean&#148; improvement due to the intervention, was a 28% absolute improvement. Therefore we calculated our sample size to detect a 0.7 standardised difference in the primary outcome, set the α error rate at 0.05 (two-sided), and the β error at 0.10 (power 90%) &#150; this yielded a sample size of 45 practitioners per study arm. If the accrual period is two months and the maximum follow-up period is six months with a loss during follow-up of 20% at the end of the study, the total number of practitioners to be randomised has been adjusted upwards to 162 (54 per intervention group).

Intervention:
ECCE is an e-learning tool that uses interactive clinical vignettes based on chapters in Clinical Evidence and a predefined sequence of questions. ECCE has four components: 
1. The Clinical Evidence chapter (e.g. headache, chronic tension-type), a clinical vignette derived from the Clinical Evidence chapter gives a plausible medical scenario (e.g. Margaret says to her family doctor: &#147;This time I didn&#146;t come for me, but to talk about Rachel, my 25-year-old daughter&#133;)
2. The lead-in for the clinical vignette and related questions that gives the doctors instructions on what to do (e.g. "more than one answer may be correct&#148;)
3. The questions addressing the recall of Clinical Evidence facts or the application of Clinical Evidence facts to the medical scenario, based on which the doctor is to select the correct answer
4. And finally the potential answers (e.g. a list of potential efficacy descriptors for a therapeutic regimen relevant to the theme) 

Group one access to ECCE for Clinical Evidence chapters and vignettes lot A and provides control data for Clinical Evidence chapters and vignettes lot B.
Group two access to ECCE for lot B and provides control data for lot A. 

To determine the possible Hawthorne effect of this trial, we added to the two-block design arms a third control arm (classical design), in which a minimal intervention was defined. The minimal intervention consisted of one of the elements of the complete intervention, namely the concise printed version of Clinical Evidence and access to the on-line full-text version.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16347-0</funderId>
      <contactId>Contact54304_16347</contactId>
      <sponsorId>Sponsor52857</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54304_16347">
    <title>Dr</title>
    <forename>Lorenzo</forename>
    <surname>Moja</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Italian Cochrane Centre
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52857">
    <organisation>Italian Cochrane Centre (Italy)</organisation>
    <website>http://www.icc.cochrane.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o  Dr Lorenzo Moja 
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7548.e</gridId>
    <rorId>https://ror.org/02d4c4y02</rorId>
  </sponsor>
  <funder id="Funder16347-0">
    <name>Italian Drug Agency (AIFA) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-03-27T00:00:00.000Z">26123577</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic Gabapentin for Prevention of Acute Mountain Sickness: a double blind, randomised, placebo controlled, clinical trial</title>
      <scientificTitle/>
      <acronym>GPAMS</acronym>
      <studyHypothesis>Prophylaxis with gabapentin will slow or stop the progression of Acute Mountain Sickness (AMS) compared to those taking a placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. AMS incidence (Lake Louise acute mountain sickness score of equal or more than three with headache and at least one other symptom) 
2. AMS severity (score of five or more)</primaryOutcome>
      <secondaryOutcome>1. Duration of high-altitude headache free phase after prophylaxis initiation
2. Duration of moderate to severe high-altitude headache free phase after prophylaxis</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the institutional review board of the Neurology Research Centre, Imam Hospital, Tehran University of Medical Sciences (Iran) on the 11th Januray 2007 (ref: 85-04-54-4708).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26123577</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>86-01-54-5304</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised, parallel group, two-armed, placebo controlled, participants/outcome assessor blinded, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b362415-80e7-4c6f-b437-4f58e07e8499">
	  <name>No. 15, Shabtab Street</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>19389</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 15 to 65 years
2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres using cable cars (within 45 to 90 minutes)
3. Consenting participant
4. May reasonably be expected to complete a 24 hour trial</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>204</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>204</totalTarget>
      <exclusion>1. Severe cardiac, pulmonary, or liver disease
2. Severely impaired kidney function
3. Current history of alcohol or drug abuse
4. Pregnancy
4. Known allergy to gabapentin
5. Treatment with anticonvulsants or tricyclic antidepressants</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute mountain sickness</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Mountain sickness</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group one: gabapentin 600 mg orally; single dose within first two hours of ascent.
Treatment group two: mono-hydrate lactose (same shape and weight to gabapentin capsules); single dose within first two hours of ascent.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gabapentin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17965148 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cf867bdb-7c3c-46a4-97ac-03068105e646" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17965148"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16208-0</funderId>
      <funderId>Funder16208-1</funderId>
      <contactId>Contact54163_16208</contactId>
      <sponsorId>Sponsor52717</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54163_16208">
    <title>Dr</title>
    <forename>Sirous</forename>
    <surname>Jafarian</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No. 15, Shabtab Street
Gheytarieh Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)91 2215 6750</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jafarian_s@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52717">
    <organisation>Tehran University of Medical Sciences (Iran)</organisation>
    <website>http://www.tums.ac.ir/index.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Professor Ghaffarpour
Neurology Research Centre
Imam Hospital
Faculty of Medicine 
Keshavarz Blvd</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder16208-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16208-1">
    <name>Darou Darman Pars Pharmaceuticals (DDP) (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-08T00:00:00.000Z">45381163</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The pharmacokinetics of nimodipine, intravenous and orally, in patients with subarachnoidal haemorrhage admitted in intensive care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Describing the pharmacokinetics of nimodipine, especially the variability of the bio-availability of orally administred nimodipine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pharmacokinetics of nimodipine in this specific group of patients
2. Variability of bio-availability of orally administred nimodipine</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45381163</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, non-randomised, pharmacokinetic study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="559b9792-ab3a-4cf1-bc06-151558b4b2de">
	  <name>VU University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. All patients admitted to the Intensive Care Unit (ICU) with subarachnoidal bleeding/haemorrhage (SAB), treated according to our SAB-protocol
2. Adults aged 18 to 70 years old</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12</totalTarget>
      <exclusion>1. Pregnancy
2. Expected mortality in less than 24 hours
3. Severe hepatic function disorders
4. Use of medication with known interaction in relation to nimodipine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subarachnoidal haemorrhage</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cerebrovascular diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Blood samples according to strict time protocol during treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nimodipine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16142-0</funderId>
      <contactId>Contact54088_16142</contactId>
      <sponsorId>Sponsor52643</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54088_16142">
    <title>Dr</title>
    <forename>B M</forename>
    <surname>Kors</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Centre 
Afdeling intensive care volwassenen
Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+ 31 (0)20 444 3900</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bm.kors@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52643">
    <organisation>VU University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Intensive Care
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16142-0">
    <name>VU University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">85744812</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Alternative Intra Osseous Devices: randomised controlled trial comparing three intraosseous methods</title>
      <scientificTitle/>
      <acronym>AIOD</acronym>
      <studyHypothesis>The aim of this study is to analyse whether or not it is possible to created a fast, reliable intraosseous entrance using the BIG and/or FAST bone needles, with less complications compared with the traditional bone needle Jamshidi.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Primary endpoint: aspiration of bone marrow upon successful placement of a bone needle.
2. Primary parameter is time required for successful placement.</primaryOutcome>
      <secondaryOutcome>Secondary endpoint: Complications encoured using an intraosseous device
Secondary parameters:
1. Adverse events
2. Success rate (%)
3. User friendliness (Visual Analogue Scale [VAS])
4. Pain scored by the patient (VAS)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Medical Ethical review board, Erasmus Medical Centre, Rotterdam, The Netherlands. The approval was completed at 15th June 2006 with reference number MEC-2006-109.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85744812</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, single blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="54f620ec-a652-4038-8812-36c07c8132fb">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients in acute life threatening situations, requiring assistance of a mobile medical team
2. Intravascular medical or fluid resuscitation is necessary and intravascular access cannot be obtained after two attempts</inclusion>
      <ageRange>Other</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Children under the age of one year
2. Patients with suspected sternumanomaly (only FAST1)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe injury, life threatening</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Severe injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consists of the application of a randomised instraosseous needle:
1. In people over 14 years: BIG versus FAST versus conventional bone needle
2. In children more than one and less than 14 years: BIG versus conventional bone needle</description>
	<interventionType>Device</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15956-0</funderId>
      <contactId>Contact53902_15956</contactId>
      <sponsorId>Sponsor52451</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53902_15956">
    <title>Dr</title>
    <forename>I B</forename>
    <surname>Schipper</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
Trauma Center ZWN
Room Z-9.15
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 5034</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.schipper@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52451">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Trauma Center ZWN
P.O. Box 2040</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15956-0">
    <name>Medirisk (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">32882895</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The variations in small vascular function and arterial compliance during the menstrual cycle in young healthy women (De cyclus afhankelijke variatie in de microcirculatie bij jonge gezonde ovulerende vrouwen)</title>
      <scientificTitle/>
      <acronym>MCycle</acronym>
      <studyHypothesis>It has been suggested in literature that insulin sensitivity and determinants of the blood pressure vary according to the past ovulation cycle. Since microcirculation plays a large role in the transport and supply of insulin to the muscle fibres, it can be assumed that the microcirculatory function cycle will be dependent on the ovulation cycle. Indeed from literature it has been suggested that this is true, however another group of researchers found no cycle dependent pattern. Moreover in the Vrije University the most unique method has been developed to measure the microcirculation (capillary microscope) and this measuring has never been examined in women in their ovulation cycle. The results of this research are very important for the interpretation of cardiovascular events in women during their ovulation cycle.

Hypothesis:
Microcirculatory function is cycle dependent in healthy ovulating women.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Microcirculatory function measured in three phases of the cycle (early and late follicular, and luteal).</primaryOutcome>
      <secondaryOutcome>Blood pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32882895</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bee72f5b-9219-42b2-b062-41b5aa6db158">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy as judged by history and physical examination
2. Regular ovulatory menstrual cycles between 21 - 35 days (proven by biphasic basal temperature curve [BTC] or midluteal progesterone more than 10 nmol/l)
3. Aged 18 to 35 years
4. No medication including oral conceptive or hormonal intra-uterine device (IUD) for at least three months
5. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Cardiovascular disease (hypertension [more than 160/90 mmHg], stroke, coronary artery disease, peripheral vascular disease, heart failure)
2. Diabetes mellitus (according to American Diabetes Association [ADA] criteria)
3. Smoking for the last three months
4. Alcohol use more than 4 units/day
5. Pregnancy
6. Diseases that influence reproductive hormone status</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Small vascular function, arterial compliance</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Small vascular function, arterial compliance</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Microcirculation measured by means of:
1. Microscopic examination of the nail bed (assessment of the refill after temporary occlusion of the finger) 
2. Ionthophoresis with acetylcholine (ACH) (endothelium dependent) and sodiumnitroprusside (SNP) (endothelium independent vasodilatation)
3. Blood pressure</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15970-0</funderId>
      <contactId>Contact53916_15970</contactId>
      <sponsorId>Sponsor52465</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53916_15970">
    <title>Dr</title>
    <forename>I J G</forename>
    <surname>Ketel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Department of Reproductive Medicine (Poli H)
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 0041</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ijg.ketel@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52465">
    <organisation>VU University Medical Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Reproductive Medicine
Postbus 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder15970-0">
    <name>Institute for Cardiovascular Research of the Vrije University of Amsterdam (ICaR-VU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-25T00:00:00.000Z">67906788</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Proof of principle study of the effect of individual and team drill on the ability of labour ward staff to manage acute obstetric emergencies</title>
      <scientificTitle/>
      <acronym>SaFE study</acronym>
      <studyHypothesis>The use of mock drills in simulation centres and labour wards (fire drills) has increased in response to issues of patient safety and the Clinical Negligence Scheme for Trusts (CNST) requirements. These provide opportunities for staff to practise emergency obstetric scenarios. However, there has been little evaluation of the effects of such training on individuals or obstetric teams. The Department of Health has funded this work, to establish proof of principle of the effect of individual and team drill training on the ability of labour ward staff to manage acute obstetric emergencies. The study evaluates training involving simulation centre and local in-house labour ward drills, so that future policies and studies can be based on the most promising methods.

The aim of this study is to evaluate the effect of individual and team drill for the management of acute obstetric emergencies. The specific research questions are:

1. Primary questions
a. Does the use of a high fidelity setting improve clinical skills in obstetric emergencies?
b. Does including team training in emergency drills improve clinical skills in dealing with obstetrics emergencies?

2. Secondary questions
a. Does team training in obstetric emergency drills improve team working?
b. Does the use of a high fidelity setting improve team working in obstetric emergencies?
c. Does team training in emergency drills improve knowledge in obstetric emergencies?
d. Does the use of a high fidelity setting improve knowledge in obstetric emergencies?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Global rating scores of individual clinical skills
2. Time taken to execute procedures
3. Number of actions, omissions and inappropriate actions</primaryOutcome>
      <secondaryOutcome>1. Knowledge assessed by a multiple choice questionnaire
2. Applied delivery force in shoulder dystocia skill station
3. Communication - as assessed by a content analysis of a sub sample of skill stations
4. Global rating scores of teamwork behaviours on a sub sample of skill stations</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Southwest Devon Medical Research Ethics Committee (reference number: 04/Q2103/68), approval gained on September 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67906788</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>0270030</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II exploratory trial within the format of a factorial 2 x 2 randomised trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="02475b0e-a8ee-48fa-8886-2be2b2b2a996">
	  <name>St Michael's Hospital</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8UG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All hospital and community midwives and obstetric medical staff (junior and senior) who provide care to mothers and babies are eligible to enter the study.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>144</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>144</totalTarget>
      <exclusion>Staff who have attended addition accredited training course in the management of obstetric emergencies (Advanced Life Support in Obstetrics [ALSO], Managing Obstetric Emergencies and Trauma [MOET], South West Obstetric Emergency Course) within the past 12 months will be excluded from the study, and also:
1. Staff who have taken part in the Simulation and Fire drill Evaluation study (SaFE) pilot study
2. Staff involved in the delivery of the training interventions
3. Local staff involved in assisting the research team
4. Staff currently on maternity leave or long term sick leave</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute obstetric emergencies</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Acute obstetric emergencies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Phase II exploratory trial of two aspects of the training intervention, high versus low fidelity and team training versus no team training, will be assessed within the format of a factorial 2 x 2 randomised trial.

The participants will be randomly allocated to one of the four training interventions.
Group A1: One day obstetric emergency training course. This will be within the low fidelity setting in the local participating hospitals and will exclude specific team training.
Group B1: One day obstetric emergency training course. This will be within the high fidelity setting of the Bristol Medical Simulation Centre and will exclude specific team training.
Group A2: Two day obstetric emergency training course. This will be within the low fidelity setting of the local participating hospitals and will include specific team training.
Group B2: Two day obstetric emergency training course. This will be within the high fidelity setting of the Bristol Medical Simulation Centre and will include specific team training.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18310377 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="54cc7507-8c93-4ddc-9e33-ac2aea462f73" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18310377"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15346-0</funderId>
      <contactId>Contact53274_15346</contactId>
      <sponsorId>Sponsor51823</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53274_15346">
    <title>Dr</title>
    <forename>Bryony</forename>
    <surname>Strachan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Michael's Hospital
Southwell Street</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8UG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 117 9285594</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bryony.strachan@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51823">
    <organisation>United Bristol Healthcare Trust (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Research and Effectiveness Department
Marlborough Street</address>
      <city>Bristol</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>BS1 3NU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 117  923 0000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">maria.palmer@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410421.2</gridId>
    <rorId>https://ror.org/04nm1cv11</rorId>
  </sponsor>
  <funder id="Funder15346-0">
    <name>The trial is funded by Policy Research Programme of the Department of Health as part of the Patient Safety Research Portfolio (PSRP) (reference number: 0270030).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-13T00:00:00.000Z">25825250</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy</title>
      <scientificTitle/>
      <acronym>IM-VIT100</acronym>
      <studyHypothesis>To determine the safety and efficacy of VIT100 (VitrenAse), a proliferating cell nuclear antigen (PCNA) ribozyme (Immusol, Inc. San Diego, CA), in preventing recurrent proliferative vitreoretinopathy (PVR) in patients with established PVR who undergo vitrectomy for retinal reattachment repair.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy variables included:
1. Failure rate of retina repair surgery secondary to PVR
2. All cause of failure rate of retina repair surgery
3. Retinal status</primaryOutcome>
      <secondaryOutcome>Safety variables included:
1. ETDRS best corrected visual acuity
2. Lens status
3. Intraocular pressure
4. Biomicroscopy findings
5. Adverse effects
6. Serum Blood Urea Nitrogen (BUN) and creatinine</secondaryOutcome>
      <trialWebsite>http://www.immusol.com/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Columbia University Institutional Review Board reviewed and approved research on the 31st July 2003 (reference number: AAA8110).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25825250</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>IM-VIT 100-01 (IND # 63,756)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, double-masked, placebo controlled, randomised clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1699ea0-d135-46c6-bcf7-3a21f1b87b8b">
	  <name>635 West 165th Street</name>
	  <address/>
	  <city>New York</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>10032</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with retinal detachment with Grade C or worse PVR who undergo vitrectomy for retinal reattachment:
1. Retinal detachment
2. Proliferative vitreoretinopathy (PVR) grade C or worse under direct visualisation
3. Visual acuity greater than no light perception
4. Aged at least 18 years
5. Patient willing and able to sign informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>170</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>170</totalTarget>
      <exclusion>1. Vision of no light perception
2. Presence of any uncontrolled, sight threatening concomitant eye disease
3. Severe non proliferative diabetic retinopathy or proliferative diabetic retinopathy according to Early Treatment Diabetic Retinopathy Study (ETDRS) criteria
4. Other pre-existing vaso-proliferative retinopathy
5. History of intraocular inflammatory disease
6. Retinoschisis detachment
7. Heredity vitreoretinopathies
8. Best corrected visual acuity less than 20/200 prior to onset of retinal detachment due to permanent pre-existing condition
9. Vision less than 5/200 or visual field less than 20 degrees in the fellow eye
10. Pregnant or nursing women or women of childbearing potential not using a reliable form of contraception
11. Concurrent participation in any other research study within 30 days of entry into the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Proliferative Vitreoretinopathy</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Proliferative Vitreoretinopathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients undergo retinal reattachment surgery with pars plana vitrectomy. Additional intraoperative procedures including scleral buckle placement or revision, pars plana lensectomy or limbal cataract extraction, Intraocular Lens (IOL) implantation or removal, temporary keratoprosthesis and penetrating keratoplasty, retinotomy, and/or gas or silicone oil tamponade could be performed at the discretion of the operating surgeon and required the assistance of an anterior segment specialist in certain cases.

All patients were to be randomly assigned to one of the three treatment groups: 0.75 mg or 0.15 mg VitrenAse and placebo (ratio 1:1:1). A single intravenous administration of VitrenAse or placebo was administered after the completion of the vitrectomy procedure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>VitrenAse (VIT100)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17846353 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c03cc984-b5ff-4406-a8da-44814ec9bb93" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17846353"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15341-0</funderId>
      <contactId>Contact53268_15341</contactId>
      <sponsorId>Sponsor51817</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53268_15341">
    <title>Dr</title>
    <forename>William</forename>
    <surname>Schiff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>635 West 165th Street</address>
      <city>New York</city>
      <country>United States of America</country>
      <zip>10032</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 212 305 5922</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wms13@columbia.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51817">
    <organisation>Immusol, Inc. (USA)</organisation>
    <website>http://www.immusol.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>10790 Roselle Street</address>
      <city>San Diego, CA</city>
      <country>United States of America</country>
      <zip>92121</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 858 824 1100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bsimon@immusol.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420473.6</gridId>
    <rorId>https://ror.org/03q43d318</rorId>
  </sponsor>
  <funder id="Funder15341-0">
    <name>Immusol, Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-07-14T00:00:00.000Z">33728802</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Labour support and evidence  based medicine: a randomised controlled trial of implementation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Providing women with evidence based maternity care, with provision of labour support as a focus, will improve the care of women during childbirth.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Whether women had a labour support person with them during labour.</primaryOutcome>
      <secondaryOutcome>Whether women during labour were:
1. Offered food or fluids
2. Left alone for long periods of time
3. Allowed to move during labour and delivery
4. Given an episiotomy
5. Given an enema
6. Shouted at
7. Struck or slapped
8. Unhappy with their care or percieved their care was bad</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Committee for Research on Human Subjects (Medical), University of the Witwatersrand on the 1st August 1998 (ref: M960512).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33728802</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>M960512</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="74bc46ec-6ffe-49b4-8cef-1f618d01ea0a">
	  <name>Effective Care Research Unit</name>
	  <address/>
	  <city>East London</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>5201</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Maternity units within Gauteng Province, South Africa, that delivered a minimum of 150 women per month.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10 maternity units</totalTarget>
      <exclusion>Maternity units within Gauteng Province, South Africa, that were directly linked to a university teaching scheme.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Support during labour and evidence based medicine</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Labour</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two educational interventions for maternity staff: one focused on provision of labour support and the other on accessing evidence based maternity care information.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17470267 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ddbdea08-bf7d-404f-b55b-396859ea2d88" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17470267"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15217-0</funderId>
      <funderId>Funder15217-1</funderId>
      <funderId>Funder15217-2</funderId>
      <funderId>Funder15217-3</funderId>
      <contactId>Contact53115_15217</contactId>
      <sponsorId>Sponsor51657</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53115_15217">
    <title>Prof</title>
    <forename>Justus</forename>
    <surname>Hofmeyr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Effective Care Research Unit
University of the Witwatersrand/University of Fort Hare/East London Hospital Complex
P Bag X9047</address>
      <city>East London </city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51657">
    <organisation>Effective Care Research Unit (South Africa)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>University of the Witwatersrand/University of Fort Hare/East London Hospital Complex
P Bag X9047</address>
      <city>East London</city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11951.3d</gridId>
    <rorId>https://ror.org/03rp50x72</rorId>
  </sponsor>
  <funder id="Funder15217-0">
    <name>Department for International Development (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15217-1">
    <name>Medical Research Council (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
  <funder id="Funder15217-2">
    <name>International Childbirth Educators Association (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15217-3">
    <name>Johnson and Johnson (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-29T00:00:00.000Z">29920470</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Patients with chronic idiopathic axonal polyneuropathy: relationships in the disablement process</title>
      <scientificTitle/>
      <acronym>EXAMPLE part II</acronym>
      <studyHypothesis>1. A specific set of variables of impairments are related or predictive of functional limitations and disabilities
2. A specific set of variables of functional limitations are related or predictive of disabilities
3. Psychological variables (defined by theory of planned behaviour [TPB], anxiety and depression) add to impairment variables in the prediction of functional limitation (in self-report and performance measures)
4. These psychological variables mediate the relationship between impairment and functional limitations</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Parameters of four domains of the disablement process will be measured:
1. Impairment: muscle strength (hand-held dynamometry), balance (Berg balance scale), sensory function (sensory modality score), pain (McGill pain questionnaire), fatigue (fatigue severity scale)
2. Functional limitations: walking (modified shuttle walk test), physical functioning (physical functioning performance 10 test), hand functioning (button test and disabilities of the arm, shoulder, and hand questionnaire), physical activity (DigiWalker stepcounter), problematic activities (McMaster-Toronto arthritis patient function preference questionnaire)
3. Disability: autonomy and participation (impact on participation and  autonomy questionnaire and Rankin score)
4. Intra-individual risk factor: cognitions; intentions and perceptions of control (TPB questionnaire), emotions (hospital anxiety and depression scale)</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN29920470</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Longitudinal study; one patient group with CIAP in which the health status will be monitored</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e586c4d4-6226-4dc0-94b7-ee0545d7b078">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic idiopathic axonal polyneuropathy (CIAP), diagnosed on established criteria
2. Patients who write and speak the Dutch language well
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Relevant co-morbidity, expected to influence the test results
2. Anticipated health risks during performance-based testing</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic idiopathic axonal polyneuropathy (CIAP)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Chronic idiopathic axonal polyneuropathy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>None: this is a longitudinal study with one patient group with chronic idiopathic axonal polyneuropathy (CIAP), in which the health status will be monitored</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15193-0</funderId>
      <contactId>Contact53075_15193</contactId>
      <sponsorId>Sponsor51625</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53075_15193">
    <title>Dr</title>
    <forename>N.L.U.</forename>
    <surname>van Meeteren</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht
Department of Neurology and Neurosurgery
Rudolf Magnus Institute of Neuroscience
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">n.vanmeeteren@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51625">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Rehabilitation
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15193-0">
    <name>University Medical Center Utrecht (UMCU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-06-19T00:00:00.000Z">34091554</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, randomised, crossover study to investigate the difference in frequency of episodes of hypoglycaemia during treatment with Biphasic Insulin Aspart 30 (NovoMix®30) compared to Biphasic Human Insulin 30 (Mixtard® 30) in patients with well-controlled, type 2 diabetes</title>
      <scientificTitle/>
      <acronym>REACH</acronym>
      <studyHypothesis>The trial is a double-blind, two-period cross-over, randomised, multicentre trial in insulin-treated subjects with type-2 diabetes comparing the efficacy and safety of NovoMix® 30 and Mixtard® 30.
Patients will first complete a screening and run-in period lasting eight weeks during which their current insulin dose will be adjusted to achieve pre-breakfast and pre-evening meal blood glucose levels of 5-7 mmol/l.
Patients who achieve an HbA1c of 6.5-8.5% at the end of the run-in period will be randomly allocated to treatment with either NovoMix® 30 or Mixtard® 30 for a 16-week treatment period.
At the end of this period patients will be crossed over to the alternative treatment. The second crossover period will also last for 16 weeks. Both insulin regimens will involve administration just before meals. Total duration of the trial will be 40 weeks. Patients will self-check blood-glucose levels daily. Insulin total dosage will be adjusted by a maximum of either plus or minus 10% using the following algorithm in order to improve blood-glucose profiles, based on the targets stated above. The primary assessment variable will be the number of glucose readings below 3.5 mmol/l as measured by continuous glucose monitoring system overview (CGMS) during two 72-hour periods mid-way through and at the end of each treatment period.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Frequency of hypoglycaemic episodes measured by CGMS for three days.</primaryOutcome>
      <secondaryOutcome>1. Frequency of reported severe hypoglycaemic episodes, minor hypoglycaemic events and nocturnal hypoglycaemia, during the last 12 weeks of each treatment period
2. HbA1c
3. Diabetes treatment satisfaction questionnaire 
4. Adverse event recording</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by South East Multicentre Research Ethics Committee (MREC) on 03/05/2002 reference number: MREC 01/1/67</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34091554</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BIAsp-1466</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, randomised, crossover study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-11-07T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8cd93d74-89eb-4534-b89b-af8e7b8fae7f">
	  <name>Department of Diabetes and Endocrinology</name>
	  <address/>
	  <city>Leicester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LE1 5WW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 160 male or female, adult subjects, with type 2 diabetes and treated with 1 - 3 injections of insulin daily for at least six months
2. HbA1c less than 9.5% at screening and 6.5 - 8.5 at randomisation
3. Judged by the investigator to be eligible for a twice a day (BID) mixed-insulin treatment regimen</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Impaired hepatic, renal or cardiac function
2. Concomitant oral hypoglycaemic agents
3. History of frequent severe hypoglycaemic episodes requiring external assistance within the last six months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-11-07T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 diabetes requiring insulin</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Crossover trial comparing the glucose control of using NovoMix® 30 to Mixtard® 30.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Biphasic Insulin Aspart 30 (NovoMix® 30), Biphasic Human Insulin 30 (Mixtard® 30)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17277042 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a2c8e56c-dc35-46ff-9406-1f39445eb270" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17277042"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15110-0</funderId>
      <contactId>Contact52963_15110</contactId>
      <sponsorId>Sponsor51512</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52963_15110">
    <title>Prof</title>
    <forename>Paul</forename>
    <surname>McNally</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Diabetes and Endocrinology
Leicester Infirmary Close</address>
      <city>Leicester</city>
      <country>United Kingdom</country>
      <zip>LE1 5WW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51512">
    <organisation>Novo Nordisk Ltd (UK)</organisation>
    <website>http://www.novonordisk.co.uk</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Broadfield Park
Brighton Road</address>
      <city>Crawley</city>
      <country>United Kingdom</country>
      <zip>RH11 9RT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1293 613555</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gcom@novonordisk.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.436696.8</gridId>
    <rorId>https://ror.org/0415cr103</rorId>
  </sponsor>
  <funder id="Funder15110-0">
    <name>Novo Nordisk Ltd (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-03-07T00:00:00.000Z">87656977</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intravenous and oral administration of amiodarone for the management of recent onset atrial fibrillation (AF): a randomized, digoxin and disopyramide controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To confirm if oral amiodarone is as effective as intravenous amiodarone in restoring sinus rhythm in patients with recent AF.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Restoration of sinus rhythm</primaryOutcome>
      <secondaryOutcome>Blood pressure monitoring</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Provided by the Ethics Committee of the Medical School of the University of Athens on 12/03/1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87656977</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-04-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1ed34b82-020f-43a4-95e1-fd3dc499ec3e">
	  <name>15B Agiou Thoma street</name>
	  <address/>
	  <city>Athens</city>
	  <state/>
	  <country>Greece</country>
	  <zip>11527</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with recent onset atrial fibrillation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>223</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>223</totalTarget>
      <exclusion>1.  Age &lt;18 years
2.  Baseline systolic blood pressure &lt;100 mmHg
3.  Known thyroid disease
4.  Serum potassium &lt;3.5 mmol/l
5.  Pre-treatment with any antiarrhythmic drug
6.  Documented permanent AF
7.  Atrial flutter and corrected heart rate (QTc) interval &gt;440 msec
8.  The duration of tachyarrhythmia estimated by medical history
9.  The current guidelines regarding prevention of thromboembolism are also followed</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-04-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Atrial fibrillation</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Atrial fibrillation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients, a total number of 338 received digoxin and disopyramide and if this restored sinus rhythm within two hours, they were excluded from the study.
Patients were randomized into two groups. One group received intravenous amiodarone
and the other group received oral amiodarone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>amiodarone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17434635 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="234302d4-4145-4ce1-aaad-b2823cf9c6ad" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17434635"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14738-0</funderId>
      <contactId>Contact52503_14738</contactId>
      <sponsorId>Sponsor51018</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52503_14738">
    <title>Dr</title>
    <forename>Theodoros</forename>
    <surname>Xanthos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>15B Agiou Thoma street</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 (0)2107462550</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">theodorosxanthos@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51018">
    <organisation>Greek National Health Service (Greece)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>15B Agiou Thoma street</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 (0) 2107462501</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dperrea@med.uoa.gr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14738-0">
    <name>Greek National Health Service</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-13T00:00:00.000Z">91576704</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Intranasal calcitonin can be effective in the treatment of acute Charcot foot.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Effect on bone remodeling markers
2. Markers of disease activity - skin temperature</primaryOutcome>
      <secondaryOutcome>1. Prevention of deformities
2. Shortening of the treatment
3. Recurrence of Charcot foot</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethics committee, and all participants gave written informed consent.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91576704</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MZO00023001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Czech Republic</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cde2359c-64fb-4dc1-8ee7-7196d95f4bff">
	  <name>Videnska 1958/9</name>
	  <address/>
	  <city>Prague 4</city>
	  <state/>
	  <country>Czech Republic</country>
	  <zip>14021</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute Charcot foot
2. Type 1 or Type 2 Diabetes</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Foot ulcer
2. Acute osteomyelitis</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetic Foot</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Acute charcot foot</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intranasal Calcitonin 200 IU + Calcium 1000 mg per day or Calcium 1000 mg per day in monotherapy; two years follow-up period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Calcitonin, calcium</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14563-0</funderId>
      <contactId>Contact52297_14563</contactId>
      <sponsorId>Sponsor50784</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52297_14563">
    <title>Dr</title>
    <forename>Robert</forename>
    <surname>Bem</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Videnska 1958/9</address>
      <city>Prague 4</city>
      <country>Czech Republic</country>
      <zip>14021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50784">
    <organisation>Institute for Clinical and Experimental Medicine (Czech Republic)</organisation>
    <website>http://www.ikem.cz</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Videnska 1958/9</address>
      <city>Prague 4</city>
      <country>Czech Republic</country>
      <zip>14021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418930.7</gridId>
    <rorId>https://ror.org/036zr1b90</rorId>
  </sponsor>
  <funder id="Funder14563-0">
    <name>Institute for Clinical and Experimental Medicine MZO00023001 (Czech Republic)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-16T00:00:00.000Z">28317455</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A controlled trial of the effectiveness of a diabetes education programme in a multi-ethnic community in Glasgow</title>
      <scientificTitle/>
      <acronym>KAP (knowledge-attitude-practice)</acronym>
      <studyHypothesis>Educational intervention could improve the knowledge and attitudes of people from ethnic minority group with diabetes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Knowledge-attitude-practice.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Greater Glasgow Community/Primary Care local Research Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28317455</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial (block design)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b750205e-fc90-41a4-9e6c-9d8088f1fc96">
	  <name>Educational &amp; Development Centre</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>14496</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All people with diabetes from ethnic minority group aged over 30 years.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>329</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>329</totalTarget>
      <exclusion>1. Disabled
2. Blind
3. Not willing to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Educational programme compared to usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16709243 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="208cb9ff-5d98-4296-8d6a-2efdcd4239b0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16709243"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14271-0</funderId>
      <funderId>Funder14271-1</funderId>
      <funderId>Funder14271-2</funderId>
      <contactId>Contact52008_14271</contactId>
      <sponsorId>Sponsor50441</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52008_14271">
    <title>Dr</title>
    <forename>Hamid Reza</forename>
    <surname>Baradaran</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Educational &amp; Development Centre
Iran University of Medical Sciences
P.O. Box 14155-5983</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14496</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 8805 2252</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">baradaran@iums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50441">
    <organisation>Iran University of Medical Sciences (Iran) </organisation>
    <website>http://www.iums.ac.ir</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Educational &amp; Development Centre
Iran University of Medical Sciences
P.O. Box 14155-5983</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14496</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 8805 2252</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">baradaran@iuma.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411746.1</gridId>
    <rorId>https://ror.org/03w04rv71</rorId>
  </sponsor>
  <funder id="Funder14271-0">
    <name>Iran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14271-1">
    <name>University of Glasgow (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000853</fundRef>
  </funder>
  <funder id="Funder14271-2">
    <name>NHS Scotland (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-11-17T00:00:00.000Z">28535118</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bowel preparation or not in elective colon surgery</title>
      <scientificTitle/>
      <acronym>Boniec</acronym>
      <studyHypothesis>Postoperative complication rate in the bowel preparation group is the same as in the non-bowel preparation group (null hypothesis).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mortality within 30 days postop
2. Local infectious complications
3. Cardiovascular complications</primaryOutcome>
      <secondaryOutcome>1. Postop bleeding
2. Reoperation
3. General infectious complications
4. Length of postop hospital stay
5. Rehospitalisation within 30 days postop</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28535118</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3734e404-b7bd-4657-9530-36df8cab668b">
	  <name>Kirurg Kliniken</name>
	  <address/>
	  <city>Umeå</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>90185</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient aged 18 - 85 years
2. Elective resection for cancer, adenoma or diverticular disease
3. Survival over 6 months foreseen
4. Written consent after written and spoken information</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1500</totalTarget>
      <exclusion>Bowel preparation given preoperatively from other reasons than surgery.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Elective colon surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colon surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study compares colon surgery with preoperatively given bowel preparation (standard today) with no given bowel preparation preoperatively.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17514668 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ebef58f9-ba8a-4d24-ad8b-6b6fccf315b6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17514668"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13290-0</funderId>
      <contactId>Contact50898_13290</contactId>
      <sponsorId>Sponsor49286</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50898_13290">
    <title>Prof</title>
    <forename>Erik</forename>
    <surname>Nilsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kirurg Kliniken
Norrlands Universitetssjukhus</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>90185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">erik.nilsson@surgery.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49286">
    <organisation>Umea University/The Health Research Council of South-East of Sweden (FORSS Sydöstra sjukvårdsregionen) (Sweden)</organisation>
    <website/>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Norrlands Universitetssjukhus</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>90185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.naredi@surgery.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.12650.30</gridId>
    <rorId>https://ror.org/05kb8h459</rorId>
  </sponsor>
  <funder id="Funder13290-0">
    <name>The Health Research Council of South-East of Sweden (FORSS Sydöstra sjukvårdsregionen) (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">75125874</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised phase III clinical trial in patients radically operated for stage III melanoma (American Joint Committee on Cancer [AJCC]): comparison between Interferon (IFN) alpha-2b (sec Eastern Cooperative Oncology Group [ECOG] 1684) versus intensified Interferon alpha-2b</title>
      <scientificTitle/>
      <acronym>IMI - Mel.A.</acronym>
      <studyHypothesis>To verify if intensive intravenously IFN regimen is better than ECOG 1684 IFN regimen in patients with high risk melanoma (Stage III AJCC).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Overall survival</primaryOutcome>
      <secondaryOutcome>1. Toxicity
2. Disease free survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75125874</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3e559ea-618c-44f1-81da-28a5cd953ff1">
	  <name>Medical Oncology Unit</name>
	  <address/>
	  <city>Venezia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>30100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Primary melanoma of any tumour stage in presence of N1 regional lymph node metastases detected at elective or selective lymph node dissection with clinically not apparent regional lymph node metastases (designed CS1PS2, any TpN1M0)
2. Clinically apparent N1 regional lymph node involvement synchronous with primary melanoma of T1-4 (designed CS2PS2, any TcN1M0)
3. Regional lymph node recurrence at any interval after appropriate surgery for primary melanoma of any depth (designed CS2R, TxrN1M0)
4. ECOG performance status (PS) zero to one
5. Age 18 to 70
6. Absence of active medical or psychiatric troubles requiring medical or pharmacological interventions
7. Absence of thyroid or auto-immune pathology
8. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>328</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>328 patients</totalTarget>
      <exclusion>1. Patients with non-cutaneous primary melanoma
2. Clinical or pathological evidence of not completely resected melanoma or of lymph-node metastases
3. Clinical history of progressed neoplasia, except for the in situ carcinoma of the cervix and of radically treated basal carcinomas
4. Patients requiring a continuous treatment with steroids, non-steroid antiinflammatory drugs or other inhibitors of the prostaglandins synthesis, antihistaminic (cimetidine, ranitidine, famotidine and nazatidine) or other known immunomodulators
5. Patients with history of (ventricular or supraventricular) heart rhythm troubles needing treatment, or congestive heart failure (class New York Heart Association [NYHA] more than two)
6. Patients with organic brain syndrome or significant deterioration of the basal cognitive function or with any psychiatric trouble which may hinder the complete participation in the protocol or which may be exacerbated from the IFN therapy (e.g. depression)
7. Patients previously submitted to adjuvant therapy, chemotherapy, immunotherapy, including any perfusion therapy before surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melanoma of cutaneous origin with regional lymph-node metastasis radically resected</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Melanoma of cutaneous origin with regional lymph-node metastasis radically resected</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dose-Dense/Dose-Intense arm: IFN alpha-2b 20 MU/m^2/day intravenously five days a week for four weeks, repeated for four times on weeks nine to 12, 17 to 20, 25 to 28

Standard arm: IFN alpha-2b 20 MU/m^2/day intravenously five days a week for four weeks followed by 10 MU/m^2 subcutaneously three times per week for 48 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Interferon alpha-2b</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16504154 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c43c2fa1-3e8d-4ff7-806f-f4ef988d0687" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-02-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16504154"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14151-0</funderId>
      <contactId>Contact51846_14151</contactId>
      <sponsorId>Sponsor50270</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51846_14151">
    <title>Dr</title>
    <forename>Adriano</forename>
    <surname>Paccagnella</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Oncology Unit
SS Giovanni e Paolo Hospital</address>
      <city>Venezia</city>
      <country>Italy</country>
      <zip>30100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">adriano.paccagnella@ulss12.ve.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50270">
    <organisation>Italian Melanoma Intergroup - IMI (Italy)</organisation>
    <website>http://www.imi-online.it</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Istituto Oncologico Romagnolo
Corso Mazzini 65</address>
      <city>Forlì</city>
      <country>Italy</country>
      <zip>47100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)543 35929</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cor.epiclin@unipd.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14151-0">
    <name>Non-profit trial, partially supported by Italian Melanoma Intergroup (IMI)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-17T00:00:00.000Z">31625370</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of POstoperative Nausea and Vomiting with metoclopramide and dexamethasone</title>
      <scientificTitle/>
      <acronym>MultiPONV</acronym>
      <studyHypothesis>A prophylactic treatment of postoperative nausea and vomiting consisting of an optimal dosage of metoclopramide combined with dexamethasone increases effectiveness and lowers side effects.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Occurrence of nausea and/or vomiting within 24 hours after the end of surgery.</primaryOutcome>
      <secondaryOutcome>1. Occurrence of post-operative nausea (PON) and vomiting (POV) separately
2. Frequency and severity of PON and POV
3. Time to first PONV event
4. Need of rescue medication
5. Frequency of hypotension and arrhythmia after intra-operative administration of the study drugs
6. Frequency and severity of adverse effects within 24 hours after the end of surgery: 
6.1. Headache
6.2. Dizziness
6.3. Drowsiness
6.4. Dry mouth
6.5. Itching
6.6. Flush
6.7. Urticaria
6.8. Restlessness
6.9. Extrapyramidal symptoms
6.10. Dyskinesia
6.11. Central-anticholinergic syndrome
6.12. Bradycardia/tachycardia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31625370</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8133f48d-1691-4391-8970-2dcb75ee7ae4">
	  <name>Liebigstr. 20</name>
	  <address/>
	  <city>Leipzig</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-04103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age greater than 18 years
2. Patient receives balanced anaesthesia (with intubation) or spinal, peridural, or combined spinal epidural anaesthesia for any of the following surgeries: 
2.1. Hysterectomy
2.2. Cholecystectomy
2.3. Hernia repair
2.4. Otorhinolaryngological surgery
2.5. Thyroid surgery
2.6. Total endoprothesis of the hip or knee
2.7. Arthroscopy
3. Patient is able to answer questions regarding symptoms (taking his/her physical, emotional and mental constitution, understanding and compliance into consideration)
4. Informed consent in writing</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>3000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>3000</totalTarget>
      <exclusion>1. Anaesthesiological risk level of American Society of Anaesthesiologists (ASA) IV
2. Presence of at least one of the following cardiac risk factors: 
2.1. Unstable angina pectoris
2.2. Heart failure with New York Heart Association (NYHA) greater than or equal to III and/or left ventricular ejection fraction (LVEF) less than 40%
2.3. Atrioventricular block grade II or III
3. Current treatment with any of the following: 
3.1. Study medication
3.2. Other anti-emetic drugs except ranitidine
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.4. Monoamine oxidase (MAO) inhibitors
3.5. Tricyclic antidepressants
3.6. Antiarrhythmics class I or III
4. Disposition of the patient to malignant hyperthermia, or known occurrence thereof
5. History of any of the following diseases: 
5.1. Parkinson's disease and other extrapyramidal-motoric impairment
5.2. Hepatic insufficiency (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] greater than 2 x upper normal value [UNV])
5.3. Renal insufficiency (Creatinine greater than 2 x UNV)
5.4. Phaeochromocytoma
5.5. Mechanical ileus
5.6. Epilepsy
6. Known anaphylaxis following any of the study drugs
7. Pregnancy or breast feeding
8. Participation in another therapeutic trial
9. Planned or foreseeable post-operative application of propofol
10. Planned or foreseeable post-operative artificial respiration
11. Planned or foreseeable leaving of a stomach tube post-operatively</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative nausea and/or vomiting following inhalational or regional anaesthesia.</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Postoperative nausea and vomiting</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomised to receive either of 0, 10, 25 or 50 mg metoclopramide in addition to 8 mg dexamethasone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Metoclopramide, dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16861255 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0723b4a0-ad4b-4e2c-9bbc-c94db2aa928f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16861255"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13519-0</funderId>
      <funderId>Funder13519-1</funderId>
      <contactId>Contact51177_13519</contactId>
      <sponsorId>Sponsor49576</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51177_13519">
    <title>Prof</title>
    <forename>Derk</forename>
    <surname>Olthoff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Liebigstr. 20</address>
      <city>Leipzig</city>
      <country>Germany</country>
      <zip>D-04103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)341 9717701</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olthoff@medizin.uni-leipzig.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49576">
    <organisation>University of Leipzig (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ritterstr. 26</address>
      <city>Leipzig</city>
      <country>Germany</country>
      <zip>D-04109</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)341 9730100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kanzler@uni-leipzig.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9647.c</gridId>
    <rorId>https://ror.org/03s7gtk40</rorId>
  </sponsor>
  <funder id="Funder13519-0">
    <name>Self-funded by the Department of Anaesthesiology and Intensive Care Medicine and by the Committee of Clinical Innovation of the University of Leipzig (Germany).</name>
    <fundRef/>
  </funder>
  <funder id="Funder13519-1">
    <name>Supply of the study drugs free of charge by the manufacturers.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">58354123</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of cryoanalgesia on pain perception during infiltration of local anaesthetic agents: a randomised double blind controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does cryoanalgesia used prior to injection of local anaesthetic agent, reduce pain perception during inflitration of the agents?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Level of pain perception during infiltration of local anaesthetic agents and the operative procedure</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58354123</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0515154546</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3987f7f0-117f-4013-84d4-eb02aa9749b8">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Harrow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HA1 3UJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients coming for hernia repairs under local anaesthetic in 'One-Stop Hernia Clinic' at ACAD will be requested to enter into trial on the day of arrival. Patient will be give complete information regarding the trial and will be explained that they are free no to enter if the so wish. Approximately 50 patients in each group.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Signs and Symptoms: Pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients from one-stop hernia clinic will be given the research protocol information sheet on arrival (i.e. one hour prior to surgery). Surgeons will explain the research and the operation and obtain an informed consent, for both the operation and entry into the trial. Surgeons will answer any and every patient query regarding the trial and the operation. Patients will have the right to withdraw from the trial at any point without explanation. Patients will be randomised alternately into:
1. The control group 
2. The trial group</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17567343 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e8bc8ef4-b09f-4005-b663-9b86969043ac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17567343"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14092-0</funderId>
      <contactId>Contact51716_14092</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51716_14092">
    <title>Mr</title>
    <forename>Raj</forename>
    <surname>Bhutiani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
North West London Hospitals NHS Trust
Northwick Park Hospital
Watford Road</address>
      <city>Harrow</city>
      <country>United Kingdom</country>
      <zip>HA1 3UJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14092-0">
    <name>North West London Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-09-28T00:00:00.000Z">38797445</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early goal directed therapy following major surgery reduces complications and duration of hospital stay: a randomised, controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>That post-operative goal directed therapy reduces the incidence of complications following major general surgery</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of post-operative complications.</primaryOutcome>
      <secondaryOutcome>Mortality and duration of hospital stay.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38797445</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="20558d9b-bfd6-4d94-a86f-af0fc96fdc6e">
	  <name>Intensive Care Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SW170QT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients aged 18 years or older presenting for major surgery expected to last more than one and a half hours were eligible for inclusion if one or more of the following criteria were satisfied before surgery:
1. Severe cardiac or respiratory illness resulting in severe functional limitation
2. Extensive surgery planned for carcinoma involving bowel anastamosis
3. Acute massive blood loss (greater than 2.5 l)
4. Aged over 70 years with moderate functional limitation of one or more organ systems
5. Septicaemia (positive blood cultures or septic focus)
6. Respiratory failure (partial pressure of oxygen in arterial blood [PaO2] less than 8 kPa on Fraction of inspired Oxygen [FiO2] greater than 0.4, i.e., PaO2 : FiO2 ratio less than 20 kPa or ventilation greater than 48 hours)
7. Acute abdominal catastrophe (e.g., pancreatitis, perforated viscous, gastro-intestinal bleed)
8. Acute renal failure (urea greater than or equal to 20 mmol/l, creatinine greater than 60 µmol/l)
9. Surgery for abdominal aortic aneurysm</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Refusal of consent
2. Pregnancy
3. Acute myocardial ischaemia prior to enrolment
4. Patients receiving palliative treatment only
5. Disseminated malignancy
6. Patients unlikely to survive more than 6 hours
7. Patients requiring intervention outside intensive care unit (ICU) within the first 6 hours following surgery
8. Patients on lithium therapy
9. Weight less than 40 kg</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major general surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Goal directed therapy protocol to achieve oxygen delivery index of 600 ml/min/m^2 compared to protocol designed to reflect standard care.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16356219 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1ef479b5-ef23-407a-badd-ff9402b688b7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16356219"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13596-0</funderId>
      <contactId>Contact51263_13596</contactId>
      <sponsorId>Sponsor49663</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51263_13596">
    <title>Dr</title>
    <forename>Rupert</forename>
    <surname>Pearse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Intensive Care Unit
1st Floor St James' Wing
St George's Hospital</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW170QT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)7718 910 440</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rupert.pearse@doctors.net.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49663">
    <organisation>St Georges Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Blackshaw Road</address>
      <city>London</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>SW17 0QT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.464688.0</gridId>
    <rorId>https://ror.org/0001ke483</rorId>
  </sponsor>
  <funder id="Funder13596-0">
    <name>The Intensive Care Research Fund managed by the St Georges Hospital charitable funds trustees (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-08-11T00:00:00.000Z">61546997</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial of a Lung-Open Ventilation Strategy in acute lung injury</title>
      <scientificTitle/>
      <acronym>LOVS</acronym>
      <studyHypothesis>The Lung Open Ventilation strategy may reduce mortality, other organ dysfunction, and the duration of mechanical ventilation, intensive care, and hospital stay.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Hospital Mortality</primaryOutcome>
      <secondaryOutcome>1. Mortality attributed to respiratory failure
2. Duration of respiratory failure and duration of mechanical failure
3. Evaluation of respiratory function during mechanical ventilation
4. Incidence of barotrauma
5. Non-respiratory organ dysfunction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Hamilton Health Sciences/McMaster University Research Ethics Board, 15/06/2004</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61546997</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00182195</clinicalTrialsGovNumber>
      <protocolSerialNumber>MCT-38141</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4fd5ebd5-b858-4f99-8a6a-8a33351f12c2">
	  <name>Clinical Epidemiology &amp; Biostatistics</name>
	  <address/>
	  <city>Hamilton, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>L8N 3Z5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Persons of either sex 18 years and older.
1. Invasive mechanical ventilation
2. Acute respiratory insufficiency (within past 28 days)
3. Bilateral infiltrates on frontal chest radiograph
4. Hypoxemia, defined as paO2/FiO2 less than or equal to 250, on any amount of Positive End-Expiratory Pressure (PEEP)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>980</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>980</totalTarget>
      <exclusion>1. Primary cause of respiratory failure is cardiac
2. Anticipated duration of mechanical ventilation &lt;48 hours, as judged by the intensivist
3. Inability to wean from other experimental ventilation strategies
4. Severe chronic respiratory disease
5. Neuromuscular disease that will result in prolonged need for mechanical ventilation
6. Conditions where hypercapnia-induced intracranial hypertension should be avoided
7. Morbid obesity (&gt;1 kg per cm body weight)
8. Pregnancy
9. Very unlikely to survive in the judgment of the investigator, and luck of commitment to life support
10. Malignancy or underlying irreversible condition with 6 month mortality greater than or equal to 50%
11. Greater than 48 hours elapsed since first eligible in study hospital
12. Current participation in competing trial
13. Lack of physician, patient or proxy consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Critically Ill Patients with Acute Lung Injury (ALI)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Acute lung injury (ALI)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control Ventilation Strategy (assist control; low tidal volume; low airway pressures; standard PEEP)
Experimental Lung Open Ventilation Strategy (pressure control; low tidal volumes; low airway pressures; high PEEP; recruitment maneuvers).

For further information, please contact Dr Meade at the address listed below or Dr Thomas Stewart at University of Toronto (tstewart@mtsinai.on.ca).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18270352 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4f995594-35de-4b90-a484-bf5d95991904" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-02-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18270352"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13359-0</funderId>
      <contactId>Contact50982_13359</contactId>
      <sponsorId>Sponsor49374</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50982_13359">
    <title>Dr</title>
    <forename>Maureen Ora</forename>
    <surname>Meade</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Epidemiology &amp; Biostatistics
McMaster University
Health Sciences Centre
Room 2C10
1200 Main Street West</address>
      <city>Hamilton, Ontario</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 525 9140 (22900)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">meadema@hhsc.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49374">
    <organisation>McMaster University (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1200 Main Street West</address>
      <city>Hamilton, Ontario</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 525 9140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">browna@mcmaster.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.25073.33</gridId>
    <rorId>https://ror.org/02fa3aq29</rorId>
  </sponsor>
  <funder id="Funder13359-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-38141)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-07-05T00:00:00.000Z">34957881</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in phacoemulsification</title>
      <scientificTitle/>
      <acronym>Ophthalmic viscosurgical devices</acronym>
      <studyHypothesis>To compare the efficacy and safety of three ophthalmic viscosurgical devices that are routinely used in phacoemulsification.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The safety and efficacy of the three viscosurgical devices namely Viscoat®, Healon GV® and Healon 5® in performing phacoemulsification is comparable.</primaryOutcome>
      <secondaryOutcome>Viscoat® can result in a mild transient rise in the intraocular pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34957881</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-27T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c8ba12ec-bfbd-42f2-8ea6-b921dc9e6e11">
	  <name>R. P. Centre</name>
	  <address/>
	  <city>New Delhi</city>
	  <state/>
	  <country>India</country>
	  <zip>110029</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. More than 40 years of age
2. Senile cataract
3. Nucleus hardness of grade 3/4
4. Not having any evidence of subluxation or pseudoexfoliation 
5. Not having any other associated ocular pathology</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>Pre-existing glaucoma and intraoperative events like manual dilatation of pupil, posterior capsular rent and placement of intraocular lens (IOL) in the sulcus</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-27T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Senile Cataract</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparing three viscosurgical devices namely Viscoat®, Healon GV® and Healon 5® in performing phacoemulsification.</description>
	<interventionType>Device</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16018819 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="07c75413-c31a-4ab6-a998-89645d3ccb29" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16018819"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13167-0</funderId>
      <contactId>Contact50732_13167</contactId>
      <sponsorId>Sponsor49118</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50732_13167">
    <title>Prof</title>
    <forename>Rasik</forename>
    <surname>Vajpayee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>R. P. Centre
AIIMS
Ansari Nagar</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49118">
    <organisation>All India Institute of Medical Sciences (AIIMS) (India) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>R. P. Centre
Ansari Nagar</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413618.9</gridId>
    <rorId>https://ror.org/02dwcqs71</rorId>
  </sponsor>
  <funder id="Funder13167-0">
    <name>All India Institute of Medical Sciences (AIIMS) (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-07-04T00:00:00.000Z">19227688</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Folate Activity Cognition Trial</title>
      <scientificTitle>The effects of physical activity and vitamin B supplementation on cognitive functioning and psychosocial health of older persons with mild cognitive impairment</scientificTitle>
      <acronym>FACT</acronym>
      <studyHypothesis>The aim of the study is to examine the effects of a walking programme and/or Folic Acid/B12/B6 supplementation on cognitive functioning and psychosocial health of older persons with mild cognitive impairment (MCI).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cognitive functioning.</primaryOutcome>
      <secondaryOutcome>1. Psychosocial health status
2. Physical activity
3. Physical fitness
4. Serum homocysteine levels</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the VU University Medical Center Medical Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19227688</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3cd1a040-b74b-47f7-91e4-7b529f5a9bd2">
	  <name>van der Boechorststraat 7</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. People aged 70 years or older 
2. MCI according to the criteria of Petersen:
2.1. Memory complaint
2.2. Objective memory impairment
2.3. Normal general cognitive function
2.4. Intact activities of daily living
2.5. Not demented
3. Recruited from the community</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>185</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>185</totalTarget>
      <exclusion>1. Diseases interfering with cognition 
2. Unable to participate in moderate-intensity physical activity</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild cognitive impairment (MCI)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Mild cognitive impairment (MCI)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Twice weekly brisk walking in a group at moderate intensity and/or daily supplementation with Folic Acid, vitamin B12 and B6.

Non-supplement groups receive a placebo supplement; non-walking groups will do stretching and relaxation exercises.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Folic Acid, vitamin B12 and B6 supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/16375760 Protocol
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18308888 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9fab1da8-1f70-4514-8343-e5fd3e2faac6" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2005-12-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16375760"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="91b1d0dd-4142-44e0-abd9-7f6b92bec2b7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18308888"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13114-0</funderId>
      <funderId>Funder13114-1</funderId>
      <funderId>Funder13114-2</funderId>
      <funderId>Funder13114-3</funderId>
      <funderId>Funder13114-4</funderId>
      <contactId>Contact50653_13114</contactId>
      <sponsorId>Sponsor49037</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50653_13114">
    <title>Dr</title>
    <forename>Marijke Jeanette Maidy</forename>
    <surname>Chin A Paw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 4448203</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.chinapaw@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49037">
    <organisation>Research Center on Physical Activity, Work and Health (The Netherlands)</organisation>
    <website>http://www.bodyatwork.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>TNO-VUmc  - Body@Work
van der Boechorststraat 7</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 8206</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.vanderleden@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13114-0">
    <name>Body@Work (The Netherlands) - Research Center Physical Activity, Work and Health</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-1">
    <name>The Netherlands Organisation for Applied Scientific Research (TNO) (The Netherlands) -VU University Medical Center (VUMC)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-2">
    <name>Fund for the Heart (Fonds voor het Hart) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-3">
    <name>Viatris B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13114-4">
    <name>Municipality of Alkmaar (Gemeente Alkmaar) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-20T00:00:00.000Z">56720616</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Glucose-insulin-potassium infusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction</title>
      <scientificTitle/>
      <acronym>Glucose-Insulin-Potassium Study (GIPS)</acronym>
      <studyHypothesis>In this study we considered the question of whether adjunction of glucose-insulin-potassium (GIK) infusion to primary coronary transluminal angioplasty (PTCA) is effective in patients with an acute myocardial infarction (MI).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>30-day mortality</primaryOutcome>
      <secondaryOutcome>Recurrent infarction, repeat coronary angioplasty, and the composite incidence of death, recurrent infarction, or repeat coronary angioplasty.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56720616</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>99.028</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4028f48b-ff9a-48f4-8bb9-279c40bbe0ac">
	  <name>Hanzeplein 1</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>30.001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All consecutive patients with symptoms consistent with acute MI of &gt;30 min duration, presenting within 24 hours after the onset of symptoms and with an ST-segment elevation of more than 1 mm (0.1 mV) in two or more contiguous leads on the electrocardiogram, or new onset left bundle branch block, were evaluated for inclusion in this single-center study. Patients presented at our center and patients referred for treatment of high-risk myocardial infarction (MI) from nine referring hospitals without angioplasty facilities were included.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>940</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>940</totalTarget>
      <exclusion>Patients were excluded when pre-treated with thrombolysis or when an illness associated with a marked restricted life expectancy was present.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>ST elevation myocardial infarction (mi)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Acute myocardial infarction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After admission, patients were randomly assigned to either glucose-insulin-potassium (GIK) infusion or no infusion. In patients randomized to GIK, a continuous infusion of 80 mmol potassium chloride in 500 ml 20% glucose with a rate of 3 ml/kg body weight/hour over an 8- to 12-hour period in a peripheral venous line was given, as soon as possible. A continuous infusion of short-acting insulin (50 U Actrapid) in 50 ml 0.9% sodiumchloride was started. Baseline insulin-infusion dose and hourly adjustments of the insulin dose were based on an algorithm to obtain blood-glucose levels between 7.0 and 11.0 mmol/l.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>glucose-insulin-potassium</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15932638 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0b4ff9e7-aa06-4e1a-86f4-5f65db4964a6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-06-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15932638"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13099-0</funderId>
      <contactId>Contact50636_13099</contactId>
      <sponsorId>Sponsor49020</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50636_13099">
    <title>Prof</title>
    <forename>Felix</forename>
    <surname>Zijlstra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>30.001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)503612355</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.zijlstra@thorax.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49020">
    <organisation>Netherlands Heart Foundation (Netherlands)</organisation>
    <website>http://www.hartstichting.nl/go/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Bordewijklaan 3</address>
      <city>The Hague</city>
      <country>Netherlands</country>
      <zip>300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)703155555</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@hartstichting.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453051.6</gridId>
    <rorId>https://ror.org/05nxhgm70</rorId>
  </sponsor>
  <funder id="Funder13099-0">
    <name>Netherlands Heart Foundation (99.028)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-05-16T00:00:00.000Z">74123635</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>TTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Preservation of visual acuity</primaryOutcome>
      <secondaryOutcome>Closure of CNV, OCT characteristics</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74123635</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Chile</country>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="71d49342-40fa-4991-b23e-59e0d9725f3c">
	  <name>Exequiel Fernández nº 920</name>
	  <address/>
	  <city>Santiago</city>
	  <state/>
	  <country>Chile</country>
	  <zip/>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Age-Related Macular Degeneration (ARMD) not available for current therapies</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Age-Related Macular Degeneration (ARMD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triamcinolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16309554 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ab1f915e-6d6b-4c40-bd5a-28e03b62b859" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16309554"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13065-0</funderId>
      <contactId>Contact50598_13065</contactId>
      <sponsorId>Sponsor48981</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50598_13065">
    <title>Dr</title>
    <forename>Ricardo</forename>
    <surname>Agurto-Rivera</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Exequiel Fernández nº 920
Casa F
Ñuñoa</address>
      <city>Santiago</city>
      <country>Chile</country>
      <zip/>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+56 8 5021968</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ricardo_agurto@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48981">
    <organisation>Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>04030</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 10841400</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">retinamex@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.464508.b</gridId>
    <rorId>https://ror.org/03sgfhr82</rorId>
  </sponsor>
  <funder id="Funder13065-0">
    <name>Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-05-16T00:00:00.000Z">18216584</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Patients prefer rizatriptan over ibuprofen for the acute treatment of migraine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Direction and strength of patient preference on a 10 cm scale ranging from -5 (strong preference for treatment 1) to +5 (strong preference for treatment 2) where 0 indicates no preference.</primaryOutcome>
      <secondaryOutcome>1. Pain free rate at 2 hours postdose
2. Migraine disability assessment (MIDAS) score at visit 1</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local Medical Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18216584</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR33</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, double dummy, crossover study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-09T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="27ce756e-0451-4ad2-8806-e6c84d21179c">
	  <name>Leiden University Medical Center</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. At least 18 years of age at visit 1
2. Current history of migraine with or without aura according to the International Headache Society (IHS) criteria
3. Experienced an average of at least one migraine attack per month for six months prior to entry to the study
4. Naïve to the use of 5HT1 agonists and ergotamine
5. Willing and able to understand and complete questionnaires
6. Willing and able to give informed consent prior to entry into the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>35</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>35</totalTarget>
      <exclusion>1. A history suggestive of ischaemic heart disease (IHD) (e.g. angina pectoris) or any atherosclerotic disease which places them at increased risk of coronary ischaemia
2. A history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
3. A history of hypertension or a current blood pressure above 160/95 mmHg (measured three times)
4. A history of basilar, hemiplegic or ophtalmoplegic migraine
5. Impaired hepatic or renal function
6. A history of gastrointestinal disease
7. A history of asthma
8. Have a known or suspected hypersensitivity to, intolerance of, or contraindications to any component of the study medication
9. Currently use propanolol as a prophylactic agent
10. Currently use monoamine oxidase (MAO) inhibitors
11. Currently abuse alcohol, analgesics or psychotropic drugs
12. A history of hypertension
13. Any severe concurrent medical condition, which may affect the interpretation in a clinical trial
14. Females who are pregnant or breastfeeding, and females of childbearing potential who are not using a medically acceptable form of contraception
15. Have participated in a clinical trial within the previous month or are currently participating in any other clinical research study or clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-09T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Thirty-five triptan naive patients treat three attacks within each crossover period with either:
1. Rizatriptan 10 mg
2. Ibuprofen 400 mg

Preference is measured after the second period on a 10 cm scale.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rizatriptan, ibuprofen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13094-0</funderId>
      <funderId>Funder13094-1</funderId>
      <contactId>Contact50632_13094</contactId>
      <sponsorId>Sponsor49015</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50632_13094">
    <title>Dr</title>
    <forename>N.J.</forename>
    <surname>Wiendels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center
Department of Neurology, K5Q-106
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 526 1730</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">N.J.Wiendels@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49015">
    <organisation>Merck Sharp and Dohme BV (MSD) (The Netherlands)</organisation>
    <website>http://www.msd.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 581</address>
      <city>Haarlem</city>
      <country>Netherlands</country>
      <zip>2003 PC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)23 515 3153</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">msdbvnl@merck.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420097.8</gridId>
    <rorId>https://ror.org/05y28vr04</rorId>
  </sponsor>
  <funder id="Funder13094-0">
    <name>Merck Sharp and Dohme BV (MSD) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13094-1">
    <name>Booth Healthcare International (The Netherlands) - now Reckittbenckiser</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-10T00:00:00.000Z">14751911</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee: a randomised controlled study</title>
      <scientificTitle/>
      <acronym>Knee study</acronym>
      <studyHypothesis>The study was designed to investigate the analgesic effects and mechanisms of acetaminophen (paracetamol) in symptomatic osteoarthritis (OA) of the knee.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The functional status of the knee joint was assessed by the Western Ontario McMaster Universities Osteoarthritis (WOMAC) questionnaire in German. Visits and measurements were scheduled upon entry (T0), month 1 (T1) and month 3 (T3).</primaryOutcome>
      <secondaryOutcome>The intensity of joint pain was evaluated by 100-mm visual analogue scale (VAS) at rest. Visits and measurements were scheduled upon entry (T0), month 1 (T1) and month 3 (T3).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethical committee (Kantonale Ethikkommission, Spezialisierte Unterkommission fur Spezialfa cher) (ref: 343)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14751911</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f1f0ea77-ae50-4e48-8d57-d18ca02c8d8c">
	  <name>Department of Rheumatology and Institute of Physical Medicine</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients and healthy subjects: 20 patients fulfilled the American College of Rheumatology criteria for knee OA accompanied with joint pain (visual analogue scale [VAS] ≥60) were recruited to the study. For control, blood from 20 age and gender-matched healthy subjects was obtained from a local blood bank, the Blutspenderdienst Zürich. All patients signed the informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Secondary OA as a consequence of inflammation, gout, pseudogout or tumour
2. Kidney insufficiency 
3. OA-influencing concomitant diseases
4. Drug medication with opioids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After washout of earlier OA medications, patients were randomly allocated into two groups treated with either acetaminophen up to 4 g per day (n = 10, age 60-77 years) or rofecoxib 25 mg per day (n = 10, age 48-80 years) for 3 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acetaminophen (paracetamol), rofecoxib</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16449370 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="60e83253-e59a-48c1-841c-129ea23c16aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16449370"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13063-0</funderId>
      <funderId>Funder13063-1</funderId>
      <contactId>Contact50596_13063</contactId>
      <sponsorId>Sponsor48979</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50596_13063">
    <title>Dr</title>
    <forename>Haiko</forename>
    <surname>Sprott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology and Institute of Physical Medicine
University Hospital Zurich
Gloriastrasse 25</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)44 2558679</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">haiko.sprott@usz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48979">
    <organisation>Merck Sharp and Dohme (MSD) (Switzerland)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Schaffhauserstrasse 136</address>
      <city>Glattbrugg</city>
      <country>Switzerland</country>
      <zip>8152</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)1 8287111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">claude_fischlewitz@merck.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.474492.8</gridId>
    <rorId>https://ror.org/009nc9s30</rorId>
  </sponsor>
  <funder id="Funder13063-0">
    <name>Merck Sharp and Dohme (MSD) (Switzerland) - gave a Medical School Grant in 2001 to perform the study, and provided the drug Vioxx (rofecoxib). The acetaminophen drugs and the other research costs were paid for from the grant.</name>
    <fundRef/>
  </funder>
  <funder id="Funder13063-1">
    <name>University Hospital Zurich (Switzerland) - provided the infrastructure</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-09T00:00:00.000Z">65784760</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The N-methyl-D-aspartate (NMDA)-antagonist memantine affects training induced motor cortex plasticity: a study using transcranial magnetic stimulation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Training of a repetitive synchronised movement of two limb muscles leads to short-term plastic changes in the primary motor cortex, which can be assessed by transcranial magnetic stimulation (TMS) mapping.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The differential effects of different treatment regimens.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65784760</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d41b3459-55cf-4d45-beb2-2e1c3b347b0f">
	  <name>Department of Neurology</name>
	  <address/>
	  <city>Bochum</city>
	  <state/>
	  <country>Germany</country>
	  <zip>44789</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy subjects (adults, either sex)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Left-handedness
2. Neurological disorders
3. Intake of central acting drugs</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Training induced motor cortex plasticity</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Memantine versus placebo either given as a single dose or daily over 8 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Memantine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15890074 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2579bdb5-216d-400c-b1d8-645495a47e5b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15890074"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13058-0</funderId>
      <funderId>Funder13058-1</funderId>
      <contactId>Contact50591_13058</contactId>
      <sponsorId>Sponsor48974</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50591_13058">
    <title>Prof</title>
    <forename>Martin</forename>
    <surname>Tegenthoff</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Neurology
BG-Kliniken Bergmannsheil
Buerkle-de-la-Camp-Platz 1</address>
      <city>Bochum</city>
      <country>Germany</country>
      <zip>44789</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48974">
    <organisation>BG-Kliniken Bergmannsheil (Germany) - Department of Neurology</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Buerkle-de-la-Camp-Platz 1</address>
      <city>Bochum</city>
      <country>Germany</country>
      <zip>44789</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412471.5</gridId>
    <rorId>https://ror.org/04j9bvy88</rorId>
  </sponsor>
  <funder id="Funder13058-0">
    <name>BG-Kliniken Bergmannsheil (Germany) - Department of Neurology; main funders</name>
    <fundRef/>
  </funder>
  <funder id="Funder13058-1">
    <name>Merz Pharmaceuticals GmbH (Germany) - funded the measurement of the memantine serum levels</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-05-09T00:00:00.000Z">68505294</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of moderate red wine consumption on antioxidant and redox-sensitive immunological parameters in healthy volunteers</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Moderate consumption of red wine shows antioxidant activity in vivo and modulates functions of the specific and unspecific immune response. The effects of native and dealcoholised red wine are compared to control intervention (short term: water; dietary intervention: no study drink).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Concentration of total phenolic compounds in plasma (folin assay)
2. Deoxyribonucleic acid (DNA) strand breaks in peripheral leukocytes (single cell gel electrophoresis)
3. Antioxidant capacity in plasma (trolox equivalent antioxidant capacity)
4. Apoptosis of PHA activated T lymphocytes (annexin-V binding test)
5. Phagocytosis in monocytes and granulocytes (Phagotest® test kit)
6. Respiratory burst in monocytes and granulocytes (Bursttest® test kit)</primaryOutcome>
      <secondaryOutcome>1. Vitamin C concentration in plasma a-tocopherol concentration in serum (dietary intervention trial only)
2. Concentration of uric acid, albumin and bilirubin in plasma</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ethics committee of the University of Bonn.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68505294</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="57757722-075d-4002-9711-7e89d8e3182c">
	  <name>Institute for Molecular Biotechnology</name>
	  <address/>
	  <city>Aachen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>52074</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy, normal-weight male and female subjects between 18 and 50 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>105</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>105</totalTarget>
      <exclusion>1. Pregnancy and lactation: women not taking oral contraceptives underwent a pregnancy test to exclude an unknown pregnancy before starting the intervention
2. Known diseases of the liver and pancreas or dysfunctions of the gastro-intestinal tract associated with maldigestion or malabsorption
3. Hypertension
4. Dysfunctions of the lipid metabolism
5. Hyperuricaemia/gout
6. Kidney dysfunctions
7. Autoimmune diseases
8. Diabetes mellitus type I or type II
9. Acute infectious diseases
10. Eating disorders
11. Allergy to hen's eggs (albumen used as finings in red wine)
12. Alcohol abuse (more than 40 g/day) or previous addiction to alcohol
13. Drug abuse
14. Tobacco smoking during the last 6 months prior to the study
15. Regular intake of pharmaceuticals, which influence the immune system and/or the antioxidant capacity in plasma (anti-inflammatory drugs including cortisol containing medications, immune stimulants) as well as intake of drugs which might cause adverse affects by interacts with alcohol
16. Intake of nutritional supplements e.g. multivitamins, supplements containing vitamin A, C and/or vitamin E, fish oil or red wine preparations, bioactive concentrates
17. Excessive exercising (competitive athletes) defined as greater than 10 hours strenous exercise per week
18. Limited contractual capability
19. Every other state opposed to participation in the study stated by the medical supervisor
20. Participation in any other clinical trial (ongoing or completed less than 30 days prior to the present study)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Oxidative stress in healthy subjects</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. One single dose (one glass) of red wine, dealcoholised red wine or water in a fasting state (Single dose analysis) OR
2. One glass of red wine, dealcoholised red wine or no special drink (controls) daily after dinner for a period of 6 weeks (dietary intervention trial)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16287499 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c18facfa-511b-4f88-a3c0-8b7e75ee98b1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16287499"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13022-0</funderId>
      <funderId>Funder13022-1</funderId>
      <funderId>Funder13022-2</funderId>
      <funderId>Funder13022-3</funderId>
      <contactId>Contact50552_13022</contactId>
      <sponsorId>Sponsor48931</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50552_13022">
    <title>Prof</title>
    <forename>Roland</forename>
    <surname>Goerlich</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Molecular Biotechnology
RWTH Aachen University
Worringerweg 1</address>
      <city>Aachen</city>
      <country>Germany</country>
      <zip>52074</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)241 8026627</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">goerlich@molbiotech.rwth-aachen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48931">
    <organisation>Institute for Molecular Biotechnology (Germany)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>RWTH Aachen University
Worringerweg 1</address>
      <city>Aachen</city>
      <country>Germany</country>
      <zip>52074</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder13022-0">
    <name>German Wine Academy (Deutsche Weinakademie) (Germany) - Funding</name>
    <fundRef/>
  </funder>
  <funder id="Funder13022-1">
    <name>Landesgraduiertenfoerderung Nordrheinwestfalen (Germany) - Scholarship</name>
    <fundRef/>
  </funder>
  <funder id="Funder13022-2">
    <name>Friedrich-Ebert-Stiftung (Germany) - Scholarship</name>
    <fundRef/>
  </funder>
  <funder id="Funder13022-3">
    <name>Staatliche Weinbaudomaene Marienthal (Germany) - Wine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-05-06T00:00:00.000Z">34467885</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Using the Internet to Improve Hypertension Care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Access to the website would decrease patient satisfaction with hypertension care</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Satisfaction with hypertension care</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34467885</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>R43HL074458-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0200a319-6d26-45e1-a44c-e4deb128f9bc">
	  <name>Jefferson Medical College</name>
	  <address/>
	  <city>Philadelphia</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>19107</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adults with self-reported hypertension.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: A patient activation website that provides computer-tailored hypertension feedback. The website asks questions and provides feedback that highlights areas where their care adheres to guidelines and areas where their care does not, and encourages patients to ask questions during doctor visits that would lead to changes in their hypertension care. The feedback is based on standard guidelines for the treatment of hypertension and the feedback suggests specific questions that patients should ask during doctor visits, in order to receive higher quality care.

Control: A delayed treatment control. Control subjects got access to the website after completing the follow-up measures.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder13052-0</funderId>
      <contactId>Contact50584_13052</contactId>
      <sponsorId>Sponsor48965</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50584_13052">
    <title>Dr</title>
    <forename>Christopher</forename>
    <surname>Sciamanna</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Jefferson Medical College
Department of Health Policy
1015 Walnut Street, Suite 115</address>
      <city>Philadelphia</city>
      <country>United States of America</country>
      <zip>19107</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48965">
    <organisation>The National Heart, Lung, and Blood Institute (USA) </organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>NHLBI Health Information Center
P.O. Box 30105</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20824-0105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.279885.9</gridId>
    <rorId>https://ror.org/012pb6c26</rorId>
  </sponsor>
  <funder id="Funder13052-0">
    <name>The National Heart, Lung, and Blood Institute (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-03T00:00:00.000Z">74938765</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Increasing weight-bearing physical activity and calcium-rich foods to promote bone mass gains among 9-11 year old girls: the Cal Girls study</title>
      <scientificTitle/>
      <acronym>Cal Girls</acronym>
      <studyHypothesis>It was hypothesised that the behavioural intervention would result in increases in dietary Calcium (Ca) intake and weight-bearing physical activity (PA), and in the rate of bone mass accrual. Innovative aspects of the present study included:
1. Its focus on changing eating and PA behaviors to increase bone mass growth
2. Its focus on pre-adolescent girls, a group at risk for declines in Ca intake and PA levels as they develop into adolescence
3. Its unique collaboration with a community-based organisation (the Girl Scouts of America) as a channel to implement a health behaviour intervention</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in areal bone mineral content (aBMC) was the primary outcome variable for the study because it best reflects bone mass change in developing children.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was reviewed and approved by the University of Minnesota Research Participants Internal Review Board.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74938765</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>R01 HD 037743</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d6f180e3-eefc-41eb-923f-0c19594eefe4">
	  <name>Division of Epidemiology</name>
	  <address/>
	  <city>Minneapolis</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>55454</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>30 5th-grade Girl Scout troops from the Minneapolis and St Paul metropolitan area were recruited to take part in the study through mailed fliers to troop leaders and troop leader meeting announcements. Troop eligibility criteria were:
1. Troop size greater than or equal to 8 girls
2. Parental consent and girl assent from each troop member to participate in troop meetings with intervention program activities
3. Troop plans to remain together at minimum two more years</inclusion>
      <ageRange>Child</ageRange>
      <gender>Female</gender>
      <targetEnrolment>322</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>322</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoporosis prevention</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoporosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Thirty 5th-grade Girl Scout troops were recruited and randomised to a two-year behavioural intervention program (n = 15 troops) or to a no-treatment control group (n = 15 troops). The behavioural program was implemented during 5th and 6th grades by trained troop leaders as part of the regular troop meetings. The intervention program was based on Social Cognitive Theory and consisted of ten 90-minute activity-based sessions during each of the two years. It focused on the development of behavioural skills to choose Ca-rich foods and to engage in weight-bearing physical activity. Behavioural goals for the intervention were to
increase daily dietary Ca intake to 1300 mg/day (increase of 4 daily servings of Ca rich foods; about 800 Ca mg/day) and to increase weight-bearing physical activity to 120 minutes per week. A continuously available, interactive web-based program, and a one-week summer camp between 5th and 6th grade years, were implemented as components of the intervention program. Parents were also targeted through the web-based program.

Control troops did not receive any program and conducted their usual troop meeting activities during the two-year intervention period.

Evaluation was conducted with individual girls and a parent at clinic visits at baseline prior to randomisation, at one-year follow-up, and at the end of the study (two year follow-up).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16029507 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f6593532-6cf3-463e-ab23-2da52ddb2666" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16029507"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13042-0</funderId>
      <contactId>Contact50573_13042</contactId>
      <sponsorId>Sponsor48953</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50573_13042">
    <title>Prof</title>
    <forename>Simone</forename>
    <surname>French</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Epidemiology
&amp; Community Health
1300 S 2nd St, #300</address>
      <city>Minneapolis</city>
      <country>United States of America</country>
      <zip>55454</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 612 626 8495</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">french@epi.umn.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48953">
    <organisation>University of Minnesota (USA)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Division of Epidemiology
&amp; Community Health
1300 S 2nd St, #300</address>
      <city>Minneapolis</city>
      <country>United States of America</country>
      <zip>55454</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 612 624 1818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">french@epi.umn.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.17635.36</gridId>
    <rorId>https://ror.org/017zqws13</rorId>
  </sponsor>
  <funder id="Funder13042-0">
    <name>National Insititutes of Health (NIH) (USA) (ref: R01 HD 037743)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-04-20T00:00:00.000Z">46561076</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of racemic epinephrine versus salbutamol for treatment of respiratory distress in bronchiolitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Aerosolised racemic epinephrine given to hospitalised children under two years of age with bronchiolitis is more effective than aerosolised salbutomol in relieving respiratory distress.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Wheezing and retractions measured by the Respiratory Distress Assessment Instrument each day during hospitalisation.</primaryOutcome>
      <secondaryOutcome>1. Length of stay
2. RSV antigen detection test
3. Feeding pattern
4. Adverse events
5. Parental report of feeding and respiratory status one week after discharge</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the Ethics Review Board at both participating institutions.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46561076</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41006c83-d0b9-421b-b37c-45974e5ef0d1">
	  <name>5850 University Avenue</name>
	  <address/>
	  <city>Halifax, Nova Scotia</city>
	  <state/>
	  <country>Canada</country>
	  <zip>B3K 6R8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children less than two years of age with first episode wheezing.</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="2.0"/>
      <gender>Both</gender>
      <targetEnrolment>62</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>62</totalTarget>
      <exclusion>Children were not eligible for enrollment if they:
1. Had a previous diagnosis of asthma
2. Were critically ill
3. Had chronic pulmonary or cardiac disease

Other exclusion criteria included: 
4. Allergy to sodium metabisulfite
5. Presence of tachycardia exceeding 200 beats per minute
6. Use of glucocorticoids
7. Sympathomimetic amines or monoamine oxidase inhibitor therapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bronchiolitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Bronchiolitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Racemic epinephrine or salbutamol.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Racemic epinephrine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15876347 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="29bd801c-8692-4bb9-9a6a-d9c1da545ed7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15876347"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13009-0</funderId>
      <funderId>Funder13009-1</funderId>
      <contactId>Contact50536_13009</contactId>
      <sponsorId>Sponsor48914</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50536_13009">
    <title>Dr</title>
    <forename>Joanne</forename>
    <surname>Langley</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>5850 University Avenue</address>
      <city>Halifax, Nova Scotia</city>
      <country>Canada</country>
      <zip>B3K 6R8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48914">
    <organisation>Lung Association of Nova Scotia (Canada)</organisation>
    <website>http://www.ns.lung.ca/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>17 Alma Crescent</address>
      <city>Halifax, Nova Scotia</city>
      <country>Canada</country>
      <zip>B3N 3E6</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder13009-0">
    <name>Lung Association of Nova Scotia (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13009-1">
    <name>IWK Health Center Research Office (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-04-19T00:00:00.000Z">77370654</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of the efficacy of pimecrolimus 1% cream and hydrocortisone 1% cream in facial seborrheic dermatitis: a single-blind randomized clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pimecrolimus 1% cream improves facial seborrheic dermatitis better than hydrocortisone 1% cream</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical response (erythema, pruritis, scaling) at 2, 4 and 6 weeks after treatment
2. Patient's general perception about treatment result 
3. Adverse events in each treatment group</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77370654</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0bd15087-5885-4149-860d-a9d8b21126d8">
	  <name>79 Taleghani Avenue</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>14166</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with facial seborrheic dermatitis older than 8 years.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Presence of active malignancy on the facial lesion
2. Presence of any kind of active viral skin disease on the facial lesion
3. Use of oral steroids in the past two weeks
4. Use of psoralen plus ultraviolet A (PUVA), ultraviolet B (UVB), ultraviolet A (UVA), azathioprine or cyclosporin in past month
5. Application of any topical treatment in past week 
6. Use of any systemic antibiotics or antifungals in past 2 weeks 
7. Attending in any other research study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seborrheic dermatitis</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Dermatitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: pimecrolimus 1% cream applied twice daily for 2 weeks
Group 2: hydrocortisone acetate 1% cream applied twice daily for 2 weeks</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pimecrolimus, hydrocortisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16924062 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5cc13c41-6e12-4f5e-87eb-fd16d546d581" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16924062"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12862-0</funderId>
      <contactId>Contact50356_12862</contactId>
      <sponsorId>Sponsor48725</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50356_12862">
    <title>Dr</title>
    <forename>Alireza</forename>
    <surname>Firooz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>79 Taleghani Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14166</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 21 8978190</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">firozali@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48725">
    <organisation>Tehran University of Medical Sciences (Iran) - Center for Research and Training in Skin Diseases and Leprosy </organisation>
    <website>http://www.tums.ac.ir/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>79 Taleghani Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14166</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder12862-0">
    <name>Tehran University of Medical Sciences (Iran) - Center for Research and Training in Skin Diseases and Leprosy</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-04-19T00:00:00.000Z">41671411</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Decreased salivary flow rate as a dipsogenic factor in haemodialysis patients: a pilocarpine clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We conducted a 3-month prospective observational study followed by a trial of pilocarpine - a parasympathomimetic agent shown to effectively increase salivary flow in radiation-induced xerostomia or Sjögren syndrome (27 - 30) - to determine whether the reduction of salivary flow contributes to exaggerated thirst and excess interdialytic weight gain (IDWG) in haemodialysis (HD) patients, and whether pilocarpine can alleviate it.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes were:
1. Changes in the visual analogue scale (VAS) scores of xerostomia, thirst, and stress of fluid restriction
2. Unstimulated salivary flow rate (UWS)
3. Mean IDWG2days and IDWG3days in each intervention period</primaryOutcome>
      <secondaryOutcome>The secondary outcomes were:
1. Changes in mean blood pressure
2. Adverse events
3. Blood test results</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by ethics committees of National Cheng Kung University Hospital and Kuo&#146;s General Hospital, Tainan, Taiwan, and adhered to the Declaration of Helsinki.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41671411</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bf4c118e-034c-4044-847e-81dfe98b8c66">
	  <name>138 Shing-Li Road</name>
	  <address/>
	  <city>Tainan</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>70428</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>In the observational study, we collected prospective data for 3 consecutive months (December 2002 to February 2003) from 90 participants recruited from a pool of 217 patients undergoing HD at the outpatient dialysis unit of the Kuo's General Hospital. Inclusion criteria included: 
1. Maintenance HD three times weekly for at least 6 months
2. Over 18 years of age
3. Daily urine output less than 200 ml
4. Stable clinical condition with stable dry weight and hematocrit

The inclusion and exclusion criteria for the intervention study (March to October 2003), were the same as those for the observation study except that: 
5. Only hyperdipsic patients (IDWG % greater than 2%/day) were included
6. Patients using the xerogenic mediations were included if these drugs could be stopped at least 14 days before entering and throughout the interventional study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Haemodynamic instability preventing sufficient ultrafiltration
2. Hospitalisation within the preceding 3 months
3. Dementia or terminal diseases
4. Those not feasible to investigate for logistic reasons
5. Depression or anxiety (which cause xerostomia possibly due to the dysfunction of both brain and salivary glands)
6. Using xerogenic mediations (including anticholinergies, antidepressants, antipsychotics, antihistamines, antiparkinsonian agents, and diuretics)
7. Unwilling to participate in this study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haemodialysis (HD) patient with large weight gain (&gt;2%/day)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Haemodialysis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>5 mg pilocarpine OPD solution (1% pilocarpine HCl ophthalmic solution, Shionogi &amp; Co., Taipei, Taiwan) was used. The placebo was constructed using normal saline and Mill-Q water with 3:7 mixing. The sodium concentration of the two solutions was identical, with both administered in fixed doses (10 drops four times/day, 30 minutes before each meal and at bed time). Ten drops of pilocarpine is equivalent to 5 mg.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pilocarpine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12962-0</funderId>
      <contactId>Contact50485_12962</contactId>
      <sponsorId>Sponsor48861</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50485_12962">
    <title>Prof</title>
    <forename>Junne-Ming</forename>
    <surname>Sung</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>138 Shing-Li Road</address>
      <city>Tainan</city>
      <country>Taiwan</country>
      <zip>70428</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 6 2353535 ext.2591</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jmsung@mail.ncku.edu.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48861">
    <organisation>National Cheng Kung University (Taiwan)</organisation>
    <website>http://www.ncku.edu.tw/en/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>138 Shing-Li Road</address>
      <city>Tainan</city>
      <country>Taiwan</country>
      <zip>70428</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.64523.36</gridId>
    <rorId>https://ror.org/01b8kcc49</rorId>
  </sponsor>
  <funder id="Funder12962-0">
    <name>Cheng Kung University Hospital Research Committee (Taiwan) - research grants (ref: NCKUH-2003-05 and NCKUH-2004-63)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-04-08T00:00:00.000Z">41221647</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Chiropractic Manipulation in Adolescent Idiopathic Scoliosis: a pilot study</title>
      <scientificTitle/>
      <acronym>MSU-AIS</acronym>
      <studyHypothesis>A large scale, multi-disciplinary, collaborative clinical trial is needed to explore the effectiveness of chiropractic manipulation of patients with Adolescent Idiopathic Scoliosis (AIS). But prior to conducting such a trial, we needed to perform a pilot randomised controlled trial to explore issues of safety, patient recruitment and compliance, treatment standardisation, sham treatment refinement, inter-professional cooperation, quality assurance, outcome measure selection and statistical analysis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was Cobb, and the psychosocial measure was Scoliosis Quality of Life Index.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Institutional Review Board of Borgess Medical Center, Kalamazoo approved the study protocol.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41221647</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d48a198f-d7e7-4319-93b7-398b8508011d">
	  <name>1000 Oakland Drive</name>
	  <address/>
	  <city>Kalamazoo</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>49008</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 10 - 16 years
2. Diagnosis of Adolescent Idiopathic Scoliosis
3. Spinal curvature on Posterior/Anterior (P/A) radiographs of between 20 and 30 degrees measured by the Cobb method in non-braced individuals and 30 to 40 degrees in braced individuals
4. Palpatory evidence of subluxation (manipulative lesion) on chiropractic screening examination
5. No contraindications to spinal manipulative therapy
6. Signed informed consent by parent/guardian
7. Signed child assent form
8. Availability for follow-up evaluation</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="10.0"/>
      <upperAgeLimit unit="Years" value="16.0"/>
      <gender>Both</gender>
      <targetEnrolment>6</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>6</totalTarget>
      <exclusion>1. Age less than 10 or greater than 16 years
2. Diagnosis other than AIS following clinical, radiographic and advanced imaging assessment
3. Contraindications to manipulation
4. Congenital or acquired structural spinal abnormalities
5. Leg length inequality greater than 3/8 inch
6. Pregnancy
7. Pain as a primary clinical feature
8. Mentally incapacitated patient
9. Planning to move/unwilling to return for follow-up
10. Previous back surgery
11. Significant trauma
12. Obesity impairing ability to manipulate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Adolescent Idiopathic Scoliosis (AIS)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Scoliosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were treated for six months by:
1. Standard medical care (observation or brace treatment)
2. Standard medical care plus chiropractic manipulation
3. Standard medical care plus sham manipulation</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16923185 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="889c14a0-70f9-4de2-9d1e-90d3ac956903" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16923185"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12980-0</funderId>
      <funderId>Funder12980-1</funderId>
      <funderId>Funder12980-2</funderId>
      <funderId>Funder12980-3</funderId>
      <contactId>Contact50503_12980</contactId>
      <sponsorId>Sponsor48881</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50503_12980">
    <title>Dr</title>
    <forename>Dale</forename>
    <surname>Rowe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1000 Oakland Drive</address>
      <city>Kalamazoo</city>
      <country>United States of America</country>
      <zip>49008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48881">
    <organisation>Michigan State University (USA) - Kalamazoo Center for Medical Studies</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1000 Oakland Drive</address>
      <city>Kalamazoo</city>
      <country>United States of America</country>
      <zip>49008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17088.36</gridId>
    <rorId>https://ror.org/05hs6h993</rorId>
  </sponsor>
  <funder id="Funder12980-0">
    <name>Michigan State University (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12980-1">
    <name>Kalamazoo Center for Medical Studies, Kalamazoo, Michigan (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12980-2">
    <name>American Chiropractic Scoliosis Foundation, Fort Collins, Colorado (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12980-3">
    <name>Canadian Memorial Chiropractic College, Toronto (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-03T00:00:00.000Z" version="27">
    <isrctn dateAssigned="2005-04-01T00:00:00.000Z">27140757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, controlled trial in primary care of a nicotine replacement therapy (NRT) assisted cessation intervention amongst adult smokers with established vascular disease to confirm effectiveness, safety and genetic influences</title>
      <scientificTitle/>
      <acronym>RESCINDING</acronym>
      <studyHypothesis>Not provided at time of registration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27140757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>TRIAL TERMINATED BEFORE RECRUITMENT started due to lack of funding</reasonAbandoned>
      <overallStartDate>2005-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="19ac8b6b-8d83-4122-b1de-8d1a3a60ecd9">
	  <name>General Practice Research Group</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX2 2BE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All smokers (self-report ≥10 cigarettes per day) aged 18 years and over who wish to stop with (at least) one of the following diagnoses:
1. Ischaemic Heart Disease:
i. Stable Angina, clinically or exercise electrocardiogram (ECG) diagnosed
ii. Myocardial infarction more than 2 months previously with recovery uncomplicated by any rhythm disturbances other than atrial fibrillation
2. Cerebrovascular disease: No exclusions
3. Peripheral vascular disease: No exclusions</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>2400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2400</totalTarget>
      <exclusion>1. Patients the GP, for whatever reason, does not wish to include
2. Known skin hypersensitivity to nicotine, plasters or widespread active eczema/psoriasis or other skin conditions that would restrict patch application
3. Pregnant or breast feeding women or those who are not using reliable contraceptive methods
4. Phaeochromocytoma/Hyperthyroidism and severe renal and/or hepatic impairment
5. Severe (life threatening) arrhythmia
6. Command of English (+/- interpreter) or impairment of faculties does not allow informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Nicotine replacement therapy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Nicotine replacement therapy in the form of patches versus placebo</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12860-0</funderId>
      <contactId>Contact50351_12860</contactId>
      <sponsorId>Sponsor48721</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50351_12860">
    <title>Dr</title>
    <forename>Paul</forename>
    <surname>Aveyard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>General Practice Research Group 
Department of Clinical Pharmacology
Radcliffe Infirmary
Woodstock Road</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX2 2BE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 228484</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.aveyard@clinpharm.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48721">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Offices
Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2JD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 270000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research.services@admin.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder12860-0">
    <name>Medical Research Council (MRC) (Grant number: G0200247)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-03-23T00:00:00.000Z">04517206</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multicentre, parallel group, randomised, double blind study to investigate the efficacy of fluticasone 100 mcg metered dose inhaler (MDI) twice a day (bd) versus placebo MDI bd both via Babyhaler® spacer in 1 to 5 year old children with asthma or asthma-like symptoms during a 6 month study period</title>
      <scientificTitle/>
      <acronym>ASTERISK</acronym>
      <studyHypothesis>To compare the efficacy of fluticasone propionate (FP) with placebo (PBO) using daily record card symptoms (shortness of breath, cough, wheezing, rescue medication use).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Symptom score (cough, wheeze, shortness of breath during night and day) as measured by a symptom diary card.</primaryOutcome>
      <secondaryOutcome>1. Symptom-free days and nights
2. Use of rescue medication
3. Lung function as measured by the interrupter technique and forced oscillation technique</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04517206</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FLU 9705</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0151e149-93d2-4002-b623-d85257fef5c4">
	  <name>Dept. General Practice</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9713 AV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 1 to 5 years with recurrent respiratory symptoms for which the GP considered prescribing inhaled corticosteroids
2. During the 2-week run-in period, children are eligible if they have symptoms on at least 7 days</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="1.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>96</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>96 children (140 were screened, from whom 96 were randomised)</totalTarget>
      <exclusion>1. Use of oral steroids within 8 weeks prior to the study
2. Use of inhaled steroids within 4 weeks prior to the study
3. Other respiratory disease
4. Inability of parents to fill in diaries
5. Incapable of using the inhaler device in a proper way
6. Participation in other trials</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Recurrent respiratory symptoms in children</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>6 months treatment with
1. Fluticasone propionate 50 mcg 2 puffs MDI bd via Babyhaler®, or
2. Placebo 2 puffs MDI bd via Babyhaler® and salbutamol 200 mcg MDI via Babyhaler® as rescue medication</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone, salbutamol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12878-0</funderId>
      <funderId>Funder12878-1</funderId>
      <contactId>Contact50384_12878</contactId>
      <sponsorId>Sponsor48753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50384_12878">
    <title>Prof</title>
    <forename>Thys</forename>
    <surname>van der Molen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. General Practice
University Medical Center Groningen
A. Deusinglaan 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9713 AV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48753">
    <organisation>GlaxoSmithKline (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Huis ter Heideweg 62</address>
      <city>Zeist</city>
      <country>Netherlands</country>
      <zip>3705 LZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491225.9</gridId>
    <rorId>https://ror.org/05atcw115</rorId>
  </sponsor>
  <funder id="Funder12878-0">
    <name>GlaxoSmithKline (The Netherlands) (ref: flu9705)</name>
    <fundRef>http://dx.doi.org/10.13039/100004330</fundRef>
  </funder>
  <funder id="Funder12878-1">
    <name>Stichting Astma Bestrijding (The Netherlands) (ref: 2000/006)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-21T00:00:00.000Z">18873428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of bimatoprost and latanoprost on ocular hemodynamics in normal tension glaucoma: a randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It is hypothesised that locally applied prostaglandins improve ocular haemodynamics in normal tension glaucoma patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Ocular perfusion is assessed by Doppler imaging. Primary endpoints are the peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the short posterior ciliary artery.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints are:
1. The PSV and EDV in:
1.1. The long posterior ciliary artery,
1.2. The central retinal artery, and 
1.3. The ophthalmic artery
2. Resistivity index, pulsatility index and time average velocity (maximum and mean) in all four vessels 
3. Intraocular pressure</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was performed in accordance to institutional, national, and international guidelines and was approved by the local ethics committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18873428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1723427327/3</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3cb5a302-8fb0-49bc-b310-c93eb73605a5">
	  <name>Martinistr. 52</name>
	  <address/>
	  <city>Hamburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>20246</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Progressive normal tension glaucoma patients. Progression was defined as progressive excavation of the optic disc (funduscopic and controlled by the Heidelberg retina tomography [HRT]) and/or progressive visual field loss in the Humphrey perimeter over the last 6 - 12 months.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Treated open angle glaucoma
2. Intraocular pressure greater than 21
3. Non-compliance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Normal tension glaucoma</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of latanoprost or bimatoprost eye drops.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bimatoprost, latanoprost</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15811188 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8d195645-9313-4d38-b1fd-57a3fa18ce47" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-04-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15811188"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12925-0</funderId>
      <contactId>Contact50443_12925</contactId>
      <sponsorId>Sponsor48818</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50443_12925">
    <title>Dr</title>
    <forename>Oliver</forename>
    <surname>Zeitz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martinistr. 52</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>20246</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48818">
    <organisation>University Medical Center Hamburg-Eppendorf (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Martinistr. 52</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>D-20246</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.13648.38</gridId>
    <rorId>https://ror.org/01zgy1s35</rorId>
  </sponsor>
  <funder id="Funder12925-0">
    <name>University Medical Center Hamburg-Eppendorf (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-08T00:00:00.000Z">54513166</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Glucosamine in osteoarthritis: long-term effectiveness</title>
      <scientificTitle/>
      <acronym>GOAL</acronym>
      <studyHypothesis>Pharmacological treatment for osteoarthritis (OA) can be divided into two groups: symptom-modifying drugs and disease-modifying drugs. Symptom-modifying drugs are currently the prescription of choice for patients with OA, as disease-modifying drugs are not yet available in usual care. However, there has recently been a lot of debate about glucosamine sulphate (GS), a biological agent that is thought to have both symptom-modifying and disease-modifying properties. This assumption has yet to be proved. This blind randomised clinical trial examines the long-term symptom-modifying and disease-modifying effectiveness of GS in patients with hip OA.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measures, which are joint space narrowing (JSN), and change in the pain and function score of the Western Ontario McMaster Universities Osteoarthritis index (WOMAC), are determined at baseline and after two years of follow-up during the final assessment. Intermediate measures at three-month intervals throughout the trial are used to study secondary outcome measures.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures are changes in WOMAC stiffness score, quality of life, medical consumption, side effects and differences in biomarker CTX-II.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Trial approved by the Medical Ethics Committee at the Erasmus MC - University Medical Centre Rotterdam.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54513166</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, blinded, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5a475361-d50d-4a03-aee5-62b3191eff72">
	  <name>Department of General Practice, room Ff320</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients are eligible for participation when they meet one of the American College of Rheumatology (ACR) criteria for osteoarthritis of the hip.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>222</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>222</totalTarget>
      <exclusion>1. Patients that have already undergone hip replacement surgery
2. Patients on the waiting list for hip replacement surgery
3. Patients that have a Kellgren-Lawrence score of 4
4. Patients with renal or hepatic disease or diabetes mellitus or a disabling co-morbidity</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised to either 1500 mg of oral glucosamine sulphate or a placebo daily for the duration of two years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Glucosamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/15850497 Study protocol
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18283204 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9304a290-2364-49a5-b443-8853b5f5d57c" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2005-04-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15850497"/>
	<description>Study protocol</description>
	<productionNotes/>
      </output>
      <output id="0324ec09-ebaa-4024-af47-a5818eec5220" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-02-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18283204"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12852-0</funderId>
      <contactId>Contact50340_12852</contactId>
      <sponsorId>Sponsor48711</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50340_12852">
    <title>Dr</title>
    <forename>Sita M.A.</forename>
    <surname>Bierma-Zeinstra</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Practice, room Ff320
Erasmus MC
PO Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 408 7633</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bierma-zeinstra@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48711">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Board of Directors
PO Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 2578</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.festen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder12852-0">
    <name>Erasmus Medical Centre (The Netherlands) - Breedtestrategie</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-07T00:00:00.000Z">38432711</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind randomised placebo controlled trial to compare two doses of a mineral supplement and a herbomineral combination in alleviating the symptoms of osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym>HerbomineralOA</acronym>
      <studyHypothesis>It was proposed that a natural mineral supplement, which has been shown to attenuate the degradation of human cartilage caused by the cytokine, interleukin-1 (IL-1), and catabolic pathways like nitric oxide production, would provide relief of the symptoms of osteoarthritis (OA) of the knee. The study examined two doses of this mineral supplement, as well as the combination of the low dose with a botanical extract, cat's claw, which had previously been reported to be effective in treating OA. These three groups were compared to a placebo treated group and treatment was for an 8 week period.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Western Ontario McMaster Arthritis Index (WOMAC) A, B, C and total scores (scores are for pain, stiffness, function).</primaryOutcome>
      <secondaryOutcome>1. Visual Analogue Score (VAS) for pain
2. Consumption of rescue medication (paracetamol)
3. Recovery (physician and patients' assessments)
4. Tolerability
5. Safety variables
6. Vitals (pulse rate, temperature, blood pressure, respiration rate) measured at baseline and weeks 1, 2, 4, 6 and 8
7. Laboratory investigations - complete blood count, serum glutamate pyruvate transaminase (SGPT), serum creatinine, erythrocyte sedimentation rate (ESR) at screening and week 8, adverse event monitoring at week 1, 2 4, 6, 8.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of K.J. Somaiya Medical College &amp; Hospital, Mumbai (India) and was in compliance with the Helsinki Declaration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38432711</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3062/RF</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11ef9433-d674-486b-92f5-55fcd67a92d2">
	  <name>118, Morya House</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>4000 053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ambulatory adults of either sex of greater than 20 years of age
2. OA of the knee diagnosed as per radiologic examination and the American Rheumatology Association (ARA) functional classification (II or III) or Kellgren-Lawrence Classification of grade II or grade III
3. Functional assessments of overall pain of at least 50 mm on a 100 mm Visual Analogue Scale</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>107</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>107</totalTarget>
      <exclusion>1. Osteoarthritis of grade I or grade IV
2. ARA functional class I or IV
3. Any arthritis other than OA
4. Arthroscopy of either knee for the past year
5. Intraarticular steroids for the last 3 months or hyaluronic acid in the last 9 months
6. Pregnant or lactating women
7. Evidence of severe renal, haematologic disease or severe cardiac insufficiency as revealed by laboratory investigations and other tests
8. Unwilling to come to regular follow up visits for the duration of the study
9. Moderate to severe peripheral neuropathy
10. Any condition that the investigator feels does not allow participation in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA) of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group A: Mineral supplement SierraSil (high dose 750 mg/capsule, 4 capsules a day)
Group B: Mineral supplement SierraSil (low dose 500 mg/capsule, 4 capsules a day)
Group C: Herbomineral supplement (low dose SierraSil 500 mg, 4 times a day, plus cat's claw extract, vincaria, 25 mg/capsule, 4 times a day)
Group D: Placebo (750 mg/capsule, 4 times a day)
Rescue Medication: Paracetamol</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mineral supplement (SierraSil), herbomineral supplement (SierraSil, cat's claw extract and vincaria)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16242032 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3aacdf77-b787-4c58-9b53-e5381fb05b86" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16242032"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12901-0</funderId>
      <contactId>Contact50411_12901</contactId>
      <sponsorId>Sponsor48780</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50411_12901">
    <title>Mr</title>
    <forename>Jayesh</forename>
    <surname>Chaudhary</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>118, Morya House
Off Link Road
Anheri-west</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>4000 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 267 33092</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vedic@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48780">
    <organisation>Vedic Lifesciences (India)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>118, Morya House
Off Link Road
Andheri-west</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>4000 053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)22 267 33092</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vedic@ayuherbal.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.497496.1</gridId>
    <rorId>https://ror.org/00xd7fg81</rorId>
  </sponsor>
  <funder id="Funder12901-0">
    <name>Sierra Mountain Minerals, Inc. (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-03-02T00:00:00.000Z">97552320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of timing of cord clamping on postnatal packed red blood cells value and clinical outcome in term newborns: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the effect of timing of umbilical cord clamping on neonatal venous haematocrit, clinical outcome and maternal postpartum haemorrhage.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Venous haematocrit six hours after birth.</primaryOutcome>
      <secondaryOutcome>1. Neonatal haematocrit at 24 - 48 hours of age
2. Plasma bilirubin level at 24 - 48 hours of age
3. Early neonatal morbidity (tachypnea, respiratory grunting, respiratory distress, jaundice, seizures, sepsis, necrotising enterocolitis, neonatal death)
4. Admission to Neonatal Intensive Care Unit
5. Length of newborn hospital stay
6. Any neonatal disease that occurs between birth and one month of age
7. Weight and type of feeding at one month of age
8. Postpartum maternal blood loss volume 
9. Maternal haematocrit level at 24 hours postpartum</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial was approved by the ethics committees of both hospitals (Hospital Italiano de Buenos Aires protocol number: 681/2002).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97552320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-04-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Argentina</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e3033eac-b57f-49a3-a76a-7ea1023aa308">
	  <name>Pueyrredón 985</name>
	  <address/>
	  <city>Rosario</city>
	  <state/>
	  <country>Argentina</country>
	  <zip>2000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women were eligible if they had uneventful cephalic vaginal or cesarean section delivery with the following characteristics: 
1. Singleton pregnancy at term
2. No evidence of clinical disease (diabetes, preeclampsia, hypertension) or any other complications
3. No evidence of congenital malformations or intrauterine growth restriction (estimated foetal weight less than 10th percentile)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>276</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>276</totalTarget>
      <exclusion>Does not comply with above inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-04-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Timing of cord clamping on newborns at term</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Timing of cord clamping</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Early cord clamping within the first 15 seconds of life
2. Cord clamping at first minute of life
3. Cord clamping at third minute of life</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16567393 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d7fcbdff-4dc7-476a-b90e-98c0783b2bac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16567393"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12899-0</funderId>
      <contactId>Contact50407_12899</contactId>
      <sponsorId>Sponsor48776</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50407_12899">
    <title>Dr</title>
    <forename>Guillermo</forename>
    <surname>Carroli</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Pueyrredón 985</address>
      <city>Rosario</city>
      <country>Argentina</country>
      <zip>2000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+54 (0)341 447 2625</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gcarroli@crep.com.ar</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48776">
    <organisation>United Nations Children's Fund (UNICEF) (Argentina) </organisation>
    <website>http://www.unicef.org/argentina/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Junin 1940</address>
      <city>Buenos  Aires</city>
      <country>Argentina</country>
      <zip>C 1113AAX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+54 (0)11 5093 7100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mthourte@unicef.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420318.c</gridId>
    <rorId>https://ror.org/02dg0pv02</rorId>
  </sponsor>
  <funder id="Funder12899-0">
    <name>United Nations Children's Fund (UNICEF) (Argentina)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-02-23T00:00:00.000Z">30487061</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of combination versus single antipyretic treatment in febrile children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Our study hypothesis is that combined antipyretic therapy (a single dose of 10 mg/kg ibuprofen followed by a single dose of 15 mg/kg of acetaminophen after 4 hours) is more effective than ibuprofen (10 mg/kg) followed by placebo, in reducing the temperature of children with high fever.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint of this study is the proportion of children in each group, with body temperature of 37.8°C or less at time 6 hours.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints include the proportion of children in each group, with body temperarures of 37.8°C and below, at times 7 and 8 hours, and the change in hourly temperature from baseline, at times 4, 5, 6, 7, 8 hours.
 The proportion of patients in each group with any immediate adverse effect (within 24 hours from administration) that may be related to either drug, such as gastrointestinal bleed, hypothermia or others.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30487061</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lebanon</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e93e3694-8f88-4dbd-a43d-ac5843956771">
	  <name>American University of Beirut Medical Center</name>
	  <address/>
	  <city>Beirut</city>
	  <state/>
	  <country>Lebanon</country>
	  <zip>113-6044/C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 6 months and 14 years
2. Rectal temperature greater than or equal to 38.8°C
3. Consent of treating physician
4. Consent of parent(s) and child if old enough to give consent (greater than 7 years)
5. No antipyretic intake for 8 hours prior to enrolment</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="14.0"/>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Presence of concurrent hepatic or renal disease
2. Chronic and/or serious disease such as malignancy, septic shock, malabsorption syndromes etc.
3. Any condition that may interfere with the absorption of the investigational drugs such as gastritis, diarrhoea, ileus etc.
4. Hypersensitivity to acetaminophen or ibuprofen
5. Bleeding disorder or tendency
6. Asthma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fever</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Fever</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Experimental group: A single dose (10 mg/kg) of Ibuprofen at zero time, followed by a single dose (15 mg/kg) of Acetaminophen at time = 4 hours
2. Control group: A single dose (10 mg/kg) of Ibuprofen at time zero, followed by a single dose (15 mg/kg) of Placebo at time = 4 hours
3. Rectal temperature recordings at baseline and at time = 4, 5, 6, 7 and 8 hours</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16515705 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a6fdc44a-2e43-4b76-8faa-62a17d5ac82f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-03-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16515705"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12898-0</funderId>
      <contactId>Contact50406_12898</contactId>
      <sponsorId>Sponsor48775</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50406_12898">
    <title>Dr</title>
    <forename>Mona</forename>
    <surname>Nabulsi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>American University of Beirut Medical Center</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>113-6044/C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)3 628528</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mn04@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48775">
    <organisation>American University of Beirut (Lebanon)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Medicine, Medical Practice Plan
Riyad El-Solh</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>11-02-36</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)1 350000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">resdean@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22903.3a</gridId>
    <rorId>https://ror.org/04pznsd21</rorId>
  </sponsor>
  <funder id="Funder12898-0">
    <name>American University of Beirut (Lebanon) - Medical Practice Plan of the Faculty of Medicine (ref: DCR 114170-034120)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-02-15T00:00:00.000Z">48076318</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to evaluate the effectiveness of a pharmacist's telephone reminders in reducing mortality in patients receiving polypharmacy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To investigate the effects of compliance and periodic telephone counselling by a pharmacist on mortality in patients receiving polypharmacy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time from randomisation to death from any cause.</primaryOutcome>
      <secondaryOutcome>1. Changes in the rate of admission to hospital
2. Number of emergency room visits
3. Hospital stay in the two years before and after the screening visit
4. Changes in compliance</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 22/10/2007: 
Ethics approval received from the Chinese University of Hong Kong clinical research ethics committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48076318</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HSRC/HCPF226103</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0c4a876c-a93f-4ae5-91f5-3b23b03a23f5">
	  <name>Dept of Medicine and Therapeutics</name>
	  <address/>
	  <city>-</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients receiving polypharmacy defined as five or more chronic medications who were found to be non-compliant upon first assessment by pharmacist</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>502</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Added as of 22/10/2007: 502 recruited</totalTarget>
      <exclusion>1. Speak non-Cantonese dialects or a different language 
2. Conditions that prevented effective communication (for example, patients who are deaf, mute, or have dementia or other psychological disorders)
3. Live in nursing homes with supervised treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Compliance to polypharmacy</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Compliance to polypharmacy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomised to the intervention group received a 10 - 15 minute telephone call from the pharmacist for education and counselling between clinic visits for 2 years. Patients in the control group did not receive any telephone reminders.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16916809 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2108e074-2afc-465a-9d04-df6bb071d317" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16916809"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12766-0</funderId>
      <contactId>Contact50223_12766</contactId>
      <sponsorId>Sponsor48591</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50223_12766">
    <title>Prof</title>
    <forename>Juliana CN</forename>
    <surname>Chan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Medicine and Therapeutics
Chinese University of Hong Kong
The Prince of Wales Hospital
Shatin</address>
      <city>-</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+852 (0)2632 3138</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jchan@cuhk.edu.hk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48591">
    <organisation>Hong Kong Health Services Research Fund (Hong Kong)</organisation>
    <website>http://www.fhb.gov.hk/index.html</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Health Welfare and Food Bureau
Government Secretariat, HKSAR
20th floor Murray Building
Garden Road</address>
      <city>-</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+852 (0)2973 8288</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hsrf@hwfb.gov.hk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453538.c</gridId>
    <rorId>https://ror.org/03qh32912</rorId>
  </sponsor>
  <funder id="Funder12766-0">
    <name>Hong Kong SAR Government Health Services Research Committee (Hong Kong)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-02-09T00:00:00.000Z">26222607</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of hydroxyethyl starch (HES) 130/0.4 versus glucose solution in haemodilution therapy of idiopathic sudden hearing loss: a dose-finding, double-blind multicentre trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Objective: Obtain first data on HES 130/0.4 (hydroxyethyl starch) as monotherapy in patients with acute idiopathic sudden sensorineural hearing loss (ISSNHL).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Absolute hearing gain (AHG) in decibel at Day 7, calculated as mean audiometric hearing threshold (MAHT) at baseline minus MAHT at Day 7, whereby MAHT was the arithmetic mean of the hearing thresholds in dB at the main speech frequencies of 0.5, 1, 2, 3, and 4 kilohertz</primaryOutcome>
      <secondaryOutcome>Efficacy:
1. AHG at other timepoints (i.e. Days 3, 14, and 90)
2. AHG based on geometric MAHT
3. Hearing gain based on the Schwab/Ewert formula i.e. the arithmetic mean of the delogarithmed pure tone thresholds
4. AHG based on arithmetic and geometric MAHT calculated only on speech frequencies with an initial hearing loss of 20 dB or more
5. Outcome categorised in complete/partial/no recovery or deterioration
6. Changes of subjective hearing, vertigo, and tinnitus

Safety:
1. Adverse events
2. Laboratory parameters (haematology, haemostasis, clinical chemistry, urinalysis)
3. Vital signs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26222607</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HS-13-26-EU</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7847e82b-5c31-46b1-84c9-d3aa04e7456a">
	  <name>HNO-Klinik Krankenhaus Dresden-Friedrichstadt</name>
	  <address/>
	  <city>Dresden</city>
	  <state/>
	  <country>Germany</country>
	  <zip>01067</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>210 inpatients with first-time idiopathic sudden sensorineural hearing loss (ISSNHL) of 20 dB or more at two or more frequencies and 95 dB or less at all of the speech frequencies (0.5, 1.0, 2.0, 3.0, 4.0 kHz) with respect to the other (normal) ear for up to 7 days.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>210</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>210</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sudden hearing loss</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Sudden hearing loss</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infusion of 750 ml per day with HES 45 g per day (group H), 30 g per day (M), 15 g per day (L), or glucose 5% (G) acting as 'placebo' control over 6 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydroxyethyl starch</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12880-0</funderId>
      <contactId>Contact50386_12880</contactId>
      <sponsorId>Sponsor48755</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50386_12880">
    <title>Prof</title>
    <forename>Eckart</forename>
    <surname>Klemm</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>HNO-Klinik Krankenhaus Dresden-Friedrichstadt
Friedrichstr. 41</address>
      <city>Dresden</city>
      <country>Germany</country>
      <zip>01067</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)351 480 1220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Raehder-Co@khdf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48755">
    <organisation>Fresenius Kabi Deutschland GmbH (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Else Kröner Str. 1</address>
      <city>Bad Homburg v.d.H</city>
      <country>Germany</country>
      <zip>61352</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6172 686 7324</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Daniela.Baus@fresenius-kabi.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.462236.7</gridId>
    <rorId>https://ror.org/01v376g59</rorId>
  </sponsor>
  <funder id="Funder12880-0">
    <name>Fresenius Kabi Deutschland GmbH (Germany) (ref: HS-13-26-EU)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-02-09T00:00:00.000Z">45687883</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective multicentre double blind placebo controlled trial to evaluate the effectiveness of patent foramen ovale (PFO) closure with the STARFlex® septal repair implant to resolve refractory migraine headache</title>
      <scientificTitle/>
      <acronym>MIST - Migraine Intervention with STARFlex® Technology</acronym>
      <studyHypothesis>To investigate the effect of PFO closure with the STARFlex® Septal Repair Implant System in a selected refractory migraine with aura population on the resolution of migraine attacks.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of migraine headache during the 90 days analysis period following the healing phase.</primaryOutcome>
      <secondaryOutcome>1. Incidence of migraine during the healing phase (the first 90 days post procedure)
2. Change in the severity of migraine attacks, based on MIDAS (Migraine Disability Assessment) and HIT-6 (Headache Impact Test) scores
3. Change in the frequency of migraine attacks other than elimination of attacks
4. Change in characteristics of migraine (with or without aura and change thereon)
5. Change in severity, frequency and character of migraine relative to effective closure rate or presence of residual leak
6. Change in quality of life based on SF36-v2 QOL survey

The secondary endpoints of safety are:
 7. Device success, defined as successful delivery of one or more STARFlex® device(s) to the site during the index procedure without a procedural complication, deployment of the device at the intended site, and removal of the delivery system
8. Procedural success, defined as device success without the occurrence of procedural complications prior to discharge, including device embolisation, cerebral or pulmonary embolism, cardiac perforation, and infective endocarditis

The secondary endpoints of failure are: 
9. Incidence of major adverse events from the STARFlex® Septal Repair Implant
10. Incidence of major vascular access complications related to the index procedure, including access site haematoma &gt;5 cm, false aneurysm, AV fistula, retroperitoneal bleed, peripheral ischaemia/nerve injury, procedure related transfusion, and the need for vascular surgical repair or ultrasound compression
11. Incidence of adverse drug reactions to medications used in the index procedure
12. Incidence of adverse drug reactions to procedure specific medications required during the follow phase
13. Major bleeding, defined as the occurrence of intracranial, intraocular, or retroperitoneal hemorrhage or any hemorrhage requiring a blood transfusion during the index hospitalisation, or during the follow-up time period
14. Death (due to any cause) during the first 30 days following treatment
15. Death caused directly by a malfunction of the implant after the first 30 days
16. Incidence of other major adverse events


The tertiary endpoints of efficacy are: 
17. Relationship between PFO and associated atrial septal aneurysm and frequency of migraine
18. Relationship between patient sex and change in migraine frequency, or severity
19. Effective closure rate, defined as procedural success with either grade 0 (none) or 1 (trace) residual shunt as measured by TTE at 180&#150;210 days post-procedure</secondaryOutcome>
      <trialWebsite>http://www.migraine-mist.org/index.asp</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>MREC approved 04/11/2004</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45687883</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MIST01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, multicentre, double blind, placebo controlled parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="63f2fd68-39e0-465a-be24-16bf8dc19809">
	  <name>King's Healthcare</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with refractory migraine

Inclusion criteria:
1. The patient is greater than or equal to 18 years of age and less than or equal to 60 years of age
2. Patients must meet the definition of 'with aura'
3. Patients with a history of migraine onset prior to age 50
4. Patients must meet the definition of refractory migraine
5. Patients must have a positive contrast valsalva bubble trial by TTE, demonstrating grade 2 or 3 right to left shunting. An atrial septal aneurysm may or may not be identified.
6. Patients must be available for follow-up in accordance with the protocol 
7. The patient is able to provide a signed informed consent form signed at three stages to participate.  Informed consent from guardians is not acceptable. 
8. Patients critical cardiac structures are not expected to come in contact with the device (e.g. AV valves and pulmonary veins). It is recommended that the device be approximately 1 mm from these structures. 
9. Patients must agree not to get pregnant during the trial


Post-randomisation - Device Patients Only:
10. The vascular access from the femoral vein is expected to accommodate the 11F delivery system
 11. The size of the PFO (measured by indentation with a soft balloon) must demonstrate the defect to be amenable to selection of a STARFlex® Septal Repair Implant as described in the Instructions for Use</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150 - first patient was enrolled 24/11/04, last patient 31/05/05</totalTarget>
      <exclusion>1. Patients are less than 18, or greater than 60, years of age
2. Failure to meet the definition of migraine 'with aura'
3. Failure to meet the definition of refractory migraine
4. A contrast valsalva bubble study demonstrates no or trivial shunting from right to left through a PFO
5. Any cardiovascular condition, including those requiring chronic medications that would interfere with the conduct or assessment of outcome of the trial, or that would increase patient risk relative to undergoing the procedure or with the ability to deliver and deploy the STARFlex® Septal Repair System
6. Inability of the patient to personally give and sign the informed consent
7. A large, redundant atrial septal aneurysm which cannot, in the judgment of the investigator, be covered by the STARFlex® Septal Repair System without (1) causing the device to interfere with other intracardiac structures, or (2) prohibiting the ability of the operator to adequately deploy the distal/proximal arms in the left/right atrium prior to final placement on the septum. 
8. Patients with an elongated waist (long tunnel), any other reason requiring Transseptal puncture for device placement
9. Other cardiac defects, whether or not repaired, including:  Atrial septal defect; Ventricular septal defect; Coarctation of the aorta; Patent ductus arteriosus; or Mitral or aortic stenosis. 
10. Thrombus in or occlusion of the venous lumen between the femoral vein access site (or superior access site, if used) and the right atrium
11. A previously implanted atrial septal device
12. Echocardiography evidence of an intra-atrial or ventricular thrombus
13. History of drug abuse
14. Known active endocarditis or documented bacteraemia
15. Elevated serum creatinine such that the use of contrast dye during the implant procedure would expose the patient to unnecessary risks of additional renal dysfunction
16. Active infections requiring current antibiotic therapy (if temporary illness, patients may enroll after discontinuation of antibiotics, once asymptomatic for 4 weeks)
17. Patients who are pregnant, nursing, or planning pregnancy over the duration of the patient&#146;s participation in the study
18. A known sensitivity to medications used in general anaesthesia
19. A known contraindication to aspirin or clopidogrel
20. Sensitivity to contrast media, which cannot be adequately pre-medicated
21. A platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, or a WBC of &lt;3,000 cells/mm3, or a known disorder of platelet function 

22. Any patient with a known coagulopathy for which they are currently being treated medically with anticoagulants
23. Patients with any neurological disorder or disease that would interfere with proper assessment and or conduct of the trial

24. Patients unable to perform a satisfactory valsalva manoeuvre 
25. Patients in whom transoesophageal echocardiography is contraindicated
26. Active peptic ulcer or upper gastrointestinal bleeding within the prior 6 months
27. Concurrent medical condition with a life expectancy of less than 12 months
28. Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints.  [NOTE: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.]
29. The presence of a permanent pacemaker
30. The presence of an inferior vena cava filter 
31. Haemodynamic conditions generally contraindicating closure of a PFO or any other right to left decompressive shunt.  (i.e., normal RV function and PVR &gt;10 indexed Wood units if RV pressure &lt;1/2 systemic pressure or, PVR &gt;8 indexed Wood units if RV pressure &gt;1/2 systemic pressure)
32. If echocardiography suggests moderate or greater tricuspid regurgitation
33. Suspected/recognised cirrhosis or portal hypertension or known pulmonary arterio-venous malformations
34. Any PFO that requires closure for reasons unrelated to the migraine history (e.g., orthodeoxia, stroke, TIA, decompression illness)
35. Patients known to be headache medication over users 
36. Patients diagnosed with chronic daily headache
37. Patients with a documented medical history of oesophageal stricture, diverticulae, symptomatic hiatus hernia, oesophagitis or oesophageal varices
38. If in the investigator&#146;s opinion, the patient is unsuitable to be entered in the trial for any other reason</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>PFO/Migraine</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blinded study randomising migraine patients with PFOs to either PFO closure with the STARFlex® implant or a control arm who received a sham procedure, assessments of PFO were made using trans oesophageal echo and trans thoracic echo.  Baseline headache data has been obtained for both groups and has been followed up with 6 months of post-procedure headache diary data and physicians' assessments of migraine profile for both implant and placebo groups.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18316488 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9729252c-3969-4e18-aada-c2c8d8d0dba5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18316488"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12801-0</funderId>
      <contactId>Contact50270_12801</contactId>
      <sponsorId>Sponsor48641</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50270_12801">
    <title>Dr</title>
    <forename>Andy</forename>
    <surname>Dowson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>King's Healthcare
Neuroscience Centre
King's College Hospital
Demmark Hill</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE5 9RS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48641">
    <organisation>NMT Medical Inc. (USA) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>27 Wormwood St</address>
      <city>Boston</city>
      <country>United States of America</country>
      <zip>MA 02210</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12801-0">
    <name>NMT Medical Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-02-01T00:00:00.000Z">23032971</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomised controlled study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of this study was to examine the efficacy of the antihistamine desloratadine at different time points during the day and to evaluate whether the time of dosing of desloratadine has any impact on the treatment efficacy in seasonal allergic rhinitis (SAR).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The mean change from baseline for the AM last hour total symptom score (TSS) over the 2 weeks treatment period.</primaryOutcome>
      <secondaryOutcome>1. Interference with sleep and interference with daily activity 
2. The number of hours spent outdoors</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol and the patient informed consent form were approved by Ethics Committees and Health Authorities in each of the participating countries.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23032971</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P02278</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
	<country>Finland</country>
	<country>Iceland</country>
	<country>Norway</country>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d4f6369-6c76-4028-8678-98c6efdfe9f8">
	  <name>Dept. of Otolaryngology</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>0027</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients 18 years or above with a minimum of two years history of SAR confirmed by either a positive skin prick test or a positive serologic allergen test to the relevant seasonal allergen
2. Clinically symptomatic with SAR at baseline/inclusion with a minimum total nasal symptom score (rhinorrhoea, congestion, itching and sneezing) of at least 6 and rhinorrhoea being minimum 2 (moderate)
3. Willingness to adhere to dosing and visit schedule
4. Females of childbearing potential have to use medically accepted methods of birth control 
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>663</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>663</totalTarget>
      <exclusion>1. Pulmonary disease, perennial rhinitis, sinusitis, rhinitis medicamentosa, pollen desensitisation during the last 6 months
2. Respiratory tract infection within the last two weeks
3. Structural nasal abnormalities (including polyps)
4. Use of oral, nasal, ocular decongestants, corticosteroids in any form (except mild dermatological group I corticosteroids allowed in only small areas), other antihistamines (oral or topical), any investigational drug during the last 30 days
5. Pregnant or nursing females</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal allergic rhinitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Allergic rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised into one of two treatment groups with dosing of 5 mg desloratadine tablets either in the morning between 07 - 09 (AM-group) or evening between 19 - 21 (PM-group) in a 1:1 ratio.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Desloratadine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15686600 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="52c055c7-bc9d-4d18-b649-08422ff26b61" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-02-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15686600"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12873-0</funderId>
      <contactId>Contact50374_12873</contactId>
      <sponsorId>Sponsor48743</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50374_12873">
    <title>Prof</title>
    <forename>Rolf</forename>
    <surname>Haye</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. of Otolaryngology
Rikshospitalet</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0027</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48743">
    <organisation>Schering-Plough AS (Norway)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Ankerv. 209</address>
      <city>Eiksmarka</city>
      <country>Norway</country>
      <zip>1359</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.488502.3</gridId>
    <rorId>https://ror.org/0118bra88</rorId>
  </sponsor>
  <funder id="Funder12873-0">
    <name>Schering-Plough in the Nordic countries</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-01-25T00:00:00.000Z">64733264</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase III study of neoadjuvant bicalutamide in patients with intermediate risk prostate cancer undergoing radiation therapy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64733264</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>99-07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7f2adff-1a6b-4e5e-b953-2235e6a7b1db">
	  <name>610 University Avenue</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 2M9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. T1/T2a prostate cancer with:
1.1. Gleason 7, prostate specific antigen (PSA) less than 20 ng/ml
1.2. Gleason less than 7, PSA 10 - 20 ng/ml
2. T2b prostate cancer with:
2.1. PSA less than 20 ng/ml
2.2. Gleason less than or equal to 7</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Localised prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Bicalutamide 150 mg daily for 3 months before and 2 months during radiation therapy versus no hormonal therapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bicalutamide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12782-0</funderId>
      <funderId>Funder12782-1</funderId>
      <contactId>Contact50246_12782</contactId>
      <sponsorId>Sponsor48617</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50246_12782">
    <title>Dr</title>
    <forename>Padraig</forename>
    <surname>Warde</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>610 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2M9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 946 2122</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">padraig.warde@rmp.uhn.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48617">
    <organisation>Princess Margaret Hospital (Canada) - Department of Radiation Oncology </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>610 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2M9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415224.4</gridId>
    <rorId>https://ror.org/03zayce58</rorId>
  </sponsor>
  <funder id="Funder12782-0">
    <name>Princess Margaret Hospital (Canada) - internal genitourinary (GU) group funds</name>
    <fundRef/>
  </funder>
  <funder id="Funder12782-1">
    <name>AstraZeneca (Canada) - small unrestricted grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-12-08T00:00:00.000Z">32740751</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical trial on enzymatic agent Salizolis</title>
      <scientificTitle/>
      <acronym>SALIZOLIS</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32740751</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lithuania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="652f90c8-eabc-468e-b9da-f57953e0ef30">
	  <name>Kaunas Medical University Hospital</name>
	  <address/>
	  <city>Kaunas</city>
	  <state/>
	  <country>Lithuania</country>
	  <zip>50009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with acute and chronic wounds containing necrotic tissue (thermal and chemical burns, frostbites, trophic ulcers, injuries of truncal and limb, injuries of wrist and hand, injuries of tarsus and foot, varicosis of lower limbs with ulcers and inflammation, foot ulcers, pressure sores, infections on dermal and hypodermal tissue and other purulent inflammations).

Inclusion criteria:
1. Older than 18 years</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Children under the age of 18
2. Pregnant women
3. Soldiers of active service
4. Incurable patients
5. Patients with mental disorder
6. Patients dependent on drugs and alcohol
7. Subjects incapable of giving consent
8. Subjects disagree with participation in clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Wounds</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Acute and chronic wounds</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The randomised and controlled, single blind and parallel group study will be carried out on two groups. Each group consists of 15 patients.
Patients of group A are being treated according to the current standards of therapy. The wounds will be self-purged out of necrotic tissues.
Patients of group B are being treated according to the new regimen under investigation - enzymatic agent Salizolis. Necrotic tissue of the wounds will be purged out by enzymatic agent.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Salizolis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12795-0</funderId>
      <contactId>Contact50263_12795</contactId>
      <sponsorId>Sponsor48634</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50263_12795">
    <title>Dr</title>
    <forename>Rimdeika</forename>
    <surname>Rytis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kaunas Medical University Hospital
Department of Surgery
Division of Plastic Surgery and Burns
Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+370 37 326083</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rimdeika@kmu.lt</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48634">
    <organisation>JSC Biocentras (Lithuania)</organisation>
    <website>http://www.biocentras.lt/about_en.html</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Graiciuno str. 10</address>
      <city>Vilnius</city>
      <country>Lithuania</country>
      <zip>02241</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+370 5 2661313</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">biocentras@biocentras.lt</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.426447.7</gridId>
    <rorId>https://ror.org/005gk6w44</rorId>
  </sponsor>
  <funder id="Funder12795-0">
    <name>Sixth framework programme horizontal research activities involving small and medium sized enterprises (SMEs) co-operative research project - Ultimate Pressure Dressing System for the Management of Venous Ulcers (European Union)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">84553798</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Ketamine on post-operative intraocular inflammation following cataract surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does ketamine reduce post-operative cystoid  macula oedema in patients who undergo cataract surgery?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To define population for definitive randomised prospective trial on effects of ketamine on cystoid macula oedema in patients undergoing cataract surgery</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84553798</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0207129695</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, parallel group, double blind, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a55ba400-97eb-48b2-84ce-0e22836c1d7c">
	  <name>St Pauls Eye Unit</name>
	  <address/>
	  <city>Liverpool</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>L7 8XP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>33</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Pilot study; 3 groups of 11.</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Cataract</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group A receive ketamine under general anaesthetic
Group B receive general anaesthetic without ketamine
Group C receive local anaesthetic without ketamine</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>ketamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17653058 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="319f197d-89d0-48fe-bb35-a14d5828d175" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17653058"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12612-0</funderId>
      <contactId>Contact50132_12612</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50132_12612">
    <title>Mr</title>
    <forename>S B</forename>
    <surname>Kaye</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Pauls Eye Unit
8Z Link
Royal Liverpool University Hospital
Prescot Street</address>
      <city>Liverpool</city>
      <country>United Kingdom</country>
      <zip>L7 8XP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)151 706 2134</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Stephen.kaye@rlbuht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12612-0">
    <name>Royal Liverpool and Broadgreen University Hospitals Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">45665423</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of a personalised letter on response rates to a postal questionnaire: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does a personalised addressed letter compared with a standard letter increase response rate to a postal questionnaire on service quality sent to people referred to an exercise referral scheme?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The number of completed questionnaires returned after completing all methods of follow-up.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval for the study was received in advance from the local research ethics committee and the research governance committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45665423</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0311114507</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a19060e4-63ad-4a03-b4a2-e8ba17bc50c3">
	  <name>Bolton Primary Care Trust</name>
	  <address/>
	  <city>Bolton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BL1 1PP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People living in the community of Bolton who had been referred to the exercise referral scheme over a three year period.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>627</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>627</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Exercise referral</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A two-group randomised trial of a personalised letter versus a standard letter.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15537429 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="354b295e-9cb3-4562-92d8-c70d6d07ddf2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-10T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15537429"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12710-0</funderId>
      <contactId>Contact49985_12710</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact49985_12710">
    <title>Dr</title>
    <forename>R A</forename>
    <surname>Harrison</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bolton Primary Care Trust
St Peter's House
Silverwell Street</address>
      <city>Bolton</city>
      <country>United Kingdom</country>
      <zip>BL1 1PP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1204 907728</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Roger.Harrison@bolton.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12710-0">
    <name>Bolton Primary Care Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">69248640</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does prophylactic N acetylcysteine decrease the incidence of contrast nephropathy in patients undergoing endovascular abdominal aortic aneurysm (AAA) repair?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is peri-operative oral N acetylcysteine nephroprotective in patients undergoing endovascular abdominal aortic aneurysm repair?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN69248640</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0544139644</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4683ab13-eb7f-43de-9942-115596f31709">
	  <name>Cambridge Vascular Unit</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB2 2QQ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Abdominal aortic aneurysm (AAA) repair</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Abdominal aortic aneurysm (AAA) repair</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participation offered to all patients undergoing endovascular abdominal aortic aneurysm repair in the Cambridge Vascular Unit, Addenbrooke's Hospital. Consenting patients will be randomised to receive either intra venous saline hydration (current practice) or intravenous saline hydration and oral N acetyl-cysteine (600 mg twice a day (bd) orally (PO) on the day before the procedure; and 600 mg bd PO on the day of the procedure, one dose before, and one dose after the procedure).  Evidence of renal injury will be monitored post-procedure by assay of serum creatinine levels, and also by measuring urinary low molecular weight proteins such as N acetyl beta glucosaminidase (NAG) a subclinical marker of renal injury, and albumin and creatinine.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17042662 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fd5a6aa1-f301-4583-9ea3-b0b60af0167f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17042662"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12734-0</funderId>
      <contactId>Contact50087_12734</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50087_12734">
    <title>Mr</title>
    <forename>J</forename>
    <surname>Boyle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cambridge Vascular Unit
Dept. of General Surgery
Box 201
Addenbrooke's Hospital</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB2 2QQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1223 217246</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jonathan.boyle@addenbrookes.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12734-0">
    <name>Cambridge Consortium - Addenbrooke's (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-30T00:00:00.000Z">40732847</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of 4% articaine and bupivacaine/lignocaine for sub-tenon anaesthesia in phacoemulsification cataract surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess if articaine 4% is a suitable and SAFE agent for use in sub-tenon anaesthesia of the eye (for cataract surgery).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The aim of the trial is to examine the possibility that the success rate of sub-tenon anaesthesia can be improved by using 4% articaine rather than the presently used combination of lignocaine/bupivacaine. Sub-tenon's anaesthesia has distinct advantages over 'sharp needle' technique, chiefly being globe perforation but currently, acceptance of this technique is hampered by poor success rate. If the success rate of sub-tenons anaesthesia could be enhanced by 4% articaine then it would become a widely used technique. 

Study endpoints: Collating data and to see if 4% articaine is safe and effective compared to existing lignocaine/bupivacaine anaesthetic agent.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40732847</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0203132063</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="00e187b4-232c-4cb3-8bd5-da6a75c3632f">
	  <name>Royal Devon &amp; Exeter Hospital (Wonford)</name>
	  <address/>
	  <city>Exeter</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EX2 5DW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patient will be selected at random from the waiting list. Letters will be sent out to the patient along with appointment letter. They will be contacted a day prior to surgery and their willingness to participate ascertained on the day of surgery.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>65</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>65</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Previous intra-ocular surgery
3. Pupil diameter less than 5 mm when fully dilated
4. Pregnant females or of child bearing potential
5. Those known to have reduced plasma chlolinesterase levels
6. Patient unwilling to participate in the study
7. A history of allergy to amide-type anaesthetics
8. Subjects of non-therapeutic research</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cataract surgery</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Cataract surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomly allocated to one of two groups using sealed, numbered envelopes and computer randomisation. Group A will receive sub-tenon's anaesthesia using 4% articaine and group B will receive a mixture of equal volume of 0.5% bupivicaine and 2% lignocaine. Ocular movements will be scored for each direction of gaze in the superior, inferior, medial and lateral directions with a maximum score for each direction of 3 points and a possible total maximum of 12 points. Patients will be considered to be ready for surgery when the ocular scores are 5 or less. Table showing scoring system for ocular movements. Full Movement 3/ Moderate Movement 2/ Flicker of movement 1/ No movement 0. In addition formal ocular motility testing will be undertaken at the orthoptics department immediately before and after surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Articaine, bupivacaine/lignocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18211939 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="abea4235-4148-4836-976d-f02b64fc757d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18211939"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12595-0</funderId>
      <contactId>Contact50149_12595</contactId>
      <sponsorId>Sponsor48583</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50149_12595">
    <title>Mr</title>
    <forename>Vasant</forename>
    <surname>Raman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Devon &amp; Exeter Hospital (Wonford)
Barrack Road</address>
      <city>Exeter</city>
      <country>United Kingdom</country>
      <zip>EX2 5DW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1392 406033</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Vasant317@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48583">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12595-0">
    <name>Royal Devon and Exeter NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-08-09T00:00:00.000Z">73254583</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Glutamine-Enriched Enteral Feeding in very low birth weight infants</title>
      <scientificTitle/>
      <acronym>GEEF study</acronym>
      <studyHypothesis>Very Low Birth Weight (VLBW) infants may be susceptible to glutamine depletion as nutritional supply of glutamine is limited in the first weeks after birth. Glutamine depletion has negative effects on functional integrity of the gut and leads to immunosuppression. This double-blind randomised controlled trial is designed to investigate the effect of glutamine-enriched enteral nutrition on feeding tolerance, infectious morbidity and short-term outcome in VLBW infants. Furthermore, an attempt is made to elucidate the role of glutamine in postnatal adaptation of the gut and modulation of the immune response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to full enteral feeding, defined as a feeding volume greater than or equal to 120 mL/kg/day.</primaryOutcome>
      <secondaryOutcome>1. Feeding tolerance:
1.1. Age at finishing parenteral nutrition
1.2. Days of no enteral feeding during study period  
1.3. Necrotising enterocolitis 
2. Infectious morbidity:
2.1. Serious infections  
2.2. Number of infectious episodes  
2.3. Cultured micro-organisms 
3. Short-term outcomes:
3.1. Weight z scores at birth, day 30 and at discharge
3.2. Patent ductus arteriosus  
3.3. Ventilatory support  
3.4. Use of oxygen at postmenstrual age of 36 weeks
3.5. Intraventricular hemorrhage
3.6. Retinopathy of prematurity
3.7. Death  
3.8. Age at discharge from NICU and at discharge home 
4. Intestinal permeability, determined during the 30 day study period
5. Faecal flora, determined during the 30 day study period
6. Plasma Th1/Th2 cytokine concentrations, determined during the 30 day study period
7. Plasma amino acid profiles, determined during the 30 day study period</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The National Central Committee on research involving human subjects and the Medical Ethical Review Board of our hospital approved the study protocol.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73254583</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR205</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="39db807d-8bc2-4935-9e3c-7dbc121c1e3a">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Infants with a gestational age less than 32 weeks and/or a birth weight less than 1500 g 
2. Admitted to the level III Neonatal Intensive Care Unit (NICU) of the Vrije University Medical Centre (VUMC)
3. Written informed consent obtained from all parents</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>107</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>107</totalTarget>
      <exclusion>1. Major chromosomal or congenital anomalies
2. Death less than 48 hours after birth
3. Transfer to another hospital less than 48 hours after birth 
4. Admission from an extraregional hospital</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Very low birth weight infants</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Very low birth weight infants</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Enteral glutamine supplementation in a dose of 0.3 g/kg/day between days three and 30 of life versus isonitrogenous placebo supplementation (alanine).</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Enteral glutamine supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/15341667 Protocol
2005 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/15941893
2005 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/15990633
2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16931609
2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17499398
2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17984413</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="22ae7c70-dcdc-4fdc-964d-cc2fa6ccdcd3" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15341667"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="0e2d0257-4506-4e8a-ab8b-2f9ba9f80d20" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15941893"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="584b352d-3f8f-4b1d-924b-7c097468d4ee" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15990633"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="be8e6540-b23e-4265-87e0-e233b4229ee2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16931609"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="413a6d3e-2685-47f8-a875-aaf5ff748c35" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17499398"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="f6648dff-c982-45f5-9121-7aecdc2a522d" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17984413"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11283-0</funderId>
      <contactId>Contact41734_11283</contactId>
      <sponsorId>Sponsor39479</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41734_11283">
    <title>Prof</title>
    <forename>Willem</forename>
    <surname>Fetter</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2413</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.fetter@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39479">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands) </organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2413</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.fetter@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder11283-0">
    <name>Nutricia Nederland B.V. (The Netherlands) - provided neonatal glutamine and placebo supplementation</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2004-02-06T00:00:00.000Z">27290841</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and efficacy of the combination of chloroquine and methylene blue in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso</title>
      <scientificTitle/>
      <acronym>BlueCQ2</acronym>
      <studyHypothesis>Safe, effective and affordable drug combinations against falciparum malaria are urgently needed for the poor populations in malaria endemic countries. Methylene blue (MB) combined with chloroquine (CQ) has been considered as one promising new regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of severe haemolysis or other serious adverse events (SAEs).</primaryOutcome>
      <secondaryOutcome>Efficacy outcomes were defined according to the WHO 2003 classification system.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the Ethics Committee of the Medical Faculty of Heidelberg University and the local Ethics Committee in Burkina Faso.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27290841</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="401f8608-7a43-454f-995e-50f1a17410d1">
	  <name>Department of Tropical Hygiene and Public Health</name>
	  <address/>
	  <city>Heidelberg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-69120</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children (6 - 59 months) with uncomplicated falciparum malaria
2. Greater than or equal to 2000 Plasmodium falciparum
3. Burkinabe nationality</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>225</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>225</totalTarget>
      <exclusion>1. Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment)
2. Anaemia (haemoglobin less than 8 g/dl or haematocrit less than 24%) 
3. Any other apparent significant disease (e.g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Uncomplicated falciparum malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Arm A (N = 45): 25 mg/kg oral chloroquine within 3 days
Arm B (N = 180): 25 mg/kg oral chloroquine and 15 mg/kg methylene blue within 3 days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Chloroquine, methylene</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16179085 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="52c68beb-6de0-46a5-b7b9-87cdca080278" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-22T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16179085"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5735-0</funderId>
      <contactId>Contact7168_5735</contactId>
      <sponsorId>Sponsor5331</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7168_5735">
    <title>Dr</title>
    <forename>Olaf</forename>
    <surname>Müller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Tropical Hygiene and Public Health
University of Heidelberg</address>
      <city>Heidelberg</city>
      <country>Germany</country>
      <zip>D-69120</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6221 56 5035</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Olaf.Mueller@urz.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5331">
    <organisation>DSM Fine Chemicals (Austria)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr. Wolfgang Schiek
St. Peter-Str. 25
PO Box 933</address>
      <city>Linz</city>
      <country>Austria</country>
      <zip>A-4021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0)732 6916 2150</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wolfgang.schiek@dsm.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.451620.4</gridId>
    <rorId>https://ror.org/01j7tpx52</rorId>
  </sponsor>
  <funder id="Funder5735-0">
    <name>DSM Fine Chemicals (Austria) - Dream Award</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">77561786</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A preventative programme for victims of violent crime</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We tested the efficacy of two brief interventions, education and psychological debriefing, designed to prevent adverse psychological reactions to criminal victimisation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>PTSD and depression are the primary outcome measures.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77561786</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NMH2</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="39beb544-996e-4bfc-8499-a3e0d57f83a3">
	  <name>Subdepartment of Clinical Health Psychology</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 6BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Individuals who had been the victims of a violent crime within the past month. Subjects were recruited from police and hospital sources and interviewed in their own homes.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>157</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>157</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mental and behavioural disorders: Depression, anxiety, neuroses</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>2161 were contacted and 243 replied, of whom 157 were eligible and were randomly assigned either to an education condition, to a psychological debriefing plus education condition, or to an assessment only condition. Education involved providing information about normal post-traumatic reactions. Debriefing involved in-depth probing about events, thoughts and feelings experienced during the crime. 138 participants were followed up at 6 months, and 92 at 11 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10473306 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4b2acd46-518c-4e56-9f36-073277db2ca3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10473306"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5827-0</funderId>
      <contactId>Contact7256_5827</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7256_5827">
    <title>Prof</title>
    <forename>Chris</forename>
    <surname>Brewin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Subdepartment of Clinical Health Psychology
University College London
Gower Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 6BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7679 5927</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.brewin@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5827-0">
    <name>NHS Mental Health National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">85788243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Chemonucleolysis or manipulation for lumbar disc herniation?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The purpose of this study is to compare the effects of two treatment modalities available for lumbar disc herniation. The principle aim of the project is to ascertain which, if either, treatment is superior in terms of reducing symptoms/disability, and the relative cost effectiveness/patient satisfaction. The treatments to be studied are chemonucleolysis and osteopathic manipulation.  Despite the choice of a well defined low back pathology for this trial, it may be that some 'types' of patient respond better to one or other of the treatments; strenuous attempts will be made to identify any such categories. The benefits to the NHS will be the determination of the more cost-effective treatment for this condition. Should the result favour manipulation, there will be the potential for reduction both of therapeutic costs and of orthopaedic waiting lists.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Symptoms/disability and the relative cost effectiveness/patient satisfaction.
2. Pain (back and leg) and disability</primaryOutcome>
      <secondaryOutcome>Therapeutic failure</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85788243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ND0020 T367  Burton R&amp;D</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="81bca07f-48f8-4e47-ad93-5aec54b048e1">
	  <name>Spinal Research Unit</name>
	  <address/>
	  <city>Huddersfield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HD1 2SP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with lumbar disc herniation</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lumbar disc herniation</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Spinal conditions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Chemonucleolysis
2. Osteopathic manipulation</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2000 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10905437 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4b9f986a-f8ca-4d4f-8a62-c24a1c0b1c5d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2000-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10905437"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5875-0</funderId>
      <contactId>Contact7582_5875</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7582_5875">
    <title>Prof</title>
    <forename>Kim</forename>
    <surname>Burton</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Spinal Research Unit
30 Queen Street</address>
      <city>Huddersfield</city>
      <country>United Kingdom</country>
      <zip>HD1 2SP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1484 535200</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kim@spineresearch.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5875-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">67214289</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of strategies to encourage implementation of brief alcohol interventions by primary health care nurses</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the clinical impact and cost-effectiveness of strategies promoting screening at brief alcohol intervention by nurses in primary care. The hypothesis was that more intensive implementation interventions would be more effective but also more costly.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Nurse activity in terms of number of patients screened using the Alcohol Use Disorders Identification Test (AUDIT) and number of 'risk positive' drinkers receiving brief intervention.</primaryOutcome>
      <secondaryOutcome>Accuracy of intervention delivery.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67214289</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G106/840 Kaner</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-01-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="38100a8e-adfb-497e-b780-ac9138551288">
	  <name>The Department of Primary Health Care</name>
	  <address/>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NE2 4AA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>General practices with attached nurse</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>212</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>212</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-01-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mental and behavioural disorders: Addiction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control practices - written guidance on screening and brief alcohol intervention
Trained practices - in addition to written guidance, outreach training provided
Trained and supported practices - in addition to training and guidance, two weekly support calls</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/pubmed/14630384 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b8637e66-5289-4a91-a866-24e40a847ea5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/14630384"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5882-0</funderId>
      <contactId>Contact7355_5882</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7355_5882">
    <title>Dr</title>
    <forename>Eileen</forename>
    <surname>Kaner</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Department of Primary Health Care
Centre for Health Service Research
21 Claremont Place
Framlington Place</address>
      <city>Newcastle upon Tyne</city>
      <country>United Kingdom</country>
      <zip>NE2 4AA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)191 222 7884</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.f.s.kaner@newcastle.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5882-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">92205535</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treating patients with dyspepsia with acupuncture and homeopathy: a randomised pilot study of effectiveness and costs.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>For patients with dyspepsia who are receiving orthodox general practice care, what is the effect on outcome and on NHS costs of adding treatment by a choice of acupuncture or homeopathy?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Clinical outcome will be measured by validated outcome questionnaires: 
1. The 36-item short form health survey (SF-36) 
2. Measure Yourself Outcome Profile (MYMOP)
3. The General Well-Being Index

Follow-up will be six-months. 

NHS costs collected for each patient will be prescribing costs, referral costs, and number of general practitioner consultations. Complementary practitioner costs will be their fees and homeopathy prescriptions.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92205535</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RS/08/04.98</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-11-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-06-12T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="be49927b-d10f-4a23-b419-91cdc1ae3878">
	  <name>Department of Social Medicine</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS8 2PR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Sixty patients with dyspepsia presenting in one UK general practice.
Participants expressed their preference for homeopathy or acupuncture before being randomised to receive their choice or be in the control group receiving normal GP care.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-11-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-06-12T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Peptic ulcer disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Peptic ulcer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients chose between acupuncture and homeopathy and were then randomised to this preference or to the control group of normal GP care:
1. Homeopathy versus placebo 
2. Acupuncture versus placebo

Treatment and follow-up were for six months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12801492 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0111a207-fe53-473c-89da-673c6abfe2c9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12801492"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6056-0</funderId>
      <contactId>Contact7332_6056</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7332_6056">
    <title>Dr</title>
    <forename>Charlotte</forename>
    <surname>Paterson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Social Medicine
Canynge Hall
University of Bristol
Whiteladies Road</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS8 2PR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 331 3901</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.Paterson@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6056-0">
    <name>NHS Executive South West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">37977053</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Development and evaluation of an education programme in rheumatoid arthritis: impact on compliance, function, disease progression and quality of life</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Although patient education is assuming an increasingly important role in patient management in many medical disciplines, evaluation of the medium term impact of patient education has not been carried out in rheumatological practice. We wish to know whether a patient education programme will improve compliance with drug, exercise and attendance regimes and the impact of education on disease progression, function and quality of life. We plan a randomised controlled trial of patient education in rheumatoid arthritis based on an ambulant population. We will evaluate the educational benefits of the programme over a four week period and make further outcome assessments for the 12 months following entry into the trial. We hope to show increased compliance with drug regimes and drug monitoring, retention of knowledge and orthodox attitudes to disease management, a reduction in periods of inpatient treatment and unscheduled outpatient attendance. The benefits would accrue primarily to the patients in terms of quality of life and disease progression but would contribute to the cost efficient organisation of the rheumatology department (including number of patient episodes) and in pharmacy costs (currently due, in part, to poor drug compliance and wastage).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Compliance with drug, exercise and attendance regimes and disease progression, function and quality of life. The main outcome variables were the modified Larsen radiological score for the hands and the 36-item short form health survey (SF-36) quality of life questionnaire.</primaryOutcome>
      <secondaryOutcome>1. Health Assessment Questionnaire (HAQ)
2. Ritchie Articular Index (RAI)
3. Patient Knowledge Questionnaire (PKQ)
4. Compliance Questionnaire (CQ)
5. Plasma viscosity (PV)
6. Pharmaceutical changes and consulting behaviour</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37977053</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>535913</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1992-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1994-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d77a0152-6064-4111-9179-834dfd12a00c">
	  <name>University of Leeds</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS2 9NZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with rheumatoid arthritis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>77</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>77</totalTarget>
      <exclusion>1. Unable to speak or read english
2. Previous education programme</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1992-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1994-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Musculoskeletal diseases: Arthritis (rheumatoid)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis (RA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Patient education programme
2. Standard care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10378705 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="14a31867-5aa5-4130-bd51-69c6e099e658" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10378705"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6095-0</funderId>
      <contactId>Contact7452_6095</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7452_6095">
    <title>Dr</title>
    <forename>Philip</forename>
    <surname>Helliwell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Leeds
Rheumatology &amp; Rehabilitation Research Unit
36 Clarendon Road</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS2 9NZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)113 233 4952</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.helliwell@leeds.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6095-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">76146656</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Warfarin/Aspirin Study in Heart failure</title>
      <scientificTitle>What is the most cost effective anti-thrombotic strategy to reduce mortality in heart failure? The WASH Study</scientificTitle>
      <acronym>WASH Study</acronym>
      <studyHypothesis>Heart failure is common and causes appreciable morbidity and mortality. It is associated with recurrent myocardial infarcts, strokes, and other thrombo-embolic events. For these reasons anti-thrombotic therapy using aspirin or warfarin is seen as normal clinical practice. However aspirin has a number of side-effects, and warfarin requires regular blood tests, increasing its cost and inconvenience for patients. Thus using these agents should be justified by clinical benefit. The aim of this study was to see if it would be possible to organise a trial of aspirin, warfarin, and no anti-thrombotic treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Deaths
2. Myocardial infarction
3. Stroke
4. Bleeding episodes
5. Dyspepsia
6. A number of laboratory tests</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76146656</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>D15</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d570e446-081c-422c-b141-1026b37601b7">
	  <name>Castle Hill Hospital</name>
	  <address/>
	  <city>Kingston upon Hull</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>HU16 5UQ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients were being treated for heart failure, and had evidence of ventricular dysfunction to a defined level on echocardiography.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>279</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>279</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heart disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Aspirin
2. Wafarin
3. No anti-thrombotic treatment</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15215806 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="74ad202d-b557-47db-9952-99257b3472ea" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15215806"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5799-0</funderId>
      <contactId>Contact7275_5799</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7275_5799">
    <title>Prof</title>
    <forename>John</forename>
    <surname>Cleland</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Castle Hill Hospital
University of Hull
Cottingham</address>
      <city>Kingston upon Hull</city>
      <country>United Kingdom</country>
      <zip>HU16 5UQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1482 624 083/084</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">J.G.Cleland@hull.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5799-0">
    <name>NHS Cardiovascular Disease and Stroke National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">62032215</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of needle size on serum antibody responses and incidence of general reactions following routine immunisations in infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>When giving routine immunisations to infants, does the needle size used to administer the vaccines affect the serum antibody responses and/or the incidence of local and general reactions.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Comparison of geometric mean titres of Diphtheria/Tetanus and Hib antibodies between needle size groups
2. Comparison of incidence of general and local reactions between needle size groups at three time points - following vaccination at two, three and four months</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the Mid and South Buckinghamshire and Oxfordshire local research ethics committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN62032215</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SEO232</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-06-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="52739649-e2ab-46cf-bcb6-d334315ec0f3">
	  <name>Oxford Vaccine Group</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX3 9DU</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy infants attending routine immunisation clinics at eight general practices.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>696</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>696</totalTarget>
      <exclusion>1. Infants with severe chronic disease
2. Infants who may receive treatment likely to alter the immune response or infants with any conditions which could preclude evaluation of the response, e.g. congenital or acquired immunodeficiency
3. Infants who have already received Diphtheria-Tetanus-Pertussis (DPT)/Hib vaccines</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-06-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccination</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 23 gauge 25 mm - wider gauge long needle
2. 25 gauge 16 mm - narrower gauge short needle
3. 25 gauge 25 mm - narrower gauge long needle</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16891328 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="876c1b25-42d6-4911-8cc7-0ed0d506ff3e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-16T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16891328"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5983-0</funderId>
      <contactId>Contact7533_5983</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7533_5983">
    <title>Mrs</title>
    <forename>Linda</forename>
    <surname>Diggle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Oxford Vaccine Group
Room 4250, Level 4
University Department of Paediatrics
John Radclifffe Hospital
</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX3 9DU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 01865 221229</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">linda.diggle@paediatrics.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5983-0">
    <name>NHS Executive South East (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">65396765</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of intravenous salbutamol and aminophylline in the management of acute severe asthma in children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine whether a bolus of intravenous salbutamol or an aminophylline infusion is the most effective therapy for children with acute severe asthma.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Duration of the need for supplementary oxygen to maintain saturations of above 91%.</primaryOutcome>
      <secondaryOutcome>Other end points:
1. Asthma severity score two hours after starting intravenous therapy
2. Time to stopping intravenous therapy
3. Time to decision to discharge subject</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Thames Multicentre Research ethics committee and the local ethics committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65396765</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RDC01664</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-01-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="643c2f57-6f9f-43e6-a142-2e335484a8f4">
	  <name>West Middlesex Hospital</name>
	  <address/>
	  <city>Isleworth</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>TW7 6AF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 1 to 15 years 
2. Acute severe asthma with an asthma severity score of greater than 7 
3. Poor response to 3 "back to back" salbutamol/ipratropium nebulisers with an improvement in asthma severity score of less than 2</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="1.0"/>
      <upperAgeLimit unit="Years" value="15.0"/>
      <gender>Both</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. A life threatening exacerbation
2. An underlying respiratory disease other than asthma
3. Cardiac disease
4. Treatment with a medication that alters the metabolism of aminophylline</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-01-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Bolus of intravenous salbutamol 
2. Aminophylline infusion</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Salbutamol, aminophylline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12668792 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c6ce49aa-21ef-47c1-84d4-5c5cf5417da3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12668792"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5988-0</funderId>
      <contactId>Contact7320_5988</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7320_5988">
    <title>Dr</title>
    <forename>Alex</forename>
    <surname>Habel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>West Middlesex Hospital</address>
      <city>Isleworth</city>
      <country>United Kingdom</country>
      <zip>TW7 6AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5988-0">
    <name>NHS Executive London (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">81861513</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial of a General Practice based intervention to reduce repeat deliberate self harm (parasuicide).</title>
      <scientificTitle/>
      <acronym>DASH</acronym>
      <studyHypothesis>To what extent can a general practitioner (GP) based intervention affect the rate of repetition of deliberate self harm?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Deliberate self-harm repetition rates
2. Cost effectiveness of the intervention
3. Production of GP management guidelines for DSH</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81861513</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>C/HP/07/11.95/Gunnell</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cd9eaa00-ed4c-47d2-b301-bdf25049eea5">
	  <name>University  of Bristol</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS8 2PR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients attending accident and emergency (A&amp;E) departments in Bristol and Bath after an episode of deliberate self harm (DSH), registered with general practitioners in Avon. 

1932 - patients were studied in total.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1932</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1932</totalTarget>
      <exclusion>Cases of alcohol taken alone and illicit drug overdose, except where the casualty officer felt that the purpose of the act was self-harm or suicide.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression, anxiety, neuroses</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. GP intervention
2. Standard care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12028981 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8281657a-5272-4b1b-adf6-b30f6f5b8618" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-05-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12028981"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6136-0</funderId>
      <contactId>Contact7343_6136</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7343_6136">
    <title>Dr</title>
    <forename>David</forename>
    <surname>Gunnell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University  of Bristol
Department of Social Medicine
Canynge Hall
Whiteladies Road</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS8 2PR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 9287253</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">D.J.Gunnell@Bris.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6136-0">
    <name>NHS Executive South West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">85078221</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Single centre randomised controlled trial (RCT) of a chest pain observation unit versus routine care</title>
      <scientificTitle/>
      <acronym>ESCAPE</acronym>
      <studyHypothesis>To measure the effect of availability of a Chest Pain Observation Unit upon outcome of patients attending with chest pain and measure the cost-effectiveness of a Chest Pain Observation Unit in a UK hospital.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of cases of myocardial infarction (MI) inappropriately sent home by 72 hours after attendance.</primaryOutcome>
      <secondaryOutcome>1. Quality of life, health and patients satisfaction at one month
2. Hospital reattendance rates and adverse cardiac event rates at one year and hospital resource usage over one year
3. Quality of life questionnaire (36-item short form health survey [SF-36]) anxiety/depression scales (Hospital anxiety and depression scale [HADS]) and health utility scale (EQ-5D)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the North Sheffield Research Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85078221</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RBP 00XX4</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-02-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f9b27f7f-7dc2-4194-a818-8e93b44b2673">
	  <name>Medical Care Research Unit</name>
	  <address/>
	  <city>Sheffield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>S1 4DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>900 patients attending accident and emergency with a primary complaint of chest pain between 7.00am and 7.00pm.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>900</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>900</totalTarget>
      <exclusion>1. Electrocardiogram (ECG) abnormality
2. Unstable angina
3. Co-morbidity
4. Less than 25 years
5. Unable to consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-02-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular diseases: Heart disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Chest pain observation unit
2. Standard care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15283863 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c7bf28a2-d386-4654-85e9-12c709c867ea" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-07-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15283863"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6152-0</funderId>
      <contactId>Contact7473_6152</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7473_6152">
    <title>Dr</title>
    <forename>Steve</forename>
    <surname>Goodacre</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Care Research Unit
School of Health and Related Research
University of Sheffield
Regent Court
30 Regent Street</address>
      <city>Sheffield</city>
      <country>United Kingdom</country>
      <zip>S1 4DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)114 222 0842</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.goodacre@sheffield.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6152-0">
    <name>NHS Executive Trent (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">37525568</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of low dose versus high dose Botulinum toxin (Dysport) in the treatment of children with hemiplegic cerebral palsy.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is 24 ng Dysport/Kg body weight more efficacious than 8 ng Dysport/Kg (using impairment measures)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Impairment measure using gait analysis
2. Gastrocnemius muscle length was calculated at each visit using the method described by Eames and used as primary outcome measure</primaryOutcome>
      <secondaryOutcome>Secondary outcome variable was maximum ankle angle measured during stance and swing phases.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37525568</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RBF 96X23</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="20c3e933-be9c-4c84-abcc-1a21754b770b">
	  <name>Southern Derbyshire Acute Hospitals NHS Trust</name>
	  <address/>
	  <city>Derby</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>DE22 3NE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children with hemiplegic cerebral palsy</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nervous system diseases: Cerebral palsy</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Cerebral palsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 24 ng Dysport/kg body weight
2. 8 ng Dysport/kg (using impairment measures)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames>Botulinum toxin (Dysport)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12206622 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3c896deb-c138-4fd9-a44a-8e0d1da1427e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12206622"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6156-0</funderId>
      <contactId>Contact7560_6156</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7560_6156">
    <title>Prof</title>
    <forename>Chris</forename>
    <surname>Ward</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Southern Derbyshire Acute Hospitals NHS Trust
Derby City General Hospital
Uttoxeter Road</address>
      <city>Derby</city>
      <country>United Kingdom</country>
      <zip>DE22 3NE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1332 340141 Ext 5680</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.d.ward@nottingham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6156-0">
    <name>NHS Executive Trent (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">51028168</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised clinical trial to compare the AV impulse foot pump with low molecular weight Heparin in the prevention of deep vein thrombosis after total knee replacement</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>What is the relative effectiveness (against deep vein thrombosis [DVT]), safety and cost of Low Molecular Weight Heparin and the AV Impulse Foot Pump after total knee replacement surgery?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Frequency of DVT as shown by the results of ipsilateral ascending venography between the sixth and eighth postoperative days.</primaryOutcome>
      <secondaryOutcome>1. Perioperative blood loss: a single drain was used routinely and blood loss was derived from a summation of intraoperative blood loss and postoperative drainage at 36 hours
2. Haemoglobin and haematocrit: measured before operation, on the second day after surgery and just before discharge
3. Blood loss index: transfusion requirements of the patients were noted. We recorded whether or not the patient had bruising or oozing from the site of the wound on the fourth and seventh postoperative days.
4. Swelling: assessed by measuring the circumference of the thigh and calf at 10 cm above and below the joint, respectively on the fourth and seventh postoperative days. The level was marked by an indelible pen to maintain consistency.
5. Knee flexion: measured active knee flexion with a goniometer on the fourth and seventh postoperative days. The soft-tissue side-effects were assessed in an open-label manner as it was apparent whether or not the patient was using a foot pump.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Our study had the approval of the local Medical Research and Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN51028168</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>R/41/1.97/Warw</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ab6afcbf-784b-4e1c-a89d-9aeba5e5cd6c">
	  <name>Southampton University Hospitals NHS Trust</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO16 6YD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients scheduled for unilateral primary total knee replacement at the Avon Orthopaedic Centre.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>229</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>229</totalTarget>
      <exclusion>1. Refusal of consent
2. Long-term warfarin therapy for pre-existing cardiac or cerebral disease
3. A bleeding tendency
4. Painful joints or wounds in the feet which would preclude the use of the foot pump</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Total knee replacement</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Total knee replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Enoxaparin (40 mg) was administered, subcutaneously, 12 hours before surgery (in accordance with the UK licence) and every 24 hours thereafter until discharge from hospital. The slippers for the foot pump were applied in the recovery room and the controller was then engaged. The foot pump was then used whenever the patient was not weight-bearing until discharge from hospital. The patient lay in bed with the legs parallel to the floor. The controller activated the pump every 20 seconds at a pressure of 130 mmHg for a period of one second.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Enoxaparin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12002490 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3cc57f52-c5ed-4db8-ab16-c57d60c8d669" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12002490"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5867-0</funderId>
      <contactId>Contact7499_5867</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7499_5867">
    <title>Mr</title>
    <forename>David</forename>
    <surname>Warwick</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Southampton University Hospitals NHS Trust
Department of Orthopaedic Surgery
Southampton General Hospital
Tremona Road</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO16 6YD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8079 6245</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">davidwarwick@handsurgery.co.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5867-0">
    <name>NHS Executive South West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">28223466</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study of the efficacy of a psychosocial intervention for frequent parasuicide attempters with personality disturbance</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A pilot study will test the efficacy of a new psychological treatment for patients seen after an episode of deliberate self-harm (parasuicide or attempted suicide). The treatment is based on a self-treatment manual (suicide behaviour prevention manual) developed by us from previous work by Linehan and Davidson on the cognitive treatment of patients with borderline and anti-social personality disorder. Although the previous treatment has been shown to be successful in reducing episodes of deliberate self-harm it is very intensive and not suitable for general use. Our treatment comprises one session of explanation of the manual followed by a maximum of five further sessions of treatment using a psychoeducational and problem solving approach to suicide behaviour.

60 patients aged between 16 and 40 living in Paddington, Marylebone, Chelsea and Kensington will be seen after an episode of deliberate self-harm who have at least one previous suicide attempt in the past year and qualify for personality disturbance (either difficulty or disorder) in one of the flamboyant categories (histrionic, borderline, impulsive, anti-social). They will be randomised to treatment as usual or to the experimental group and treated for up to three months. Assessment of health service costs, suicide intent and acts, mood disturbance and social functioning will be made before randomisation and after six months by an independent research psychologist. 

If the treatment is found to be successful an application will be made to the MRC for a larger study in a population with less restrictive entrance criteria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The main outcome measures will be the time of the next parasuicide act (using Linehan's definition of this, which is more minor than an actual suicide attempt). Our expectation is that our experimental treatment will extend this from a mean of three weeks to a mean of three months and this will require a sample size of 30 in each treatment group.</primaryOutcome>
      <secondaryOutcome>1. Time to first suicidal act
2. Rate of suicidal acts
3. Change in anxiety and depressive symptoms</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28223466</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RDC00388</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6abeebeb-9750-447c-aadc-f3ba49811d7c">
	  <name>St Mary's Hospital Medical School</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W2 1PD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Efficacy of a new brief manualised form of cognitive behaviour therapy in those with personality disturbance within the flamboyant (cluster B) group. Thirty four patients were enrolled and 32 (18 MACT; 14 TAU) were seen at follow-up.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>34</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>34</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mental and behavioural disorders: Other mental disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Personality disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Psychological treatment using a psychoeducational and problem solving approach to suicide behaviour: manual-assisted cognitive-behaviour therapy (MACT)
2. Standard care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10077290 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3c808e8d-df0a-4f87-b15d-d875bd0ad0df" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10077290"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6015-0</funderId>
      <contactId>Contact7599_6015</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7599_6015">
    <title>Prof</title>
    <forename>Peter</forename>
    <surname>Tyrer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Mary's Hospital Medical School
Patterson Centre
20 South Wharf Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W2 1PD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7886 1648</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.tyrer@ic.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6015-0">
    <name>NHS Executive London (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">47132534</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of a parent-held record for disabled children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To test whether a child health record designed for pre-school children with a disability would:
1. Be used
2. Be valued by carers
3. Change the perception of the health care received by the child
4. Influence the amount of communication between the family and a professional who is seeing their child</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>At the end of the study, copies of the records were examined and the number of entries was taken as a measure of their value to the users. The parents also completed a questionnaire about the value of the record. The way families viewed their child's health care was tested by experimental control using a questionnaire before and after the intervention. At the same times, the amount of communication between the parents and professionals was assessed by both parties completing an identical questionnaire about the child; the similarity between their replies was taken to be a measure of communication.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47132534</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCH 14-11</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11b9db7b-c91c-417e-96ac-8b8a9a1ce8fe">
	  <name>Greenwood Institute of Child Health</name>
	  <address/>
	  <city>Leicester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LE3 0JU</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The participants were randomly selected pre-school children in the community who had been notified to the Education Department as likely to have special educational needs.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>99</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>99</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mental and behavioural disorders: Behavioural disorders</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention was a parent-held record for the parents of disabled children in which they could record contact details of the professionals seeing the child, the child's medical conditions and any medication and equipment used. A diary section allowed parents and professionals to record the child's progress and programme. There was also information about organisations relevant to children with disability. This was a quantitative individual controlled trial of AB design in which outcomes after six months without the intervention were compared those after a six-month intervention period. The participants were randomly allocated to three groups as follows:
Group 1: compared periods without and with the intervention
Group 2: measured any change without the intervention due to the passage of time
Group 3: estimated any effect due to the assessment after the first period without the intervention in Groups 1</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in https://doi.org/10.1046/j.1467-0658.2000.00091.x Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2e76c7ec-59f5-4ef0-9a40-3be1de66e66e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-06-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://doi.org/10.1046/j.1467-0658.2000.00091.x"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5782-0</funderId>
      <contactId>Contact7220_5782</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7220_5782">
    <title>Dr</title>
    <forename>John</forename>
    <surname>Moore</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Greenwood Institute of Child Health
University of Leicester
Westcotes Drive</address>
      <city>Leicester</city>
      <country>United Kingdom</country>
      <zip>LE3 0JU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)116 225 2880</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">johnmoore11@doctors.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5782-0">
    <name>NHS Mother and Child Health National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">17418323</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised clinical trial to compare the AV impulse foot pump with low molecular weight Heparin in the prevention of deep vein thrombosis after total hip replacement</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Without prophylaxis, 45% of patients develop a deep vein thrombosis (DVT) after total hip replacement (THR). Prophylaxis is mandatory to reduce this potentially fatal complication. Low molecular weight heparin (LMWH) is well-established as the most effective method available, reducing the rate to 19% but carrying a perceived risk of haemorrhagic complications. The AV Impulse Foot Pump is a promising new device. Early reports (three relatively small randomised studies) report a DVT rate of 7 to 13%, without haemorrhagic complications. LMWH has not been directly compared with the Foot Pump. A large randomised study is required to determine which of these two prophylactic measures is most effective against DVT, with least complications, best patient acceptability and most favourable cost-benefit ratio.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The prevalence of deep-vein thrombosis, as determined by venography on the sixth, seventh, or eighth postoperative day.</primaryOutcome>
      <secondaryOutcome>1. Transfusion requirements
2. Intraoperative blood loss
3. Postoperative drainage
4. Blood-loss index
5. Appearance of the site of the wound according to a subjective visual-analogue scale
6. Swelling of the thigh.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17418323</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>R/41/1.97/Warw</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="54a4c7b2-558f-4c33-badf-bb66a8309513">
	  <name>Southampton University Hospitals NHS Trust</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO16 6YD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>300 consecutive primary Total Hip Replacement patients; randomised to have either Foot Pump or LMWH until discharge.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>290</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>290</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular diseases: Thromboembolic disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Thromboembolic disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Foot pump
2. Low molecular weight heparin</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1998 Results article in http://www.ncbi.nlm.nih.gov/pubmed/9730125 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50ef41bf-c2c7-4998-b5c2-6957f53c62a3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1998-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/9730125"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5943-0</funderId>
      <contactId>Contact7499_5943</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7499_5943">
    <title>Mr</title>
    <forename>David</forename>
    <surname>Warwick</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Southampton University Hospitals NHS Trust
Department of Orthopaedic Surgery
Southampton General Hospital
Tremona Road</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO16 6YD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8079 6245</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">davidwarwick@handsurgery.co.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5943-0">
    <name>NHS Executive South West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2003-10-23T00:00:00.000Z">28124664</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Italian Society of Endocrinology Prevention Study</title>
      <scientificTitle/>
      <acronym>ISEPS</acronym>
      <studyHypothesis>Randomized controlled trial designed to test the hypothesis that an intensive life style intervention is able to prevent the metabolic
syndrome in 20-50 years old subjects affected by visceral obesity.
Follow-up 5 years.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Prevention of metabolic syndrome</primaryOutcome>
      <secondaryOutcome>Reduction of body weight
Reduction of CHD risk</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28124664</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="78e1aa60-c777-42d8-83ee-647861845c44">
	  <name>DIMI</name>
	  <address/>
	  <city>Perugia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>06126</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women with visceral obesity 
20-50 years old
Waist &gt;88cm (women) 
Waist &gt;102cm (men)
Without metabolic syndrome (according to the Adult Treatment Panel III [ATPIII] classification)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Visceral obesity, metabolic syndrome</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: Individual intensive counseling to induce life-style change as described in detail in the article: "Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subject&#148; by Di Loreto et al (PubMid reference PMID: 12547870)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder5712-0</funderId>
      <contactId>Contact7143_5712</contactId>
      <sponsorId>Sponsor5305</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7143_5712">
    <title>Prof</title>
    <forename>Pierpaolo</forename>
    <surname>De Feo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>DIMI
Via E dal Pozzo</address>
      <city>Perugia</city>
      <country>Italy</country>
      <zip>06126</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 0755783673</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">defeo@dimisem.med.unipg.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5305">
    <organisation>Italian Society of Endocrinology</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Fasi Congress
Viale Gorizia, 24</address>
      <city>Roma</city>
      <country>Italy</country>
      <zip>00198</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 068540296</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">defeo@dimisem.med.unipg.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5712-0">
    <name>Foundation of Italian Society of Endocrinology</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">72911449</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised double-blind placebo-controlled trial of nasal oxytocin spray in mothers of preterm infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does oxytocin nasal spray enable mothers of preterm infants to express more breast milk more easily?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total volume of expressed breast milk, proportion of mothers breast feeding their infant.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72911449</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0263115170</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7d04ef14-cbe0-498a-a548-c99d0defb536">
	  <name>MRC Childhood Nutrition Research Centre</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1N 1EH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>60 Patients from Obstetrics</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pregnancy and Childbirth: Breast feeding</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Breast feeding</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A. Oxytocin nasal spray
B. Placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>oxytocin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16223754 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f957d4dd-a66f-4f4a-a99b-e45a4e3041f1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16223754"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5437-0</funderId>
      <contactId>Contact6793_5437</contactId>
      <sponsorId>Sponsor5287</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact6793_5437">
    <title>Dr</title>
    <forename>M</forename>
    <surname>Fewtrell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC Childhood Nutrition Research Centre
Institute of Child Health
30 Guilford Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1N 1EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 020 7905 2389</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.fewtrell@ich.ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5287">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5437-0">
    <name>University College London Hospitals NHS Trust</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">95588376</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of intravenous steroids at home versus outpatients department for treatment of acute multiple sclerosis relapses</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is there a difference between patients and carer perception of management of MS relapse in outpatients department versus home?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patient and carer perception of management of MS relapse.</primaryOutcome>
      <secondaryOutcome>Other measures include patients' safety, MS impact scores and cost of health case resources.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95588376</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0263115172</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7e696b47-22ae-4360-a344-c8fae6e37117">
	  <name>Neurorehabilitation</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1N 3BG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>164 Patients from Neurology.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>164</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>164</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nervous System Diseases: Multiple sclerosis (MS)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment in outpatients department versus home</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16781986 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a0219de3-658c-4691-b8e9-89e4d7530ad6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16781986"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5438-0</funderId>
      <contactId>Contact7065_5438</contactId>
      <sponsorId>Sponsor5287</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7065_5438">
    <title>Ms</title>
    <forename>B</forename>
    <surname>Porter</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neurorehabilitation
National Hospital for Neurology &amp; Neurosurgery
Queen Square</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1N 3BG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5287">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5438-0">
    <name>University College London Hospitals NHS Trust (UK). NHS R&amp;D Support Funding.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2003-09-12T00:00:00.000Z">31962758</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The evaluation of a primary care based dermatology service</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the effectiveness, cost-effectiveness, accessibility and acceptability of a Primary Care Dermatology Service. This service is an example of the model, promoted in the NHS Plan, of services provided by GPs with special interests (GPSIs) to other GPs across a PCT area.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Disease-related quality of life assessed using the dermatology life quality index (DLQI) and a single-item measure of improvement
2. Improved patient-perceived access, assessed using a new scale</primaryOutcome>
      <secondaryOutcome>1. Patient satisfaction with consultation (Consultation Satisfaction Questionnaire) and with facilities (new scale)
2. Preference for site of care
3. Proportion of failed appointments
4. Waiting times to first appointment</secondaryOutcome>
      <trialWebsite>http://www.bris.ac.uk/Depts/PrimaryHealthCare/research.htm</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31962758</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SDO/34/2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c35e541a-0cf1-47ea-a59b-6ae578e2e741">
	  <name>University of Bristol</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS6 6JL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult patients referred to a hospital dermatology clinic assessed on the basis of the referral letter to be potentially suitable for GPSI management. Suitable patients had non-urgent problems with a provisional diagnosis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>544</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>544 (363 primary care arm; 181 hospital arm)</totalTarget>
      <exclusion>1. Children aged less than 16 years
2. Urgent skin problems
3. Patients where the referral letter indicated that the referrer specifically requested hospital management or the patient clearly needed hospital facilities</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non-urgent skin problems</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Dermatology</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The Bristol primary care dermatology service is staffed by two GPs with Special Interests (GPSIs) and a specialist nurse, and operates from a suburban health centre. It provides care for patients registered with the 29 general practices in one primary care trust. Both GPSIs have postgraduate training and experience in dermatology. All patients see a GPSI initially but may be followed up by a GPSI or the specialist nurse, or may be referred to hospital outpatient care if necessary. The control arm received care from the hospital outpatient dermatology clinic as usual.

The main study using a revised protocol applied to all patients recruited from 01/09/2002; all patients recruited before this were in the pilot study.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16332728 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9883fd42-b9c1-4055-ae4d-4b9444c33875" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-12-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16332728"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5178-0</funderId>
      <contactId>Contact6700_5178</contactId>
      <sponsorId>Sponsor49208</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact6700_5178">
    <title>Prof</title>
    <forename>Chris</forename>
    <surname>Salisbury</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Bristol
Cotham House
Cotham Hill</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS6 6JL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 954 6658</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.salisbury@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49208">
    <organisation>NHS Service Delivery and Organisation Programme (SDO) (UK)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>London School of Hygiene and Tropical Medicine
99 Gower Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 6AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7612 7980</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sdo@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.451052.7</gridId>
    <rorId>https://ror.org/02wnqcb97</rorId>
  </sponsor>
  <funder id="Funder5178-0">
    <name>NHS Service Delivery and Organisation Programme (SDO) (UK) (ref: SDO/34/2002)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2003-09-11T00:00:00.000Z">47368803</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>IBS-C Study A2306</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47368803</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CHTF919A2306</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d6356db5-95df-418f-858a-08963b5dcab0">
	  <name>Novartis Pharmaceuticals</name>
	  <address/>
	  <city>East Hanover</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>07936</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Females, 18 to 65 years, with IBS-C (Irritable Bowel Syndrome with constipation)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>THIS STUDY HAS COMPLETED PATIENT ENROLMENT</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Irritable bowel syndrome (IBS) with constipation</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Irritable bowel syndrome (IBS) with constipation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Not provided at time of registration.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder5153-0</funderId>
      <contactId>Contact5582_5153</contactId>
      <sponsorId>Sponsor5268</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5582_5153">
    <title>Ms</title>
    <forename>Marisa</forename>
    <surname>Carmen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Novartis Pharmaceuticals

One Health Plaza</address>
      <city>East Hanover</city>
      <country>United States of America</country>
      <zip>07936</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5268">
    <organisation>Novartis Pharmaceuticals Corporation</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>One Health Plaza</address>
      <city>East Hanover</city>
      <country>United States of America</country>
      <zip>07936</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418424.f</gridId>
    <rorId>https://ror.org/028fhxy95</rorId>
  </sponsor>
  <funder id="Funder5153-0">
    <name>Sponsored by Novartis Pharmaceuticals Corporation (http://click.atdmt.com/GTO/go/thbmbnov00700895gto/direct/01/)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-08-11T00:00:00.000Z">23257060</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Towards evidence-based public health</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of this study was to evaluate whether a tailored theory-based and multifaceted intervention targeted at the whole process of evidence-based practice increased the explicit integration of research in public health physicians' decision-making.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Behaviour, measured by analysing the contents of local health service reports and of a hypothetical assignment, by a postal survey, a telephone survey and a questionnaire.</primaryOutcome>
      <secondaryOutcome>1. Attitudes
2. Knowledge of evidence-based practice information sources and concepts
3. Task-related self-efficacy
4. Decision-to-adopt 
5. Job-satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23257060</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3e0770f-ad5e-40fa-b56d-c32e80c9a586">
	  <name>Norwegian Directorate for Health and Social Affairs</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>0031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Public health physicians
2. Working in municipalities in Norway with more than 3000 inhabitants</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>148</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>148</totalTarget>
      <exclusion>Does not comply with the above inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lack of knowledge about, use of and physical access to, relevant information sources</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A tailored, multifaceted intervention: workshop on evidence-based medicine, access to several databases, a tailored website, a discussion list, help desk, and an information service that searched for research literature and if possible, made reports based on this literature, on request.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12694632 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="38a1c654-4b65-471a-97cd-f1902cdfe7e7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-03-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12694632"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5147-0</funderId>
      <contactId>Contact5575_5147</contactId>
      <sponsorId>Sponsor5260</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5575_5147">
    <title>Dr</title>
    <forename>Arild</forename>
    <surname>Bjørndal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Directorate for Health and Social Affairs
PO Box 8054 Dep</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+47 24 16 30 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">arild.bjorndal@shdir.no</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5260">
    <organisation>Norwegian Research Council (Norway) </organisation>
    <website/>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>PO Box 2700 
St. Hanshaugen</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+47 22 03 70 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">post@forskningsradet.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.13985.36</gridId>
    <rorId>https://ror.org/00epmv149</rorId>
  </sponsor>
  <funder id="Funder5147-0">
    <name>Norwegian Research Council (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2003-02-19T00:00:00.000Z">72253427</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assisting decision making in menorrhagia in primary care: a randomised controlled trial to compare computerised decision analysis with patient information leaflet. MENTIP study: Menorrhagia Treatment Information and Preferences</title>
      <scientificTitle/>
      <acronym>MENTIP</acronym>
      <studyHypothesis>Aims: 
Since patient information leaflets are highly accessible and relatively cheap, they may be considered the standard against which more complex decision aids must be evaluated. 
The purpose of this study is to evaluate whether the addition of decision analysis to written information improves the process of decision-making in women consulting their doctor with heavy periods, compared with written information alone.

Objectives:
To answer the following question: Is the addition of decision analysis to written information significantly more effective at  reducing decisional conflict compared with written information alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure will be the Decisional Conflict Scale (DCS), a questionnaire developed by O'Connor (1999) for use in studies of decision-making processes. This instrument measures a person's perception of: personal uncertainty in making a choice about health care options, the modifiable factors (such as feeling uninformed, unsupported and unclear about personal values) and the quality of the decision made (in terms of satisfaction with the choice and expectation to maintain).</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72253427</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G106/1048</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-09T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d0030e4f-3d35-43c5-86fa-22c00a18af0a">
	  <name>NPCRDC</name>
	  <address/>
	  <city>Manchester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>M13 9PL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women aged 30-49 years presenting to GP with heavy periods</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Women with confirmed or provisional diagnoses of physical pathology (including cancer, endometriosis, fibroids, prolapse and cysts).
2. Women considered by their GP to be unsuitable due to physical or psychological impairment.
3. Women unable to understand English. Because of the nature of the intervention (i.e. a written computer programme), some proficiency in English is required.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-09T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Menorrhagia</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Menorrhagia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Control group: Patient Information Leaflet (PIL)
2. Intervention group: PIL and Clinical Guidance Tree (computerised Decision Analysis)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17898242 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="afa63fb5-55fc-4bfd-bd4c-a2cf358a307b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17898242"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1655-0</funderId>
      <funderId>Funder1655-1</funderId>
      <contactId>Contact5095_1655</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5095_1655">
    <title>Dr</title>
    <forename>Joanne</forename>
    <surname>Protheroe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>NPCRDC
5th Floor Williamson Building
The University of Manchester
Oxford Road</address>
      <city>Manchester</city>
      <country>United Kingdom</country>
      <zip>M13 9PL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 2757601</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.protheroe@man.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1655-0">
    <name>Medical Research Council (MRC) Special Training Fellowship (UK) (ref: G106/1048)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1655-1">
    <name>National Primary Care Research And Development Centre (NPCRDC) (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-01-28T00:00:00.000Z">32956955</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Trial of management strategies for the acute infective conjunctivitis in general practice</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess different management strategies for conjunctivitis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Symptom resolution for conjunctivitis
2. Patient satisfaction</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32956955</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G84/5610</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="80cc4592-3e46-47c3-8ecd-4e30000b0b2b">
	  <name>Division of Community Clinical Sciences</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO16 5ST</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Present to GP with acute infective conjunctivitis
2. Age over 1 year</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>Age under 1 year.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Conjunctivitis</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Infective conjunctivitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Antibiotic eye drops (chloramphenicol) immediately
2. Delayed prescription 
3. No treatment</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16847013 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a7924564-02ae-45e7-9f33-06f0b1303dc3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16847013"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1514-0</funderId>
      <contactId>Contact5083_1514</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5083_1514">
    <title>Dr</title>
    <forename>Hazel</forename>
    <surname>Everitt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Community Clinical Sciences
Primary Medical Care
University of Southampton
Aldermoor Health Centre
Aldermoor Close</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO16 5ST</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 02380 241079</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1514-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-12-16T00:00:00.000Z">85788039</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Stop smoking with mobile phones trial</title>
      <scientificTitle/>
      <acronym>STOMP</acronym>
      <studyHypothesis>Not provided at time of registration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial was approved by Auckland Ethics Committee (ref: 2001/275).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85788039</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>No 979</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="aa30125a-c8fc-4bba-9075-5813d4a95b6c">
	  <name>Clinical Trials Research Unit</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Daily smokers aged over 16 years with a mobile phone</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration.</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Personalised and free text messages</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/16046689 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="11cc46a9-8968-42c8-93ba-7b013016bddf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16046689"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1481-0</funderId>
      <funderId>Funder1481-1</funderId>
      <contactId>Contact5013_1481</contactId>
      <sponsorId>Sponsor5092</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5013_1481">
    <title>Dr</title>
    <forename>Anthony</forename>
    <surname>Rodgers</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Trials Research Unit
The University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 373 7599 ext. 84716</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.rodgers@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5092">
    <organisation>The National Heart Foundation of New Zealand (New Zealand) </organisation>
    <website>http://www.nhf.org.nz/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>9 Kalmia Street
Ellerslie
PO Box 17160
Greenlane</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 571 9191</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Info@nhf.org.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453646.6</gridId>
    <rorId>https://ror.org/02xwkbq98</rorId>
  </sponsor>
  <funder id="Funder1481-0">
    <name>The National Heart Foundation of New Zealand (New Zealand)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1481-1">
    <name>Other support in kind from Vodafone, Auckland Uniservices Ltd and Alcatel</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-10-08T00:00:00.000Z">24141277</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of lactobacillus in general practice to prevent post-antibiotic vulvovaginitis</title>
      <scientificTitle/>
      <acronym>PAV (post-antibiotic vulvovaginitis)</acronym>
      <studyHypothesis>This study aims to test in a randomised controlled trial whether oral and/or vaginal lactobacillus preparations can prevent post-antibiotic vulvovaginitis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is symptomatic vulvovaginal candidiasis, defined as:
1. Participants' report of symptoms (that is answer 'yes' to a question about symptoms of 'thrush' in survey 2: vaginal itch, irritation with or without a discharge) 
2. Swab B culture positive for Candida species</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial has received ethics approval from both the Royal Australian College of General Practitioners and the Royal Women's Hospital, Melbourne, Australia.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24141277</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2001/524 (number assigned by the Therapeutic Goods Administration in Australia)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled blinded 2 x 2 factorial design, with four intervention groups</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="23c59ef6-1361-4408-8090-781f0bc80d03">
	  <name>Department of General Practice</name>
	  <address/>
	  <city>Carlton</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women aged between 18 and 50 years of age
2. Who are experiencing a non-genital infection
3. Rrequiring a short-course of oral antibiotics or have commenced this within the 48 hours preceding enrolment
4. English-speaking: able to speak, read and write in English sufficiently to provide informed consent and complete surveys</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>496</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>496</totalTarget>
      <exclusion>1. Pregnancy
2. Experiencing any vaginal symptoms at recruitment
3. Unwilling or unable to provide two self-collected low vaginal swabs (at recruitment and on completion of trial)
4. Using or have used vaginal antifungal treatments in the past two weeks
5. Have taken antibiotics in the past month
6. Unwilling to stop taking other lactobacillus products during the trial
7. Immunocompromised, as there are rare reports in the literature of lactobacilli causing endocarditis and bacteraemia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-antibiotic vulvovaginitis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Post-antibiotic vulvovaginitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Factorial design to test oral and vaginal lactobacillus species.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lactobacillus</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/15046642 Protocol</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e8570e09-372d-4611-9a8a-669ececaea8d" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-03-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15046642"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1438-0</funderId>
      <funderId>Funder1438-1</funderId>
      <funderId>Funder1438-2</funderId>
      <contactId>Contact5092_1438</contactId>
      <sponsorId>Sponsor5115</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5092_1438">
    <title>Dr</title>
    <forename>Jane</forename>
    <surname>Gunn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Practice
200 Berkeley Street</address>
      <city>Carlton</city>
      <country>Australia</country>
      <zip>3053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 8344 4530</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.gunn@unimelb.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5115">
    <organisation>University of Melbourne (Australia)</organisation>
    <website>http://www.unimelb.edu.au</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Victoria</city>
      <country>Australia</country>
      <zip> 3010</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.1008.9</gridId>
    <rorId>https://ror.org/01ej9dk98</rorId>
  </sponsor>
  <funder id="Funder1438-0">
    <name>Shepherd Foundation (Australia)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1438-1">
    <name>Royal Australian College of General Practitioners (Australia) (ref: 00/58)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001234</fundRef>
  </funder>
  <funder id="Funder1438-2">
    <name>Department of Health and Aged Care (Australia) - scholarship for Dr Pirotta</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2002-08-19T00:00:00.000Z">72126158</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A Double Blind, Randomised, Placebo Controlled Study of Farlutal in the Treatment of Weight Loss in Patients Undergoing Radiotherapy for Head and Neck Cancer</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72126158</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MPA8801</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-08-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-08-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Italy</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="215c40de-1d73-4d61-a3b2-3716f9388973">
	  <name>UKCCCR Register Co-ordinator</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NW1 2DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged &gt;18 years 
2. Squamous cell carcinoma of the head and neck
3. Not known to have or suspected of having early breast cancer
4. No known hypersensitivity to medroxyprogesterone acetate
5. No medical contraindications to treatment</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-08-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-08-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and Neck Cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Head and Neck Cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks
2. Group B: Placebo tablets twice daily for a maximum of 12 weeks</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder1608-0</funderId>
      <contactId>Contact5427_1608</contactId>
      <sponsorId>Sponsor5039</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5427_1608">
    <title>Dr</title>
    <forename>-</forename>
    <surname>-</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>NW1 2DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5039">
    <organisation>Farmitalia Carlo Erba (Italy)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>-</city>
      <country>Italy</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.439132.e</gridId>
    <rorId>https://ror.org/03htt2d69</rorId>
  </sponsor>
  <funder id="Funder1608-0">
    <name>Not provided at time of registration.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-04-29T00:00:00.000Z">28863830</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of Immunoglobulin M (IgM) enriched immunoglobulin preparations in patients with severe sepsis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the effect of IgM-enriched immunoglobulin treatment on progression of organ failure and septic shock in patients with severe sepsis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Procalcitonin (PCT) measurements; blood samples were taken daily for eight days following study admission.</primaryOutcome>
      <secondaryOutcome>1. Severity of critical illness, assessed by obtaining daily acute physiological and chronic health evaluation score (APACHE II)
2. Sequential organ failure assessment (SOFA) score used to assess the development of organ failure
3. Duration of mechanical ventilation
4. Length of stay in the intensive care unit
5. Septic shock incidence 
6. 28-day mortality rate</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN28863830</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="30d307d0-73d6-449a-9bad-56eadd0728a0">
	  <name>IU Istanbul Tip Fakültesi Anesteziyoloji AD</name>
	  <address/>
	  <city>Istanbul</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>34390 Fatih</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Thirty-nine patients with severe sepsis, defined as:
1. Temperature of greater than 38°C or less than 36°C
2. Heart rate of greater than 90 beats/min
3. Respiratory rate greater than 20/min or arterial carbon dioxide pressure (PaCO2) less than 32 mmHg
4. White blood cell count greater than 12000/mm^3 or less than 4000/mm^3
5. Documented infection and dysfunction of an organ or hypotension</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>39</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>39</totalTarget>
      <exclusion>Does not comply with above inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe sepsis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Sepsis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients in the study group (n = 21) received intravenous immunoglobulin preparation (Pentaglobin®) in addition to standard therapy. Pentaglobin® was started on the day of diagnosis of severe sepsis. 5 mL/kg/day Pentaglobin® (38 g/L IgG, 6 g/L IgM and 6 g/L IgA) was infused over 6 hours and repeated for three consecutive days. 

Patients in the control group (n = 18) received standard sepsis therapy, but no immunoglobulin administration. Blood samples for procalcitonin measurements were taken daily for eight days. Severity of critical illness and development of organ failures were assessed by obtaining daily Acute Physiological and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pentaglobin®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12225613 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c27ca05b-5f33-46b5-95df-125c2ecca37c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12225613"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1386-0</funderId>
      <contactId>Contact5177_1386</contactId>
      <sponsorId>Sponsor5002</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5177_1386">
    <title>Dr</title>
    <forename>Simru</forename>
    <surname>Tugrul</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>IU Istanbul Tip Fakültesi Anesteziyoloji AD
Cerrahi Monoblok
Çapa</address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390 Fatih</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+90 (9)212 6318767</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mtugrul@isbank.net.tr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5002">
    <organisation>Istanbul University (Turkey)</organisation>
    <website>http://www.istanbul.edu.tr/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Anesthesiology Department
Istanbul Medical Faculty</address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.9601.e</gridId>
    <rorId>https://ror.org/03a5qrr21</rorId>
  </sponsor>
  <funder id="Funder1386-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-19T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-04-15T00:00:00.000Z">36253388</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Physiological dose steroid therapy in sepsis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the study was to assess the prognostic importance of basal cortisol concentrations and cortisol response to corticotropin, and to determine the effects of physiological dose steroid therapy on mortality in patients with sepsis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint of the study was 28-day mortality from all causes.</primaryOutcome>
      <secondaryOutcome>The secondary endpoint consisted of adverse occurrences including possible complications of drug therapy and morbid events such as the progression of initial infection and the development of secondary infection. Secondary infection was defined as the identification of a new site of infection or the emergence of a different organism at the same site, generally requiring a change in antibiotic management.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the Institutional Review Board of Erciyes University and informed consent was obtained from the patients' relatives.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36253388</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Protocol number: 97.02.20; Trial number: 97.013.46</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c4b46044-c2df-4cf3-a574-05524b7ba299">
	  <name>Erciyes Universitesi Tip Fakültesi</name>
	  <address/>
	  <city>Kayseri</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>38039</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients over 17 years old and diagnosed with sepsis were included in the study consecutively. The diagnosis of sepsis was based on the definition of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Report. The severity of illness was classified according to this definition.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Criteria for exclusion from the study were as follows: 
1. Already known pre-existing adrenal disease or adrenalectomy 
2. Known malignancies, tuberculosis that might have involved the adrenal gland
3. Administration of steroids within the three months before the admission 
4. In addition, patients with burns, hemorrhagic shock or those who had suffered myocardial infarction were not included</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sepsis and adrenal insufficiencies</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Sepsis and adrenal insufficiencies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients enrolled in the study were treated with standard therapy used in the treatment of sepsis and septic shock. This therapy could include administration of antibiotics, fluid replacement, vasoactive drugs, mechanical ventilatory support, and any other form of supportive therapy deemed necessary by the primary physicians. 

Soon after the presumptive diagnosis of severe sepsis, an adrenalcorticotropic hormone (ACTH) stimulation test was performed with 250 µg of tetracosactrin (synacthene, Ciba Geigy, Germany) given intravenously and the patients were randomised to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomisation procedure. 

Steroid therapy group received prednisolone in physiologic doses. Prednisolone was intravenously given 5 mg at 06.00 am, and 2.5 mg at 18.00 pm for ten days. 

Standard therapy group received a placebo infusion containing physiologic saline solution in an identical manner. 

Patients and their primary physicians were blinded as to which therapy was administered.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prednisolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12133187 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ab24b5f7-6d15-43dd-9562-18590272c7da" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12133187"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1385-0</funderId>
      <contactId>Contact5000_1385</contactId>
      <sponsorId>Sponsor5038</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5000_1385">
    <title>Dr</title>
    <forename>Orhan</forename>
    <surname>Yildiz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erciyes Universitesi Tip Fakültesi
Klinik mikrobiyoloji ve Infeksiyon
Hastaliklari Bilim Dali</address>
      <city>Kayseri</city>
      <country>Türkiye</country>
      <zip>38039</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+90 352 437 49 37</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yildizorhan@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5038">
    <organisation>Erciyes University (Turkey)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Tip Fakültesi 
Klinik mikrobiyoloji ve Infeksiyon
Hastaliklari Bilim Dali</address>
      <city>Kayseri</city>
      <country>Türkiye</country>
      <zip>38039</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411739.9</gridId>
    <rorId>https://ror.org/047g8vk19</rorId>
  </sponsor>
  <funder id="Funder1385-0">
    <name>Erciyes University (Turkey) - research fund (ref: 97.013.46)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2001-11-07T00:00:00.000Z">66375463</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improving question formulation for use in evidence appraisal in a tertiary care setting: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The study sought to determine whether adding simple instructions and examples on clinical question formulation would increase the specificity of the question being submitted by the health care professional compared to using a standard form without instructions and examples.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The change in the proportion of reformulated questions that described each the dimensions of specificity.</primaryOutcome>
      <secondaryOutcome>The differences in the degree by which a particular dimension was specified.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN66375463</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bfda4459-8532-48f5-a16a-99059ea16138">
	  <name>Deputy Director</name>
	  <address/>
	  <city>Victoria</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3168</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Health care professionals affiliated with a tertiary care health care network in Melbourne, Australia</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>39</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>39</totalTarget>
      <exclusion>Previous users of the service</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Question formulation by health care professionals</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>New participants were invited to reformulate clinical queries. The control group was given no instructions. The intervention group was given a brief explanation of proper formulation, written instructions, and diagrammatic examples.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2001 Results article in http://www.ncbi.nlm.nih.gov/pubmed/11716797 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="022a5aef-b730-4ab8-9852-cffc78aa59ae" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2001-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/11716797"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1254-0</funderId>
      <contactId>Contact5211_1254</contactId>
      <sponsorId>Sponsor5010</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5211_1254">
    <title>Mr</title>
    <forename>Elmer V</forename>
    <surname>Villanueva</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Deputy Director
Health Technology Assessment Centre for Clinical Effectiveness
Monash Institute of Health Services Research
246 Clayton Road
Clayton</address>
      <city>Victoria</city>
      <country>Australia</country>
      <zip>3168</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9594 7505</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Elmer.Villanueva@med.monash.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5010">
    <organisation>Centre for Clinical Effectiveness (Australia)</organisation>
    <website>http://www.med.monash.edu.au</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Monash Institute of Health Services Research
246 Clayton Road
Clayton</address>
      <city>Victoria</city>
      <country>Australia</country>
      <zip>3168</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419789.a</gridId>
    <rorId>https://ror.org/02t1bej08</rorId>
  </sponsor>
  <funder id="Funder1254-0">
    <name>Self-funded through internal research funds</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>